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Staphylococcus 
Clinical Manifestations 
Staphylococci can cause many forms of infection. (1) S aureus causes superficial 
skin lesions (boils, styes) and localized abscesses in other sites. (2) S aureus causes 
deep-seated infections, such as osteomyelitis and endocarditis and more serious skin 
infections (furunculosis). (3) S aureus is a major cause of hospital acquired (noso-
comial) infection of surgical wounds and, with S epidermidis, causes infections asso-
ciated with indwelling medical devices. (4) S aureus causes food poisoning by re-
leasing enterotoxins into food. (5) S aureus causes toxic shock syndrome by release 
of superantigens into the blood stream. (6) S saprophiticus causes urinary tract infec-
tions, especially in girls. (7) Other species of staphylococci (S lugdunensis, S haemo-
lyticus, S warneri, S schleiferi, S intermedius) are infrequent pathogens. 
Structure 
Staphylococci are Gram-positive cocci 1 µm in diameter. They form clumps. 
Classification 
S aureus and S intermedius are coagulase positive. All other staphylococci are coag-
ulase negative. They are salt tolerant and often hemolytic. Identification requires bio-
type analysis. 
Natural Habitat 
S aureus colonizes the nasal passage and axillae. S epidermidis is a common human 
skin commensal. Other species of staphylococci are infrequent human commensals. 
Some are commensals of other animals. 
Pathogenesis 
S aureus expresses many potential virulence factors. (1) Surface proteins that pro-
mote colonization of host tissues. (2) Factors that probably inhibit phagocytosis 
(capsule, immunoglobulin binding protein A). (3) Toxins that damage host tissues 
and cause disease symptoms. Coagulase-negative staphylococci are normally less 
virulent and express fewer virulence factors. S epidermidis readily colonizes im-
planted devices.  
Host Defenses 
Phagocytosis is the major mechanism for combatting staphylococcal infection. Anti-
bodies are produced which neutralize toxins and promote opsonization. The capsule 
and protein A may interfere with phagocytosis. Biofilm growth on implants is im-
pervious to phagocytosis. 
Treatment 
Infections acquired outside hospitals can usually be treated with penicillinase-
resistant ß-lactams. Hospital acquired infection is often caused by antibiotic resistant 
strains and can only be treated with vancomycin. 
 4 
Antibiotic Resistance 
Multiple antibiotic resistance is increasingly common in S aureus and S epidermidis. 
Methicillin resistance is indicative of multiple resistance. Methicillin-resistant S au-
reus (MRSA) causes outbreaks in hospitals and can be epidemic.  
Epidemiology 
Epidemiological tracing of S aureus is traditionally performed by phage typing, but 
has limitations. Molecular typing methods are being tested experimentally.  
Diagnosis 
Diagnosis is based on performing tests with colonies. Tests for clumping factor, co-
agulase, hemolysins and thermostable deoxyribonuclease are routinely used to iden-
tify S aureus. Commercial latex agglutination tests are available. Identification of S 
epidermidis is confirmed by commercial biotyping kits. 
Control 
Patients and staff carrying epidemic strains, particularly MRSA, should be isolated. 
Patients may be given disinfectant baths or treated with a topical antibiotic to eradi-
cate carriage of MRSA. Infection control programs are used in most hospitals. 
INTRODUCTION 
Bacteria in the genus Staphylococcus are pathogens of man and other mammals. 
Traditionally they were divided into two groups on the basis of their ability to clot 
blood plasma (the coagulase reaction). The coagulase-positive staphylococci consti-
tute the most pathogenic species S aureus. The coagulase-negative staphylococci 
(CNS) are now known to comprise over 30 other species. The CNS are common 
commensals of skin, although some species can cause infections. It is now obvious 
that the division of staphylococci into coagulase positive and negative is artificial 
and indeed, misleading in some cases. Coagulase is a marker for S aureus but there 
is no direct evidence that it is a virulence factor. Also, some natural isolates of S au-
reus are defective in coagulase. Nevertheless, the term is still in widespread use 
among clinical microbiologists.  
S aureus expresses a variety of extracellular proteins and polysaccharides, some of 
which are correlated with virulence. Virulence results from the combined effect of 
many factors expressed during infection. Antibodies will neutralize staphylococcal 
toxins and enzymes, but vaccines are not available. Both antibiotic treatment and 
surgical drainage are often necessary to cure abscesses, large boils and wound infec-
tions. Staphylococci are common causes of infections associated with indwelling 
medical devices. These are difficult to treat with antibiotics alone and often require 
removal of the device. Some strains that infect hospitalized patients are resistant to 
most of the antibiotics used to treat infections, vancomycin being the only remaining 
drug to which resistance has not developed. 
Taxonomy 
DNA-ribosomal RNA (rRNA) hybridization and comparative oligonucleotide analy-
sis of 16S rRNA has demonstrated that staphylococci form a coherent group at the 
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genus level. This group occurs within the broad Bacillus-Lactobacillus-
Streptococcus cluster defining Gram-positive bacteria with a low G + C content of 
DNA.  
At least 30 species of staphylococci have been recognized by biochemical analysis 
and in particular by DNA-DNA hybridization. Eleven of these can be isolated from 
humans as commensals. S aureus (nares) and S epidermidis (nares, skin) are com-
mon commensals and also have the greatest pathogenic potential. S saprophyticus 
(skin, occasionally) is also a common cause of urinary tract infection. S haemolyti-
cus, S simulans, S cohnii, S warneri and S lugdunensis can also cause infections in 
man. 
Identification of Staphylococci in the Clinical laboratory 
Structure 
Staphylococci are Gram-positive cocci about 0.5 - 1.0 µm in diameter. They grow in 
clusters, pairs and occasionally in short chains. The clusters arise because staphylo-
cocci divide in two planes. The configuration of the cocci helps to distinguish micro-
cocci and staphylococci from streptococci, which usually grow in chains. Observa-
tions must be made on cultures grown in broth, because streptococci grown on solid 
medium may appear as clumps. Several fields should be examined before deciding 
whether clumps or chains are present.  
Catalase Test 
The catalase test is important in distinguishing streptococci (catalase-negative) 
staphylococci which are catalase positive. The test is performed by flooding an agar 
slant or broth culture with several drops of 3% hydrogen peroxide. Catalase-positive 
cultures bubble at once. The test should not be done on blood agar because blood it-
self will produce bubbles. 
Isolation and Identification 
The presence of staphylococci in a lesion might first be suspected after examination 
of a direct Gram stain. However, small numbers of bacteria in blood preclude micro-
scopic examination and require culturing first. 
The organism is isolated by streaking material from the clinical specimen (or from a 
blood culture) onto solid media such as blood agar, tryptic soy agar or heart infusion 
agar. Specimens likely to be contaminated with other microorganisms can be plated 
on mannitol salt agar containing 7.5% sodium chloride, which allows the halo-
tolerant staphylococci to grow. Ideally a Gram stain of the colony should be per-
formed and tests made for catalase and coagulase production, allowing the coagu-
lase-positive S aureus to be identified quickly. Another very useful test for S aureus 
is the production of thermostable deoxyribonuclease. S aureus can be confirmed by 
testing colonies for agglutination with latex particles coated with immunoglobulin G 
and fibrinogen which bind protein A and the clumping factor, respectively, on the 
bacterial cell surface. These are available from commercial suppliers (e.g., Staphau-
rex). The most recent latex test (Pastaurex) incorporates monoclonal antibodies to 
serotype 5 and 8 capsular polysaccharide in order to reduce the number of false 
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negatives. (Some recent clinical isolates of S aureus lack production of coagulase 
and/or clumping factor, which can make identification difficult.) 
The association of S epidermidis (and to a lesser extent of other coagulase-negative 
staphylococci) with nosocomial infections associated with indwelling devices means 
that isolation of these bacteria from blood is likely to be important and not due to 
chance contamination, particularly if successive blood cultures are positive. Nowa-
days, identification of S epidermidis and other species of Staphylococcus is per-
formed using commercial biotype identification kits, such as API Staph Ident, API 
Staph-Trac, Vitek GPI Card and Microscan Pos Combo. These comprise preformed 
strips containing test substrates.  
Epidemiology of Staphylococcus Aureus Infections 
Because S aureus is a major cause of nosocomial and community-acquired infec-
tions, it is necessary to determine the relatedness of isolates collected during the in-
vestigation of an outbreak. Typing systems must be reproducible, discriminatory, 
and easy to interpret and to use. The traditional method for typing S aureus is phage-
typing. This method is based on a phenotypic marker with poor reproducibility. Al-
so, it does not type many isolates (20% in a recent survey at the Center for Disease 
Control and Prevention), and it requires maintenance of a large number of phage 
stocks and propagating strains and consequently can be performed only by specialist 
reference laboratories. 
Many molecular typing methods have been applied to the epidemiological analysis 
of S aureus, in particular, of methicillin-resistant strains (MRSA). Plasmid analysis 
has been used extensively with success, but suffers the disadvantage that plasmids 
can easily be lost and acquired and are thus inherently unreliable. Methods designed 
to recognize restriction fragment length polymorphisms (RFLP) using a variety of 
gene probes, including rRNA genes (ribotyping), have had limited success in the ep-
idemiology of MRSA. In this technique the choice of restriction enzyme used to 
cleave the genomic DNA, as well as the probes, is crucial. Random primer PCR of-
fers potential for discriminating between strains but a suitable primer has yet to be 
identified for S aureus. The method currently regarded as the most reliable is pulsed 
field gel electrophoresis, where genomic DNA is cut with a restriction enzyme that 
generates large fragments of 50-700 kb.  
Clinical Manifestations of S Aureus 
S aureus is notorious for causing boils, furuncles, styes, impetigo and other superfi-
cial skin infections in humans (Figure 12-1). It may also cause more serious infec-
tions, particularly in persons debilitated by chronic illness, traumatic injury, burns or 
immunosuppression. These infections include pneumonia, deep abscesses, osteomye-
litis, endocarditis, phlebitis, mastitis and meningitis, and are often associated with 
hospitalized patients rather than healthy individuals in the community. S aureus and 
S epidermidis are common causes of infections associated with indwelling devices 
such as joint prostheses, cardiovascular devices and artificial heart valves (Fig. 12-
2).  
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FIGURE 12-1 Pathogenesis of staphylococcal infections 
 
FIGURE 12-2 Infections associated with indwelling devices 
Pathogenesis of S Aureus Infections 
S aureus expresses many cell surface-associated and extracellular proteins that are 
potential virulence factors. For the majority of diseases caused by this organism, 
pathogenesis is multifactorial. Thus it is difficult to determine precisely the role of 
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any given factor. This also reflects the inadequacies of many animal models for 
staphylococcal diseases. 
However, there are correlations between strains isolated from particular diseases and 
expression of particular factors, which suggests their importance in pathogenesis. 
With some toxins, symptoms of a human disease can be reproduced in animals with 
pure proteins. The application of molecular biology has led to recent advances in the 
understanding of pathogenesis of staphylococcal diseases. Genes encoding potential 
virulence factors have been cloned and sequenced and proteins purified. This has fa-
cilitated studies at the molecular level on their modes of action, both in in vitro and 
in model systems. In addition, genes encoding putative virulence factors have been 
inactivated, and the virulence of the mutants compared to the wild-type strain in an-
imal models. Any diminution in virulence implicates the missing factor. If virulence 
is restored when the gene is returned to the mutant then "Molecular Koch's Postu-
lates" have been fulfilled. Several virulence factors of S aureus have been confirmed 
by this approach.  
Adherence 
In order to initiate infection the pathogen must gain access to the host and attach to 
host cells or tissues.  
S aureus Adheres to Host Proteins 
S aureus cells express on their surface proteins that promote attachment to host pro-
teins such as laminin and fibronectin that form part of the extracellular matrix (Fig-
ure 12-3). Fibronectin is present on epithelial and endothelial surfaces as well as be-
ing a component of blood clots. In addition, most strains express a fibrinogen/fibrin 
binding protein (the clumping factor) which promotes attachment to blood clots and 
traumatized tissue. Most strains of S aureus express fibronectin and fibrinogen-
binding proteins.  
 
FIGURE 12-3 Summary of virulence factors of Staphylococcus aureus 
The receptor which promotes attachment to collagen is particularly associated with 
strains that cause osteomyelitis and septic arthritis. Interaction with collagen may al-
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so be important in promoting bacterial attachment to damaged tissue where the un-
derlying layers have been exposed.  
Evidence that these staphylococcal matrix-binding proteins are virulence factors has 
come from studying defective mutants in vitro adherence assays and in experimental 
infections. Mutants defective in binding to fibronectin and to fibrinogen have re-
duced virulence in a rat model for endocarditis, suggesting that bacterial attachment 
to the sterile vegetations caused by damaging the endothelial surface of the heart 
valve is promoted by fibronectin and fibrinogen. Similarly, mutants lacking the col-
lagen-binding protein have reduced virulence in a mouse model for septic arthritis. 
Furthermore, the soluble ligand-binding domain of the fibrinogen, fibronectin and 
collagen-binding proteins expressed by recombinant methods strongly blocks inter-
actions of bacterial cells with the corresponding host protein. 
Role of Adherence in Infections Associated with Medical Devices 
Infections associated with indwelling medical devices ranging from simple intrave-
nous catheters to prosthetic joints and replacement heart valves can be caused by S 
aureus and S epidermidis (Figure 12-2). Very shortly after biomaterial is implanted 
in the human body it becomes coated with a complex mixture of host proteins and 
platelets. In one model system involving short-term contact between biomaterial and 
blood, fibrinogen was shown to be the dominant component and was primarily re-
sponsible for adherence of S aureus in subsequent in vitro assays. In contrast, with 
material that has been in the body for longer periods (e.g., human intravenous cathe-
ters) the fibrinogen is degraded and no longer promotes bacterial attachment. Instead, 
fibronectin, which remains intact, becomes the predominant ligand promoting at-
tachment.  
Adherence to Endothelial Cells  
S aureus can adhere to the surface of cultured human endothelial cells and become 
internalized by a phagocytosis-like process. It is not clear if attachment involves a 
novel receptor or a known surface protein of S aureus. Some researchers think that S 
aureus can initiate endocarditis by attaching to the undamaged endothelium. Others 
feel that trauma of even a very minor nature is required to promote attachment of 
bacteria.  
Avoidance of Host Defenses 
S aureus expresses a number of factors that have the potential to interfere with host 
defense mechanisms. However, strong evidence for a role in virulence of these fac-
tors is lacking.  
Capsular Polysaccharide 
The majority of clinical isolates of S aureus express a surface polysaccharide of ei-
ther serotype 5 or 8. This has been called a microcapsule because it can be visualized 
only by electron microscopy after antibody labeling, unlike the copious capsules of 
other bacteria which are visualized by light microscopy. S aureus isolated from in-
fections expresses high levels of polysaccharide but rapidly loses it upon laboratory 
subculture. The function of the capsule is not clear. It may impede phagocytosis, but 
in in vitro tests this was only demonstrated in the absence of complement. Converse-
ly, comparing wild-type and a capsule defective mutant strain in an endocarditis 
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model suggested that polysaccharide expression actually impeded colonization of 
damaged heart valves, perhaps by masking adhesins.  
Protein A 
Protein A is a surface protein of S aureus which binds immunoglobulin G molecules 
by the Fc region (Fig. 12-3). In serum, bacteria will bind IgG molecules the wrong 
way round by this non-immune mechanism. In principle this will disrupt opsoniza-
tion and phagocytosis. Indeed mutants of S aureus lacking protein A are more effi-
ciently phagocytozed in vitro, and studies with mutants in infection models suggest 
that protein A enhances virulence.  
Leukocidin 
S aureus can express a toxin that specifically acts on polymorphonuclear leukocytes. 
Phagocytosis is an important defense against staphylococcal infection so leukocidin 
should be a virulence factor. This toxin is discussed in more detail in the next sec-
tion. 
Damage to the Host 
S aureus can express several different types of protein toxins which are probably re-
sponsible for symptoms during infections. Some damage the membranes of erythro-
cytes, causing hemolysis; but it is unlikely that hemolysis is relevant in vivo. The 
leukocidin causes membrane damage to leukocytes and is not hemolytic. Systemic 
release of -toxin causes septic shock, while enterotoxins and TSST-1 cause toxic 
shock.  
Membrane Damaging Toxins 
(a) -toxin 
The best characterized and most potent membrane-damaging toxin of S aureus is -
toxin. It is expressed as a monomer that binds to the membrane of susceptible cells. 
Subunits then oligomerize to form hexameric rings with a central pore through which 
cellular contents leak.  
Susceptible cells have a specific receptor for a-toxin which allows low concentra-
tions of toxin to bind, causing small pores through which monovalent cations can 
pass. At higher concentrations, the toxin reacts non-specifically with membrane li-
pids, causing larger pores through which divalent cations and small molecules can 
pass. However, it is doubtful if this is relevant under normal physiological condi-
tions. 
In humans, platelets and monocytes are particularly sensitive to -toxin. They carry 
high affinity sites which allow toxin to bind at concentrations that are physiological-
ly relevant. A complex series of secondary reactions ensue, causing release of eico-
sanoids and cytokines which trigger production of inflammatory mediators. These 
events cause the symptoms of septic shock that occur during severe infections caused 
by S aureus. 
The notion that -toxin is a major virulence factor of S aureus is supported by stud-
ies with the purified toxin in animals and in organ culture. Also, mutants lacking -
toxin are less virulent in a variety of animal infection models.  
 11 
(b) ß-toxin 
ß-toxin is a sphingomyelinase which damages membranes rich in this lipid. The clas-
sical test for ß-toxin is lysis of sheep erythrocytes. The majority of human isolates of 
S aureus do not express ß-toxin. A lysogenic bacteriophage is inserted into the gene 
that encodes the toxin. This phenomenon is called negative phage conversion. Some 
of the phages that inactivate the ß-toxin gene carry the determinant for an enterotoxin 
and staphylokinase (see below). 
In contrast the majority of isolates from bovine mastitis express ß-toxin, suggesting 
that the toxin is important in the pathogenesis of mastitis. This is supported by the 
fact that ß-toxin-deficient mutants have reduced virulence in a mouse model for mas-
titis.  
(c) -toxin 
The -toxin is a very small peptide toxin produced by most strains of S aureus. It is 
also produced by S epidermidis and S lugdunensis. The role of -toxin in disease is 
unknown. 
(d) -toxin and leukocidin 
The -toxin and the leukocidins are two-component protein toxins that damage 
membranes of susceptible cells. The proteins are expressed separately but act togeth-
er to damage membranes. There is no evidence that they form multimers prior to in-
sertion into membranes. The -toxin locus expresses three proteins. The B and C 
components form a leukotoxin with poor hemolytic activity, whereas the A and B 
components are hemolytic and weakly leukotoxic.  
The classical Panton and Valentine (PV) leukocidin is distinct from the leukotoxin 
expressed by the -toxin locus. It has potent leukotoxicity and, in contrast to -toxin, 
is non-hemolytic. Only a small fraction of S aureus isolates (2% in one survey) ex-
press the PV leukocidin, whereas 90% of those isolated from severe dermonecrotic 
lesions express this toxin. This suggests that PV leukocidin is an important factor in 
necrotizing skin infections.  
PV-leukocidin causes dermonecrosis when injected subcutaneously in rabbits. Fur-
thermore, at a concentration below that causing membrane damage, the toxin releas-
es inflammatory mediators from human neutrophils, leading to degranulation. This 
could account for the histology of dermonecrotic infections (vasodilation, infiltration 
and central necrosis).  
Superantigens: enterotoxins and toxic shock syndrome toxin 
S aureus can express two different types of toxin with superantigen activity, entero-
toxins, of which there are six serotypes (A, B, C, D, E and G) and toxic shock syn-
drome toxin (TSST-1). Enterotoxins cause diarrhea and vomiting when ingested and 
are responsible for staphylococcal food poisoning. When expressed systemically, en-
terotoxins can cause toxic shock syndrome (TSS) - indeed enterotoxins B and C 
cause 50% of non-menstrual TSS. TSST-1 is very weakly related to enterotoxins and 
does not have emetic activity. TSST-1 is responsible for 75% of TSS, including all 
menstrual cases. TSS can occur as a sequel to any staphylococcal infection if an en-
terotoxin or TSST-1 is released systemically and the host lacks appropriate neutraliz-
ing antibodies. Tampon-associated TSS is not a true infection, being caused by 
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growth of S aureus in a tampon and absorption of the toxin into the blood stream. 
TSS came to prominence with the introduction of super-absorbent tampons; and alt-
hough the number of such cases has decreased dramatically, they still occur despite 
withdrawal of certain types of tampons from the market.  
Superantigens stimulate T cells non-specifically without normal antigenic recogni-
tion (Figure 12-4). Up to one in five T cells may be activated, whereas only 1 in 
10,000 are stimulated during antigen presentation. Cytokines are released in large 
amounts, causing the symptoms of TSS. Superantigens bind directly to class II major 
histocompatibility complexes of antigen-presenting cells outside the conventional 
antigen-binding grove. This complex recognizes only the Vb element of the T cell 
receptor. Thus any T cell with the appropriate Vb element can be stimulated, where-
as normally antigen specificity is also required in binding.  
 
FIGURE 12-4 Superantigens and the non-specific stimulation of T cells  
Epidermolytic (exfoliative) toxin (ET) 
This toxin causes the scalded skin syndrome in neonates, with widespread blistering 
and loss of the epidermis. There are two antigenically distinct forms of the toxin, 
ETA and ETB. There is evidence that these toxins have protease activity. Both tox-
ins have a sequence similarity with the S aureus serine protease, and the three most 
important amino acids in the active site of the protease are conserved. Furthermore, 
changing the active site of serine to a glycine completely eliminated toxin activity. 
However, ETs do not have discernible proteolytic activity but they do have esterase 
activity. It is not clear how the latter causes epidermal splitting. It is possible that the 
toxins target a very specific protein which is involved in maintaining the integrity of 
the epidermis.  
Other Extracellular Proteins 
Coagulase 
Coagulase is not an enzyme. It is an extracellular protein which binds to prothrombin 
in the host to form a complex called staphylothrombin. The protease activity charac-
teristic of thrombin is activated in the complex, resulting in the conversion of fibrin-
ogen to fibrin. This is the basis of the tube coagulase test, in which a clot is formed 
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in plasma after incubation with the S aureus broth-culture supernatant. Coagulase is 
a traditional marker for identifying S aureus in the clinical microbiology laboratory. 
However, there is no evidence that it is a virulence factor, although it is reasonable to 
speculate that the bacteria could protect themselves from host defenses by causing 
localized clotting. Notably, coagulase deficient mutants have been tested in several 
infection models but no differences from the parent strain were observed.  
There is some confusion in the literature concerning coagulase and clumping factor, 
the fibrinogen-binding determinant on the S aureus cell surface. This is partly due to 
loose terminology, with the clumping factor sometimes being referred to as bound 
coagulase. Also, although coagulase is regarded as an extracellular protein, a small 
fraction is tightly bound on the bacterial cell surface where it can react with pro-
thrombin. Finally, it has recently been shown that the coagulase can bind fibrinogen 
as well as thrombin, at least when it is extracellular. Genetic studies have shown un-
equivocally that coagulase and clumping factor are distinct entities. Specific mutants 
lacking coagulase retain clumping factor activity, while clumping factor mutants ex-
press coagulase normally.  
Staphylokinase 
Many strains of S aureus express a plasminogen activator called staphylokinase. The 
genetic determinant is associated with lysogenic bacteriophages. A complex formed 
between staphylokinase and plasminogen activates plasmin-like proteolytic activity 
which causes dissolution of fibrin clots. The mechanism is identical to streptokinase, 
which is used in medicine to treat patients suffering from coronary thrombosis. As 
with coagulase there is no evidence that staphylokinase is a virulence factor, alt-
hough it seems reasonable to imagine that localized fibrinolysis might aid in bacteri-
al spreading.  
Enzymes 
S aureus can express proteases, a lipase, a deoxyribonuclease (DNase) and a fatty ac-
id modifying enzyme (FAME). The first three probably provide nutrients for the bac-
teria, and it is unlikely that they have anything but a minor role in pathogenesis. 
However, the FAME enzyme may be important in abscesses, where it could modify 
anti-bacterial lipids and prolong bacterial survival. The thermostable DNase is an 
important diagnostic test for identification of S aureus.  
Coagulase Negative Staphylococci 
Staphylococci other than S aureus can cause infections in man. S epidermidis is the 
most important coagulase-negative staphylococcus (CNS) species and is the major 
cause of infections associated with prosthetic devices and catheters. CNS also cause 
peritonitis in patients receiving continuous ambulatory peritoneal dialysis and endo-
carditis in those with prosthetic valves. These infections are not usually nosocomial-
ly acquired. Other species such as S haemolyticus, S warneri, S hominis, S capitis, S 
intermedius, S schleiferi and S simulans are infrequent pathogens. S lugdunesis is a 
newly recognized species. It is probably more pathogenic than are other CNS spe-
cies, with cases of endocarditis and other infections being reported. It is likely that 
the incidence of infections caused by these organisms is underestimated because of 
difficulties in identification. 
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Diagnosis of CNS infections is difficult. Infections are often indolent and chronic 
with few obvious symptoms. This is due to the smaller array of virulence factors and 
toxins compared to those in the case of S aureus. S epidermidis is a skin commensal 
and is one of the most common contaminants of samples sent to the diagnostic labor-
atory, while S lugdunensis is often confused with S aureus. Precise identification of 
CNS species requires the use of expensive test kits, such as the API-Staph. 
In contrast to S aureus, little is known about mechanisms of pathogenesis of S epi-
dermidis infections. Adherence is obviously a crucial step in the initiation of foreign 
body infections. Much research has been done on the interaction between S epider-
midis and plastic material used in implants, and a polysaccharide adhesion (PS/A) 
has been identified. Mutants lacking PS/A are less virulent in an animal model for 
foreign body infection, and immunization with purified PS/A is protective. Bacteria-
plastic interactions are probably important in colonization of catheters through the 
point of entry. However, host proteins are quickly deposited on implants. S epider-
midis does not bind to fibrinogen but most isolates bind fibronectin, albeit less avidly 
than S aureus. However, it is not known if a protein analogous to the fibronectin 
binding protein of S aureus is involved. 
A characteristic of clinical isolates of S epidermidis is the production of "slime." 
This is a controversial topic. Some feel that slime is an in vitro manifestation of the 
ability to form a biofilm in vivo, for example on the surface of a prosthetic device, 
and is thus a virulence marker. In vitro, slime is formed during growth in broth as a 
biofilm on the surface of the growth vessel. The composition of this slime is proba-
bly influenced by the growth medium. One study with defined medium showed that 
the slime was predominantly secreted teichoic acid, a polymer normally found in the 
cell wall of staphylococci. Some polysaccharides in slime from bacteria grown on 
solid medium are derived from the agar.  
Resistance of Staphylococci to Antimicrobial Drugs 
Hospital strains of S aureus are often resistant to many different antibiotics. Indeed 
strains resistant to all clinically useful drugs, apart from the glycopeptides vancomy-
cin and teicoplanin, have been described. The term MRSA refers to methicillin re-
sistance and most methicillin-resistant strains are also multiply resistant. Plasmid-
associated vancomycin resistance has been detected in some enterococci and the re-
sistance determinant has been transferred from enterococci to S aureus in the labora-
tory and may occur naturally. S epidermidis nosocomial isolates are also often re-
sistant to several antibiotics including methicillin. In addition, S aureus expresses re-
sistance to antiseptics and disinfectants, such as quaternary ammonium compounds, 
which may aid its survival in the hospital environment.  
Since the beginning of the antibiotic era S aureus has responded to the introduction 
of new drugs by rapidly acquiring resistance by a variety of genetic mechanisms in-
cluding (1) acquisition of extrachromosomal plasmids or additional genetic infor-
mation in the chromosome via transposons or other types of DNA insertion and (2) 
by mutations in chromosomal genes (Table 12-1).  
Many plasmid-encoded determinants have recently become inserted into the chro-
mosome at a site associated with the methicillin resistance determinant. There may 
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be an advantage to the organism having resistance determinants in the chromosome 
because they will be more stable.There are essentially four mechanisms of resistance 
to antibiotics in bacteria: (1) enzymatic inactivation of the drug, (2) alterations to the 
drug target to prevent binding, (3) accelerated drug efflux to prevent toxic concentra-
tions accumulating in the cell, and (4) a by-pass mechanism whereby an alternative 
drug-resistant version of the target is expressed. 
Future Prospects 
Antimicrobial Drugs  
Ever since the first use of penicillin, S aureus has shown a remarkable ability to 
adapt. Resistance has developed to new drugs within a short time of their introduc-
tion. Some strains are now resistant to most conventional antibiotics. It is worrisome 
that there do not seem to be any new antibiotics on the horizon. Any recent devel-
opments have been modifications to existing drugs.  
The original strategy used by the pharmaceutical industry to find antimicrobial drugs 
was to screen natural products and synthetic chemicals for antimicrobial activity. 
The mechanism of action was then investigated. 
New approaches are being adopted to find the next generation of antimicrobials. Po-
tential targets such as enzymes involved in an essential function (e.g., in cell divi-
sion) are identified based on knowledge of bacterial physiology and metabolism. 
Screening methods are then developed to identify inhibitors of a specific target mol-
ecule. In addition, with detailed molecular knowledge of the target molecule, specific 
inhibitors can be designed.  
Vaccines and New Approaches to Combatting Nosocomial Infections 
No vaccine is currently available to combat staphylococcal infections. There may 
now be a case for considering methods to prevent disease, particularly in hospital-
ized patients. 
Hyperimmune serum from human volunteer donors or humanized monoclonal anti-
bodies directed towards surface components (e.g., capsular polysaccharide or surface 
protein adhesions) could both prevent bacterial adherence and also promote phago-
cytosis of bacterial cells. Indeed a prototype vaccine based on capsular polysaccha-
ride from S aureus has been administered to volunteers to raise hyperimmune serum, 
which could be given to patients in hospital before surgery. A vaccine based on fi-
bronectin binding protein induces protective immunity against mastitis in cattle and 
might also be used as a vaccine in humans.  
When the molecular basis of the interactions between the bacterial surface proteins 
and the host matrix protein ligands are known it might be possible to design com-
pounds that block the interactions and thus prevent bacterial colonization. These 
could be administered systemically or topically.  
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Streptococcus 
General Concepts 
Streptococcus pyogenes, other Streptococci, and Enterococcus 
Clinical Manifestations 
Acute Streptococcus pyogenes infections may take the form of pharyngitis, scarlet 
fever (rash), impetigo, cellulitis, or erysipelas. Invasive infections can result in ne-
crotizing fasciitis, myositis and streptococcal toxic shock syndrome. Patients may 
also develop immune-mediated sequelae such as acute rheumatic fever and acute 
glomerulonephritis. S agalactiae may cause meningitis, neonatal sepsis, and pneu-
monia in neonates; adults may experience vaginitis, puerperal fever, urinary tract in-
fection, skin infection, and endocarditis. Viridans streptococci can cause endocardi-
tis, and Enterococcus is associated with urinary tract and biliary tract infections. An-
aerobic streptococci participate in mixed infections of the abdomen, pelvis, brain, 
and lungs. 
Structure 
Streptococci are Gram-positive, nonmotile, nonsporeforming, catalase-negative cocci 
that occur in pairs or chains. Older cultures may lose their Gram-positive character. 
Most streptococci are facultative anaerobes, and some are obligate (strict) anaerobes. 
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Most require enriched media (blood agar). Group A streptococci have a hyaluronic 
acid capsule. 
Classification and Antigenic Types 
Streptococci are classified on the basis of colony morphology, hemolysis, biochemi-
cal reactions, and (most definitively) serologic specificity. They are divided into 
three groups by the type of hemolysis on blood agar: b-hemolytic (clear, complete 
lysis of red cells), a hemolytic (incomplete, green hemolysis), and g hemolytic (no 
hemolysis). Serologic grouping is based on antigenic differences in cell wall carbo-
hydrates (groups A to V), in cell wall pili-associated protein, and in the polysaccha-
ride capsule in group B streptococci. 
Pathogenesis 
Streptococci are members of the normal flora. Virulence factors of group A strepto-
cocci include (1) M protein and lipoteichoic acid for attachment; (2) a hyaluronic ac-
id capsule that inhibits phagocytosis; (3) other extracellular products, such as pyro-
genic (erythrogenic) toxin, which causes the rash of scarlet fever; and (4) streptoki-
nase, streptodornase (DNase B), and streptolysins. Some strains are nephritogenic. 
Immune-mediated sequelae do not reflect dissemination of bacteria. Nongroup A 
strains have no defined virulence factors. 
Host Defenses 
Antibody to M protein gives type-specific immunity to group A streptococci. Anti-
body to erythrogenic toxin prevents the rash of scarlet fever. Immune mechanisms 
are important in the pathogenesis of acute rheumatic fever. Maternal IgG protects the 
neonate against group B streptococci. 
Epidemiology 
Group A ß-hemolytic streptococci are spread by respiratory secretions and fomites. 
The incidence of both respiratory and skin infections peaks in childhood. Infection 
can be transmitted by asymptomatic carriers. Acute rheumatic fever was previously 
common among the poor; susceptibility may be partly genetic. Group B streptococci 
are common in the normal vaginal flora and occasionally cause invasive neonatal in-
fection. 
Diagnosis 
Diagnosis is based on cultures from clinical specimens. Serologic methods can detect 
group A or B antigen; definitive antigen identification is by the precipitin test. Baci-
tracin sensitivity presumptively differentiates group A from other b-hemolytic strep-
tococci (B, C, G); group B streptococci typically show hippurate hydrolysis; group D 
is differentiated from other viridans streptococci by bile solubility and optochin sen-
sitivity. Acute glomerulonephritis and acute rheumatic fever are identified by anti-
streptococcal antibody titers. In addition, acute rheumatic fever is diagnosed by clin-
ical criteria. 
Control 
Prompt penicillin treatment of streptococcal pharyngitis reduces the antigenic stimu-
lus and therefore prevents glomerulonephritis and acute rheumatic fever. Vancomy-
cin resistance among the enterococci is an emerging microbial threat. Vaccines are 
under development. 
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Streptococcus pneumoniae 
Clinical Manifestations 
S pneumoniae causes pneumonia, meningitis, and sometimes occult bacteremia. 
Structure 
Pneumococci are lancet-shaped, catalase-negative, capsule-forming, -hemolytic 
cocci or diplococci. Autolysis is enhanced by adding bile salts. 
Classification and Antigenic Types 
There are more than 85 antigenic types of S pneumoniae, which are determined by 
capsule antigens. There is no Lancefield group antigen. 
Pathogenesis 
S pneumoniae is a normal member of the respiratory tract flora; invasion results in 
pneumonia. The best defined virulence factor is the polysaccharide capsule, which 
protects the bacterium against phagocytosis. 
Host Defenses 
Protection against infection depends on a normal mucociliary barrier and intact 
phagocytic and T-independent immune responses. Type-specific anti-capsule anti-
body is protective. 
Epidemiology 
Pneumococcal pneumonia is most common in elderly, debilitated, or immunosup-
pressed individuals. The disease often sets in after a preceding viral infection damag-
es the respiratory ciliated epithelium; incidence therefore peaks in the winter. 
Diagnosis 
Diagnosis is based on a sputum Gram stain and culture; blood or cerebrospinal fluid 
may also be cultured. Capsular antigen can be detected serologically. Pneumococci 
are distinguished from viridans streptococci by the quellung (capsular swelling) reac-
tion, bile solubility, and optochin inhibition. 
Control 
Treatment is usually with penicillin. However, strains resistant to penicillin and mul-
tiple antibiotics are rapidly emerging. A vaccine is available. 
INTRODUCTION 
The genus Streptococcus, a heterogeneous group of Gram-positive bacteria, has 
broad significance in medicine and industry. Various streptococci are important eco-
logically as part of the normal microbial flora of animals and humans; some can also 
cause diseases that range from subacute to acute or even chronic. Among the signifi-
cant human diseases attributable to streptococci are scarlet fever, rheumatic heart 
disease, glomerulonephritis, and pneumococcal pneumonia. Streptococci are essen-
tial in industrial and dairy processes and as indicators of pollution. 
The nomenclature for streptococci, especially the nomenclature in medical use, has 
been based largely on serogroup identification of cell wall components rather than on 
species names. For several decades, interest has focused on two major species that 
cause severe infections: S pyogenes (group A streptococci) and S pneumoniae 
(pneumococci). In 1984, two members were assigned a new genus - the group D en-
terococcal species (which account for 98% of human enterococcal infections) be-
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came Enterococcus faecalis (the majority of human clinical isolates) and E faecium 
(associated with a remarkable capacity for antibiotic resistance). 
In recent years, increasing attention has been given to other streptococcal species, 
partly because innovations in serogrouping methods have led to advances in under-
standing the pathogenetic and epidemiologic significance of these species. A variety 
of cell-associated and extracellular products are produced by streptococci, but their 
cause-effect relationship with pathogenesis has not been defined. Some of the other 
medically important streptococci are S agalactiae (group B), an etiologic agent of 
neonatal disease; E faecalis (group D), a major cause of endocarditis, and the viri-
dans streptococci. Particularly for the viridans streptococci, taxonomy and nomen-
clature are not yet fully reliable or consistent. Important members of the viridans 
streptococci, normal commensals, include S mutans and S sanguis (involved in den-
tal caries), S mitis (associated with bacteremia, meningitis, periodontal disease and 
pneumonia), and "S milleri" (associated with suppurative infections in children and 
adults). There remains persistent taxonomic confusion regarding "S milleri." These 
and other streptococci of medical importance are listed in Table 13-1 by serogroup 
designation, normal ecologic niche, and associated disease. 
Clinical Manifestations 
In humans, diseases associated with the streptococci occur chiefly in the respiratory 
tract, bloodstream, or as skin infections. Human disease is most commonly associat-
ed with Group A streptococci. Acute group A streptococcal disease is most often a 
respiratory infection (pharyngitis or tonsillitis) or a skin infection (pyoderma). Also 
medically significant are the late immunologic sequelae, not directly attributable to 
dissemination of bacteria, of group A infections (rheumatic fever following respira-
tory infection and glomerulonephritis following respiratory or skin infection) which 
remain a major worldwide health concern. Much effort is being directed toward clar-
ifying the risk and mechanisms of these sequelae and identifying rheumatogenic and 
nephritogenic strains. S pneumoniae remains a primary cause of serious focal and 
systemic infections, the first most common cause of community acquired pneumonia 
in the United States and of fatal bacterial pneumonia in developing countries. Hem-
orrhagic shock in association with S pneumoniae sepsis in previously healthy chil-
dren has been reported recently in the United States. Of major biologic importance is 
a renewed interest in safe and effective streptococcal vaccines. 
Structure 
Both S pyogenes and S pneumoniae are Gram-positive cocci, nonmotile, and non-
sporulating; they usually require complex culture media. S pyogenes characteristical-
ly is a round-to-ovoid coccus 0.6-1.0 µm in diameter (Fig. 13-1). They divide in one 
plane and thus occur in pairs, or (especially in liquid media or clinical material) in 
chains of varying lengths. S pneumoniae appears as a 0.5-1.25 µm diplococcus, typi-
cally described as lancet-shaped but sometimes difficult to distinguish morphologi-
cally from other streptococci. Streptococcal cultures older than the logarithmic 
phase, which is the most active growth period of a culture, may lose their Gram-
positive staining characteristics. 
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FIGURE 13-1 Morphology of the streptococci in comparison with staphylococ-
ci. Streptococci divide in a single plane and tend not to separate, causing chain for-
mation. Capsules are antiphagocytic. 
Unlike Staphylococcus (Chapter 12), all streptococci lack the enzyme catalase. Most 
are facultative anaerobes but some are obligate anaerobes. Streptococci often have a 
mucoid or smooth colonial morphology, and S pneumoniae colonies exhibit a central 
depression caused by rapid partial autolysis. As S pneumoniae colonies age, viability 
is lost during fermentative growth in the absence of catalase and peroxidase because 
of the accumulation of peroxide. Some group B and D streptococci produce pigment. 
Recently, nutritionally deficient streptococci (also known as wall-deficient, L form, 
thiol-requiring, satelliting, or pyridoxal-dependent) have been recovered from a vari-
ety of clinical sources, including blood, abscesses, and oral and urethral ulcers. 
These variants demonstrate bizarre pleomorphism microscopically and do not grow 
on routine subculture. 
Classification, Antigenic Types and Extracellular Growth Products 
The type of hemolytic reaction displayed on blood agar has long been used to classi-
fy the streptococci. -Hemolysis is associated with complete lysis of red cells sur-
rounding the colony, whereas -hemolysis is a partial or "greening" hemolysis asso-
ciated with reduction of red cell hemoglobin. Nonhemolytic colonies have been 
termed -hemolytic. Hemolysis is affected by the species and age of red cells as well 
as by other properties of the base medium. Use of the hemolytic reaction in classifi-
cation is not completely satisfactory. Some group A streptococci appear nonhemolyt-
ic; group B can manifest -, -, or even -hemolysis; most S pneumoniae are -
hemolytic but can cause ß-hemolysis during anaerobic incubation. The viridans 
group, although linked by the property of -hemolysis, is actually an extremely di-
 21 
verse group of organisms that does not usually react with Lancefield grouping sera. 
The taxonomy and biochemical and genetic relationships of these organisms contin-
ue to be. 
Antigenic Types 
The cell wall structure of group A streptococci is among the most studied of any bac-
teria (Fig. 13-2). The cell wall is composed of repeating units of N-
acetylglucosamine and N-acetylmuramic acid, the standard peptidoglycan. For dec-
ades, the definitive identification of streptococci has rested on the serologic reactivi-
ty of cell wall polysaccharide antigens originally delineated by Rebecca Lancefield. 
Eighteen group-specific antigens were established. The group A polysaccharide is a 
polymer of N-acetylglucosamine and rhamnose. Some group antigens are shared by 
more than one species; no Lancefield group antigen has been identified for S pneu-
moniae or for some other - or -streptococci. With advances in serologic methods, 
other streptococci have been shown to possess several established group antigens. 
 
FIGURE 13-2 Cell surface structure of S pyogenes and extracellular substances. 
The cell wall also consists of several structural proteins (Figure 13-2). In group A 
streptococci, the R and T proteins may serve as epidemiologic markers, but the M 
proteins are clearly virulence factors associated with resistance to phagocytosis. 
More than 50 types of S pyogenes M proteins have been identified on the basis of an-
tigenic specificity. Both the M proteins and lipoteichoic acid are supported externally 
to the cell wall on fimbriae, and the lipoteichoic acid, in particular, appears to medi-
ate bacterial attachment to host epithelial cells. M protein, peptidoglycan, N-
acetylglucosamine, and group-specific carbohydrate portions of the cell wall have 
antigenic epitopes similar in size and charge to those of mammalian muscle and con-
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nective tissue. Recently emerging strains of increased virulence are distinctly mu-
coid, rich in M protein and highly encapsulated. 
The capsule of S pyogenes is composed of hyaluronic acid, which is chemically simi-
lar to that of host connective tissue and is therefore nonantigenic. In contrast, the an-
tigenically reactive and chemically distinct capsular polysaccharide of S pneumoniae 
allows the single species to be separated into more than 80 serotypes. The antiphago-
cytic S pneumoniae capsule is the most clearly understood virulence factor of these 
organisms; type 3 S pneumoniae, which produces copious quantities of capsular ma-
terial, are the most virulent. Unencapsulated S pneumoniae are avirulent. The poly-
saccharide capsule in S agalactiae allows differentiation into types Ia, Ib, Ic, II and 
III. 
Finally, the cytoplasmic membrane of S pyogenes has antigens similar to those of 
human cardiac, skeletal, and smooth muscle, heart valve fibroblasts, and neuronal 
tissues, resulting in a molecular mimicry. 
Extracellular Growth Products 
The importance of the interaction of streptococcal products with mammalian blood 
and tissue components is becoming widely recognized. The soluble extracellular 
growth products or toxins of the streptococci, especially of S pyogenes (see Fig. 13-
2), have been studied intensely. Streptolysin S is an oxygen-stable cytolysin; Strep-
tolysin O is a reversibly oxygen-labile cytolysin. Both are leukotoxic, as is NADase. 
Hyaluronidase (spreading factor) can digest host connective tissue hyaluronic acid as 
well as the organism's own capsule. Streptokinases participate in fibrin lysis. Strep-
todornases A-D possess deoxyribonuclease activity; B and D possess ribonuclease 
activity as well. Protease activity similar to that in Staph aureus has been shown in 
strains causing soft tissue necrosis or toxic shock syndrome. This large repertoire of 
products may be important in the pathogenesis of S pyogenes by enhancing viru-
lence; however, antibodies to these products appear not to protect the host even 
though they have diagnostic importance. 
Three pyrogenic exotoxins of S pyogenes (SPEs) are recognized: types A, B, C. 
These toxins act as superantigens by a mechanism similar to those described for 
staphylococci, not requiring processing by antigen presenting cells. Rather, they 
stimulate T cells by binding class II MHC molecules directly and nonspecifically. 
With superantigens about 20% of T cells may be stimulated (vs 1/10,000 T cells 
stimulated by conventional antigens) resulting in massive detrimental cytokine re-
lease. When S pyogenes is lysogenized by certain bacteriophages, the SPEs A or C 
are produced; nonlysogenized strains are atoxic. SPE B is encoded by the bacterial 
chromosome. Re-emergence in the late 1980's of these exotoxin-producing strains 
has been associated with a toxic shock-like syndrome similar in pathogenesis and 
manifestation to staphylococcal toxic shock syndrome (Ch.12) and other forms of 
invasive disease associated with severe tissue destruction. SPE's have also been iden-
tified from non group A streptococci (groups B, C, F. G) in association with the toxic 
shock-like syndrome. 
Virulence factors in the other streptococcal species, including the enterococci, are 
less well identified. In group B streptococci, carbohydrate surface antigens associat-
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ed with antiphagocytosis have been identified, as has neuraminidase, which may 
play a role in pathogenesis. Among the viridans streptococci, production of the ex-
opolysaccharide (glycocalyx) is associated with the ability to adhere to the cardiac 
valves and to form vegetations on the valve leaflets. 
Pathogenesis 
Streptococcus pyogenes and Streptococcus pneumoniae 
Streptococci vary widely in pathogenic potential. Despite the remarkable array of 
cell-associated and extracellular products previously described (Fig.13- 2), no clear 
scheme of pathogenesis has been worked out. S pneumoniae and, to a lesser extent, S 
pyogenes are part of the normal human nasopharyngeal flora. Their numbers are usu-
ally limited by competition from the nasopharyngeal microbial ecosystem and by 
nonspecific host defense mechanisms, but failure of these mechanisms can result in 
disease. More often disease results from the acquisition of a new strain following al-
teration of the normal flora. S pyogenes causes inflammatory purulent lesions at the 
portal of entry, often the upper respiratory tract or the skin. Some strains of strepto-
cocci show a predilection for the respiratory tract; others, for the skin. Generally, 
streptococcal isolates from the pharynx and respiratory tract do not cause skin infec-
tions. 
Invasion of other portions of the upper or lower respiratory tracts results in infections 
of the middle ear (otitis media), sinuses (sinusitis), or lungs (pneumonia). In addi-
tion, meningitis can occur by direct extension of infection from the middle ear or si-
nuses to the meninges or by way of bloodstream invasion from the pulmonary focus. 
Bacteremia can also result in infection of bones (osteomyelitis) or joints (arthritis). 
S pyogenes (a group A streptococcus) is the leading cause of uncomplicated bacterial 
pharyngitis and tonsillitis (Fig. 13-3). Indeed, only group A streptococci are sought 
routinely in cases of pharyngitis, although groups B, C, and G are sometimes identi-
fied. S pyogenes infections can also result in sinusitis, otitis, mastoiditis, pneumonia 
with empyema, joint or bone infections, necrotizing fasciitis or myositis, and, more 
infrequently, in meningitis or endocarditis. S pyogenes infections of the skin can be 
superficial (impetigo) or deep (cellulitis). Although scarlet fever was formerly a se-
vere complication of streptococcal infection, because of antibiotic therapy it is now 
little more than streptococcal pharyngitis accompanied by rash. Similarly, erysipelas, 
a form of cellulitis accompanied by fever and systemic toxicity, is less common to-
day. There has, however, been an apparent recent increase in variety, severity and 
sequelae of S pyogenes infections. Because cases of streptococcal disease are not re-
ported to national disease clearinghouses in the US, absolute numbers are not availa-
ble. However, the recent resurgence of severe invasive infections has prompted de-
scriptions of "flesh eating bacteria" in the news media. There has been no major 
change in susceptibility of S pyogenes to commonly used antibiotics but rather in the 
strain variations described above (antigenic types and extracellular growth products). 
However, a complete explanation for the decline and resurgence is not yet available. 
 24 
 
FIGURE 13-3 Pathogenesis of S pyogenes infections. 
The capsule of S pneumoniae renders it resistant to phagocytosis. The ability to 
evade this important host defense mechanism allows S pneumoniae to survive, mul-
tiply, and spread to various organs (Fig.13-4). The cell wall of S pneumoniae con-
tains teichoic acid. The inflammatory response induced by Gram-positive cell walls 
differs from that induced by the endotoxin of Gram-negative organisms, but does in-
clude recruitment of polymorphonuclear neutrophils, changes in permeability and 
perfusion, cytokine release, and stimulation of platelet-activating factor. The role of 
other S pneumoniae moieties in virulence is less clear: protein A, pneumolysin, and 
peptide permeases. S pneumoniae is the leading cause of bacterial pneumonia be-
yond the neonatal period. Pleural effusion is the most common and empyema (pus in 
the pleural space) one of the most serious complications of S pneumoniae. This or-
ganism is also the most common cause of sinusitis, acute bacterial otitis media, and 
conjunctivitis beyond early childhood. Dissemination from a respiratory focus results 
in serious disease: outpatient bacteremia in children, meningitis, occasionally acute 
septic arthritis and bone infections in patients with sickle cell disease and, more rare-
ly, peritonitis (especially in patients with nephrotic syndrome) or endocarditis. 
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FIGURE 13-4 Pathogenesis of S pneumoniae infections. 
Postinfectious Sequelae 
Infection with S pyogenes (but not S pneumoniae) can give rise to serious nonsuppu-
rative sequelae: acute rheumatic fever and acute glomerulonephritis. These sequelae 
begin 1-3 weeks after the acute illness, a latent period consistent with an immune-
mediated rather than pathogen-disseminated etiology. Whether all S pyogenes strains 
are rheumatogenic is still controversial; however, clearly not all are nephritogenic. 
These differences in pathogenic potential are not yet understood. 
Acute rheumatic fever is a sequela only of pharyngeal infections, but acute glomeru-
lonephritis can follow infections of the pharynx or the skin. Although there is no ad-
equate explanation for the precise pathogenesis of acute rheumatic fever or for its 
failure to occur after streptococcal pyoderma, an abnormal or enhanced immune re-
sponse seems essential. Also, persistence of the organism, due perhaps in part to the 
greater avidity with which the organism adheres to host pharyngeal cells, is associat-
ed with an increased likelihood of rheumatic fever. Acute glomerulonephritis results 
from deposition of antigen-antibody-complement complexes on the basement mem-
brane of kidney glomeruli. The antigen may be streptococcal in origin or it may be a 
host tissue species with antigenic determinants similar to those of streptococcal anti-
gen (cross-reactive epitopes for endocardium, sarcolemma, vascular smooth muscle). 
In the United States, the incidence of acute rheumatic fever had decreased dramati-
cally. Although several areas reported a resurgence in cases in the late 1980's, subse-
quently, a slow, steady decline continued. Acute rheumatic fever can result in per-
manent damage to the heart valves. Less than 1% of sporadic streptococcal pharyngi-
tis infections result in acute rheumatic fever; however, recurrences are common, and 
life-long antibiotic prophylaxis is recommended following a single case. The inci-
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dence of acute glomerulonephritis in the United States is more variable, perhaps due 
to cycling of nephritogenic strains, but appears to be decreasing; recurrences are un-
common, and prophylaxis following an initial attack is unnecessary. 
Other Streptococcal Species  
Lancefield Group Streptococci 
Streptococcal groups B, C, and G initially were recognized as animal pathogens (see 
Table 13-1) and as part of the normal human flora. Recently, the pathogenic poten-
tial for humans of some of these non-group-A streptococci has been clarified. Group 
B streptococci, a major cause of bovine mastitis, are a leading cause of neonatal sep-
ticemia and meningitis, accounting for a significant changing clinical spectrum of 
diseases in both pregnant women and their infants. Mortality rates in full-term in-
fants range from 2-8% but in pre-term infants are approximately 30%. Early-onset 
neonatal disease (associated with sepsis, meningitis and pneumonia at 6d life) is 
thought to be transmitted vertically from the mother; late-onset (from 7d to 3 mos 
age) meningitis is acquired horizontally, in some instances as a nosocomial infection. 
Group B organisms also have been associated with pneumonia in elderly patients. 
They are part of the normal oral and vaginal flora and have also been isolated in 
adult urinary tract infection, chorioamnionitis and endometritis, skin and soft tissue 
infection, osteomyelitis, meningitis, bacteremia without focus, and endocarditis. In-
fection in patients with HIV can occur at any age.  
Streptococci of groups C and G are associated with mild, as well as severe human 
disease. None of these groups has been implicated in acute rheumatic fever or acute 
glomerulonephritis. Group D streptococci are important etiologic agents of urinary 
tract infections and infections associated with biliary tract procedures, as well as cas-
es of disseminated infection, bacteremia, and endocarditis. Streptococcus bovis bac-
teremia has been recognized more often in cases of bowel disease.  
Group F streptococci are associated with abscess formation and purulent disease. 
Group R streptococci, well-documented causes of meningitis and septicemia in pigs, 
also pose a serious health hazard to workers in the pork industry. 
Viridans Streptococci 
The biochemically and antigenically diverse group of organisms classified as viri-
dans streptococci, as well as other non-groupable streptococci of the oral and gastro-
intestinal cavities and urogenital tract, include important etiologic agents of bacterial 
endocarditis. Dental manipulation and dental disease with the associated transient 
bacteremia are the most common predisposing factors in bacterial endocarditis, espe-
cially if heart valves have been damaged by previous rheumatic fever or by congeni-
tal cyanotic heart disease. S mutans and S sanguis are odontopathogens responsible 
for the formation of dental plaque, the dense adhesive microbial mass that colonizes 
teeth and is linked to caries and other human oral disease (see Ch. 99 ). S mutans is 
the more cariogenic of the two species, and its virulence is directly related to its abil-
ity to synthesize glucan from fermentable carbohydrates as well as to modify glucan 
in promoting increased adhesiveness. 
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Anaerobes 
Like their aerobic counterparts, anaerobic streptococci are part of the normal flora, 
particularly of the mouth and intestinal tract; they are also part of the normal flora of 
the upper respiratory and genital tracts and the skin. These anaerobic organisms are 
linked to a wide variety of serious mixed infections of the female genital tract as well 
as to brain, pulmonary, and abdominal abscesses. 
Host Defenses 
The streptococci are part of the endogenous microbial flora of the nasopharynx. Dis-
ease may result from circumvention of the normal specific or nonspecific host de-
fense mechanisms. More often, both S pyogenes and S pneumoniae are exogenous 
secondary invaders following viral disease or disturbances in the normal bacterial 
flora. 
In the normal host, nonspecific defense mechanisms prevent organisms from pene-
trating beyond the superficial epithelium of the upper respiratory tract. These mech-
anisms include mucociliary movement and the cough, sneeze and epiglottal reflexes. 
The host phagocytic system is a second line of defense against pathogens.  
Organisms can be opsonized by activation of the classical or alternate complement 
pathway or by specific immunoglobulin binding.  
The capsules of both S pyogenes and S pneumoniae allow the organisms to evade op-
sonization. The hyaluronic acid outer surface of S pyogenes is only weakly antigenic; 
however, protective immunity results from the development of type-specific anti-
body to the M protein of the fimbriae, which protrude from the cell wall through the 
capsular structure. This antibody, which follows respiratory and skin infections, is 
persistent. Presumably, IgA in the respiratory secretions and serum IgG are the im-
portant protective antibody classes. S pyogenes is rapidly killed following phagocy-
tosis enhanced by specific antibody. Prompt, effective antibiotic treatment of strep-
tococcal infections may preclude development of this persistent antibody. Evidence 
has shown that antibody to the erythrogenic toxin involved in scarlet fever is also 
long lasting. This is the basis of the Dick test, an in vivo skin test, rarely used today, 
which measures host antitoxin. The capsular polysaccharides of S pneumoniae are 
highly antigenic and type-specific. Type-specific anticapsular antibodies to these T-
independent antigens result in effective opsonization and host recovery. In untreated 
S pneumoniae infections, recovery clearly is due to opsonizing antibody. Even when 
adequate and appropriate antibiotic therapy is given, opsonizing antibody probably 
contributes significantly to recovery from pneumococcal disease. The normal host is 
somewhat resistant to S pneumoniae disease, but compromised hosts of several types 
are highly susceptible to serious infections: alcoholics, the semicomatose, very 
young, and very old individuals, patients who have undergone splenectomy, and pa-
tients with underlying diseases (specifically, chronic cardiac, pulmonary, or renal 
disease; sickle cell anemia; leukopenia; multiple myeloma; cirrhosis; and diabetes). 
Cross-reactive antigens, especially of S pyogenes and various mammalian tissues, 
help explain the autoimmune responses that develop following some infections. The 
level of humoral response to infection with S pyogenes is greater in patients with 
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rheumatic fever than in patients with uncomplicated pharyngitis. In addition, cell-
mediated immunity may play a significant role in acute rheumatic fever. 
Neonatal susceptibility to group B streptococci may result from immature neonatal 
phagocytic function, humoral immunity, or cell-mediated immunity, or from lack of 
passively acquired maternal antibody. 
Evidence from the Rhesus monkey animal model in dental research shows that IgG 
may be a more important antibody class than IgA or IgM in protection against caries. 
Part of the reason may be that IgG is the antibody isotype most efficient at enhancing 
phagocytosis of S mutans. Cell-mediated immunity appears to participate in the pro-
tective host response against caries. 
Epidemiology 
The streptococci are widely distributed in nature and frequently form part of the 
normal human flora (see Table 29-1). Approximately 5-15% of humans carry S py-
ogenes or S agalactiae in the nasopharynx. S pneumoniae infects humans exclusive-
ly, and no reservoir is found in nature. The carrier rate of S pneumoniae in the nor-
mal human nasopharynx is 20-40%. 
All ages, races, and sexes are susceptible to streptococcal disease. Because S pneu-
moniae is a particularly labile organism, sensitive to heat, cold, and drying, horizon-
tal transmission requires close person-to-person contact. Infection is more likely at 
the extremes of life (<2 yr, > 65 yr), when host resistance is reduced, as described in 
the preceding section, or after the introduction of a more virulent strain. In the Unit-
ed States, pneumococcal disease is most prevalent during winter, coinciding with in-
creased rates of acquisition but not necessarily of carriage. Alaskan natives have 
higher rates of invasive pneumococcal disease than do other American populations. 
The reason for this is unclear.  
The incidence of respiratory disease attributed to S pyogenes peaks at about 6 years 
of age, and then again at 13 years of age, and is most common during late winter and 
early spring in temperate climates. Skin infections are more common among pre-
school-age children, and are most prevalent in late summer and early fall in temper-
ate climates (when hot, humid weather prevails), and at all times in tropical climates. 
S pyogenes is spread by respiratory droplets or by contact with fomites used by the 
index individual, either patient or carrier. Skin infections often follow minor skin ir-
ritation, such as insect bites. There are occasional reports of streptococcal disease 
traced to rectal carriers, and of food-borne and vector-born outbreaks. In children, 
invasive disease with S pyogenes may follow varicella, or be associated with burns 
or malignancy; in adults with surgical or nonsurgical wounds or underlying medical 
problems, i.e., diabetes, cirrhosis, underlying peripheral vascular disease, or malig-
nancy. 
The world prevalence of the serious late sequelae of S pyogenes infections (acute 
rheumatic fever and acute glomerulonephritis) has shifted from temperate to tropical 
climates. In particular, acute rheumatic fever had ceased to be a major health concern 
in the US., despite no concomitant decline in group A streptococcal pharyngitis. 
These diseases previously affected persons with a low standard of living and limited 
access to medical care. Since 1985, there have been scattered outbreaks of acute 
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rheumatic fever in some regions of the United States. Temporal and geographic clus-
tering provides further evidence for "rheumatogenic" strains. Whether ethnic or ra-
cially determined factors affect this shift is not known. 
Other streptococcal groups show striking epidemiologic features. An increasing 
prevalence of non-group-A as compared to group A streptococci in throats has been 
reported. Studies of the vaginal flora among women of child-bearing age show a S 
agalactiae carrier rate of 15-40%. Vertical transmission of the organisms to neonates 
of vaginally infected mothers ranges from 40-73%, but the incidence of neonates 
with disease (in contrast to colonized, healthy neonates) is low, 1-2%. S suis has 
been linked to meningitis among meat handlers. Isolation of S milleri or S bovis from 
the bloodstream should raise suspicion of immunosuppression or underlying disease 
visceral abscess formation or other bowel disease (including colon carcinoma).  
In the United States, enterococci are the second most common nosocomial patho-
genes associated with both endogenous colonization and patient-to-patient spread. A 
wide variety of infections results, especially urinary tract and surgical wound infec-
tions, with a marked propensity for antibiotic resistance. The widespread usage of 
newer cephalosporins, which have poor activity against enterococci, allows "break 
through" of enterococci as clinically significant isolates, the development of re-
sistance in areas of heavy antibiotic use, and a selective advantage to these organ-
isms. 
Diagnosis 
Clinical 
It is not usually possible to diagnose streptococcal pharyngitis or tonsillitis on clini-
cal grounds alone. Accurate differentiation from viral pharyngitis is difficult even for 
the experienced clinician, and therefore the use of bacteriologic methods is essential. 
However, distinguishing acute streptococcal pharyngitis from the carrier state may 
be difficult. When documented streptococcal pharyngitis is accompanied by an ery-
thematous punctiform rash (Fig.13-4), the diagnosis of scarlet fever can be made. 
With streptococcal toxic shock syndrome, unlike staphylococcal toxic shock syn-
drome where the organism is elusive, there is often a focal infection or bacteremia. 
Criteria for diagnosis of streptococcal toxic shock syndrome include hypotension and 
shock, isolation of S pyogenes, as well as 2 or more of the following: ARDS, renal 
impairment, liver abnormality, coagulopathy, rash with desquamating soft tissue ne-
crosis. The invasive, potentially fatal S pyogenes infections require early recognition, 
definitive diagnosis, and early aggressive treatment.  
Rheumatic fever is a late sequela of pharyngitis and is marked by fever, polyarthritis, 
and carditis. A combination of clinical and laboratory criteria (Table 13-2) is used in 
the diagnosis of acute rheumatic fever. Since the original Jones criteria were pub-
lished in 1944, these have been modified (1955), revised (1965, 1984) and updated 
(1992). The other late sequela, acute glomerulonephritis, is preceded by pharyngitis 
or pyoderma; is characterized by fever, blood in the urine (hematuria), and edema; 
and is sometimes accompanied by hypertension and elevated blood urea nitrogen 
(azotemia). Pneumococcal pneumonia is a life-threatening disease, often character-
ized by edema and rapid lobar consolidation. 
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Specimens For Direct Examination And Culture 
S pyogenes is usually isolated from throat cultures. In cases of cellulitis or erysipelas 
thought to be caused by S pyogenes, aspirates obtained from the advancing edge of 
the lesion may be diagnostic. S pneumoniae is usually isolated from sputum or 
blood. Precise streptococcal identification is based on the Gram stain and on bio-
chemical properties, as well as on serologic characteristics when group antigens are 
present.  
Identification 
Hemolysis should not be used as a stringent identification criterion. Bacitracin sus-
ceptibility is a widely used screening method for presumptive identification of S py-
ogenes; however, some S pyogenes are resistant to bacitracin (up to 10%) and some 
group C and G streptococci (about 3-5%) are susceptible to bacitracin. Some of the 
group B streptococci also may be bacitracin sensitive, but are presumptively identi-
fied by their properties of hippurate hydrolysis and CAMP positivity. S pneumoniae 
can be separated from other a-hemolytic streptococci on the basis of sensitivity to 
surfactants, such as bile or optochin (ethylhydrocupreine hydrochloride). These 
agents activate autolytic enzymes in the organisms that hydrolyze peptidoglycan. 
In many instances, presumptive identification is not carried further. Serologic group-
ing has not been performed as often as it might be because of the lack of available 
methods and the practical constraints of time and cost; however, only serologic 
methods, provide definitive identification of the streptococci. The Lancefield capil-
lary precipitation test is the classical serologic method. S pneumoniae, which lacks a 
demonstrable group antigen by the Lancefield test, is conventionally identified by 
the quellung or capsular swelling test that employs type-specific anticapsular anti-
body. Inspection of Gram-stained sputum remains a reliable predictor for initial anti-
biotic therapy in community-acquired pneumonia. 
New methods for serogrouping that show sensitivity and specificity now are being 
explored. Organisms from throat swabs, incubated for only a few hours in broth, can 
be examined for the presence of S pyogenes using the direct fluorescent antibody or 
enzyme-linked immunosorbent technique. Additional rapid antigen detection sys-
tems for the group carbohydrate have become increasingly popular. However, the 
sensitivity (70-90%) of these currently available rapid tests for group A streptococcal 
carbohydrate does not allow exclusion of streptococcal pharyngitis without conven-
tional throat culture (sensitivity of a single throat culture is 90-99%). A third genera-
tion assay, the optical immunoassay, is currently being evaluated. S pneumoniae can 
be identified rapidly by counterimmuno-electrophoresis, a modification of the gel 
precipitin method. The coagglutination test is a more sensitive modification of the 
conventional direct bacterial agglutination test. The Fc portion of group-specific an-
tibody binds to the protein A of dead staphylococci, leaving the Fab portion free to 
react with specific streptococcal antigen. The attachment of antibody to other carrier 
particles in suspension (for example, latex) also is used. The fact that whole strepto-
coccal cells can be used in recently developed methods circumvents the difficulties 
involved in extracting components that retain appropriate antigenic reactivity. These 
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newer serogrouping methods should make it more practical to identify not only b-
hemolytic isolates from the blood or normally sterile sites, but also a-and nonhemo-
lytic strains. It has become increasingly important to identify more of these strains to 
avoid simply misclassifying them as contaminants. Such information will expand our 
understanding of the importance of non-group-A streptococci. 
Serologic Titers 
Antibodies to some of the extracellular growth products of the streptococci are not 
protective but can be used in diagnosis. The antistreptolysin O (ASO) titer which 
peak 2-4 wks after acute infection and anti-NADase titers (which peaks 6-8 weeks 
after acute infection) are more commonly elevated after pharyngeal infections than 
after skin infections. In contrast, antihyaluronidase is elevated after skin infections, 
and anti-DNase B rises after both pharyngeal and skin infections. Titers observed 
during late sequelae (acute rheumatic fever and acute glomerulonephritis) reflect the 
site of primary infection. Although it is not as well known as the ASO test, the anti-
DNase B test appears superior because high-titer antibody is detected following skin 
and pharyngeal infections and during the late sequelae. Those titers should be inter-
preted in terms of the age of the patient and geographic locale. 
Although not used in diagnosis, bacteriocin production and phage typing of strepto-
cocci are employed in research and epidemiologic studies. 
Control 
Antibiotic Treatment 
Penicillin remains the drug of choice for S pyogenes. It is safe, inexpensive, and of 
narrow spectrum, and there is no direct or indirect evidence of loss of efficacy. Prior 
to the 1990's, S pneumoniae was also uniformly sensitive to penicillin but a recent 
abrupt shift in the usefulness of penicillin has occurred. The group D enterococci are 
resistant to penicillins, including penicillinase-resistant penicillins such as methicil-
lin, nafcillin, dicloxacillin, and oxacillin, and are becoming increasingly resistant to 
many other antibiotics. Group B streptococci are often resistant to tetracycline but 
remain sensitive to the clinically achievable blood levels of penicillin, even though 
they have penicillin minimal inhibitory concentrations (MIC) considerably higher 
than those of S pyogenes. Although the duration of penicillin therapy varies with the 
degree of invasiveness, streptococcal pharyngitis is generally adequately treated with 
10 days of antibiotic therapy, and pneumococcal pneumonia with 7-14 days. If peni-
cillin allergy occurs, an alternative drug for treating pharyngitis is erythromycin, alt-
hough sporadic erythromycin and tetracycline resistance has been reported, leaving 
clindamycin or the newer macrolides as possible treatments. The most important 
goal of therapy in acute streptococcal pharyngitis is still to prevent rheumatic fever. 
However, therapy also hastens clinical recovery, avoids suppurative complications 
and renders the patient non-infectious for others. In addition to antibiotics, the pa-
tient with S pyogenes myositis or necrotizing fasciitis requires surgical debridement. 
Lifelong prophylaxis against recurrences of rheumatic fever is achieved with long-
acting penicillin or erythromycin. Sulfonamides will not eradicate the streptococcus 
and thus are not acceptable therapy for streptococcal pharyngitis, but sulfadiazine is 
effective for preventing recurrent attacks of rheumatic fever. Additional prophylactic 
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coverage before some dental and surgical procedures is necessary in the presence of 
rheumatic heart disease or prosthetic heart valves. Although streptococcal pharyngi-
tis is usually a benign, self-limited disease, therapy is important to prevent rheumatic 
fever. There is no convincing evidence that antibiotic therapy prevents glomerulone-
phritis. Disconcertingly, some patients in recent outbreaks of acute rheumatic fever 
do not give a history of preceding pharyngitis. 
Methods of treating the asymptomatic pharyngeal carrier of S pyogenes remain con-
troversial. Recent evidence suggests that up to 20% of children and young adults are 
carriers, the carrier state involves no risk to the carrier or to others, and it is frequent-
ly difficult to eradicate despite the exquisite sensitivity of the organism to penicillin 
in vitro. A similar failure of antibiotic therapy to eradicate nasopharyngeal carriage 
or to prevent reinfection with S pneumoniae also occurs.  
Although antibiotic resistance in S pneumoniae is common in many parts of the 
world, in the United States such strains previously had a geographically limited fo-
cus. Recent widespread emergence of S pneumoniae resistant to penicillin and other 
antibiotics has become a microbial threat in the United States as well. Even cefotax-
ime and ceftriaxone resistance has been documented. Isolates must be carefully 
screened for susceptibility by oxacillin disc testing, with definitive MIC determina-
tion by the E test (A B Biodisk NA, Piscataway, NJ), a convenient and reliable 
method for detection of resistance to penicillin and extended spectrum cephalospor-
ins. 
It is inappropriate to universally treat of pregnant women who are carriers of group B 
streptococci, or their colonized neonates, for several reasons: the high carrier rate; 
cost; the associated high risk of penicillin hypersensitivity; the potential increase in 
infections with penicillin-resistant organisms; the difficulty in altering colonization 
of women (even when their sexual partners were also treated); and the low risk of 
neonatal disease. The controversy continues despite recent recommendations for 
universal screening of preg nant women and selective intrapartum chemoprophylaxis 
for screen-positive mothers with preterm labor, premature or prolonged rupture of 
membranes, fever in labor, multiple births or previous infants with group B strepto-
coccal disease. 
Clearly, penicillin has reduced the severe morbidity and mortality associated with S 
pneumoniae. The emergence of resistance has now forced re-evaluation of empiric 
therapy. Clinicians must report clusters of S pneumoniae infection and be aware of 
local patterns of resistance. Penicillin susceptible organisms show MICs 0.06 mg/ml, 
intermediate strains 0.1-1.0 mg/ml and high level resistant strains 2 mg/ml. For 
nonmeningeal infection by intermediate strains, parenteral penicillin at high dose can 
probably be used since the mechanism of resistance involves alteration in penicillin 
binding proteins (PBP) and saturation. For meningeal infection with intermediate 
strains or any infection by high level resistant strains only ceftriaxone and cefotax-
ime retain sufficient activity. Resistance even to these extended spectrum cephalo-
sporins was first reported for the US in 1991. At this writing only vancomycin re-
mains uniformly effective but as discussed below, its use incurs potential for selec-
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tion of vancomycin resistant enterococci (VRE) or risk of transferring vancomycin 
resistance from enterococci to S pneumoniae.  
Currently, no single agent is reliably bactericidal against enterococci. Serious infec-
tions with group D enterococci often require a classic synergistic regime combining 
penicillin or ampicillin with an aminoglycoside, designed to weaken the cell wall 
with the ß-lactam and facilitate entry of the bacteriocidal aminoglycoside. Other ß-
lactam drugs with good activity against enterococci include piperacillin and 
imipenem. An alternate drug of choice is vancomycin, but vancomycin-resistant 
strains of enterococci have been isolated. Nosocomial acquisition of these resistant 
organisms is of grave concern. 
This antibiotic resistance among the streptococci/enterococci is an increasing prob-
lem. Studies show that in vitro exchange of resistant DNA can occur in conjugation 
via plasmids and transposons, or in transduction with bacteriophages. The mecha-
nisms involved in the in vivo genetic exchange are not clearly defined. Evidence is 
accumulating that other streptococci may be the important donors of resistance 
markers. Transposon transfer is thought to be the most likely mechanism in S pneu-
moniae, although point mutations also occur. In the setting of heavy ß-lactam use, 
selective pressure is important in emergence of resistant strains. The first penicillin-
resistant S pneumoniae were reported in 1967 in Australia and in 1974 in North 
America. In New Guinea, where the first penicillin-resistant strains were reported in 
1971, one-third of S pneumoniae isolates from patients with severe pneumococcal 
disease were resistant by 1978. In Hungary in 1992, 69% of S pneumoniae isolates 
were penicillin resistant. This resistance is not ß-lactamase mediated but due to alter-
ation in PBP which results in decreased binding of penicillin by the organism, ren-
dering the drug less effective and requiring higher concentrations for saturation. 
Some strains resistant to erythromycin or tetracycline also have been reported, as 
well as some multiply resistant strains. In South Africa, outbreaks of infection with 
strains of S pneumoniae resistant to ß-lactam antibiotics (penicillins and cephalo-
sporins) as well as to tetracycline, chloramphenicol, erythromycin, streptomycin, 
clindamycin, sulfonamides, and rifampin were reported in 1977. Although antibiotic 
resistance among S pneumoniae was infrequent in the United States, a major shift 
occurred from 1988 to 1990, resulting in the present situation of 15-25% of S pneu-
moniae intermediately or completely resistant to penicillin. Communities with "low 
prevalence" have 5-10% resistance. Single or multiply resistant strains are transmit-
ted person to person, especially in settings of frequent salivary exchange, antibiotic 
use and hand-to-hand transmission (as in day care centers) or of crowding (correc-
tions facilities, homeless shelters, nursing homes, military training groups). Control 
of the problem of emerging, antibiotic-resistant S pneumoniae is multifactorial: 1) 
surveillance for clusters of invasive disease, resistance and prevalent serotypes; 2) 
education of physicians and the public about antibiotic use (decrease unnecessary an-
tibiotic use for obviously viral infections and decrease antibiotic prophylaxis for oti-
tis by use of intermittent or expectant dosing or of non ß-lactam based prophylaxis-
sulfa. Use topical treatment for impetigo, and short course therapies and narrow 
spectrum antibiotics); 3) adherence to infection control strategies in day care centers; 
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4) aggressive promotion of the current 23-valent S pneumoniae vaccine and support 
of efforts to design a new vaccine effective in those <2 years of age, analogous to the 
eminently successful Haemophilus influenzae type B vaccine (see Ch. 30) where 
bacterial polysaccharide is conjugated to protein to elicit a T cell-dependent re-
sponse.  
Among the enterococci, resistance to a wide variety of common antibiotics has 
emerged, with some strains resistant to all currently available antibiotics. There is no 
clinically proven treatment effective against enterococci multiply resistant to lac-
tams, aminoglycosides, and vancomycin. The emergence of such organisms poses a 
stunning management dilemma. Resistance among the enterococci can be either in-
trinsic or acquired (by de novo genetic mutation or acquisition of DNA from re-
sistant organisms). Enterococcal resistance to lactams is also mediated by altered 
PBP as in pneumococci, allowing cell wall synthesis even in the presence of antibi-
otic, or much less commonly by ß-lactamase. Resistance to aminoglycosides is me-
diated by decreased uptake or aminoglycoside modifying enzymes, and to vancomy-
cin by decreased cell wall affinity for glycopeptide antibiotics. Further research into 
the mechanisms of resistance and new class(es) of antibiotics is essential.  
A final concern about emerging resistance among the enterococci is the potential for 
genetic transfer of resistance genes to more virulent pathogens: Staph aureus, S 
pneumoniae and even Gram-negative organisms. So significant is this threat of 
emerging enterococcal resistance that the Centers for Disease Control and Prevention 
has issued a document addressing national guidelines. These include recommenda-
tions for 1) education of physicians and the public about the impact of vancomycin 
resistant enterococci (VRE), 2) vigilant surveillance for and detection of VRE, 3) 
strict enforcement of infection control strategies in hospitals, and 4) prudent vanco-
mycin use or monotherapeutic use of extended spectrum cephalosporins. In a recent 
study of vancomycin use in US hospitals, use was about equally divided for treat-
ment of a specific isolate, for prophylaxis, and for empiric coverage. The recommen-
dations discourage vancomycin use for routine surgical prophylaxis, empiric prophy-
laxis in the patient with febrile neutropenia, the low birth weight infant or patients 
with vascular or peritoneal catheters, treatment of a single blood culture positive for 
coagulase-negative staphylococci, primary treatment of antibiotic-associated colitis, 
attempted eradication of colonization by methicillin-resistant Staph aureus (MRSA), 
or selective decontamination of the gastrointestinal tract. 
Vaccination 
As chemotherapeutic management becomes more difficult because of the threat of 
resistance, prevention becomes more important. With the introduction of antibiotics, 
previously successful pneumococcal vaccines fell into disuse. However, although 
prompt treatment with antibiotics has reduced the serious consequences of S pneu-
moniae infections (pre-antibiotic mortality rate of 30%), the disease incidence re-
mains unchanged, and attention has been redirected to vaccines for S pneumoniae as 
well as for other streptococci. Pneumococcal vaccines (containing the pneumococcal 
polysaccharides of the most prevalent serotypes) have been licensed in several coun-
tries, including the United States. Initial use shows them to be useful and safe, but 
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they remain under-utilized. The spectre of multidrug resistant S pneumoniae may 
provide a new incentive for their use. In 1983, the United States Food and Drug Ad-
ministration licensed a vaccine containing 23 serotypes, representing coverage 
against nearly 89% of the pneumococcal isolates submitted to the CDC in the 1987-
1988 National Surveillance Study. The population target of pneumococcal vaccines 
includes those at high risk for serious pneumococcal disease: the elderly (65 and old-
er) and children (2 years of age and older) with sickle cell anemia, with an immuno-
compromised state (lymphoma, asplenia, myeloma, acquired immunodeficiency 
syndrome), with nephrotic syndrome, or with chronic cardiopulmonary disease. Vac-
cines for the other streptococci remain experimental. 
Vaccine production for the streptococci presents several formidable problems. For 
both S pyogenes and S pneumoniae, a large number of serotypes must be included in 
effective vaccines since successful selection of a common epitope remains elusive. 
Continuing surveillance to determine prevalent serotypes is necessary to insure that 
the vaccine formulations remain appropriate. For S pyogenes, it is critical to deter-
mine rheumatogenic and nephritogenic strains to limit the required multivalency of 
the vaccines. Alternatively a newly described conserved portion of M protein is a 
distant goal. Toxicity has been associated with M protein preparations, but lack of 
immunogenicity in highly purified preparations of antigens is still a problem. With 
streptococcal vaccines, the potential risk of antigenic cross-reactivity with cardiac 
tissue and an associated increased risk of acute rheumatic fever must be appreciated. 
In group B neonatal disease chemoprophylaxis does not appear as practical as vac-
cine control. Passive immunity in group B streptococcal neonatal infection appears 
protective. Polyvalent hyperimmune gamma globulin and human monoclonal IgM 
antibody which reacts with multiple serotypes are undergoing efficacy studies. Ac-
tive immunization of pregnant women with undegraded sialic acid-containing poly-
saccharide group B antigens is another important aspect of control. 
The streptococci are ubiquitous, and their significance in medicine is remarkable. 
Exciting advances are being made in diagnosis and in understanding the mechanisms 
of pathogenesis, as well as in control of these well-known organisms. Problems with 
antibiotic resistance must preclude complacency in dealing with these common path-
ogens. 
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Neisseria 
General Concepts 
Neisseria gonorrhoeae 
Clinical Manifestations 
Symptomatic or asymptomatic localized infections include urethritis, cervicitis, 
proctitis, pharyngitis, and conjunctivitis. Disseminated infections occur either by ex-
tension to adjacent organs (pelvic inflammatory disease, epididymitis) or by bac-
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teremic spread (skin lesions, tenosynovitis, septic arthritis, endocarditis, and menin-
gitis). 
Structure 
Cells are Gram-negative cocci, usually seen in pairs with the adjacent sides flattened. 
Classification and Antigenic Types 
N gonorrhoeae strains have been typed on the basis of their growth requirements 
(auxotyping) or by antigenic differences in the porin protein (serotyping). More re-
cently, restriction fragment length polymorphisms in genes encoding ribosomal RNA 
(ribotyping) and the separation of large DNA fragments by pulsed- field gel electro-
phoresis have been used to type isolates. 
Pathogenesis 
Gonorrhea is usually acquired by sexual contact. Gonococci adhere to columnar epi-
thelial cells, penetrate them, and multiply on the basement membrane. Adherence is 
facilitated through pili and opa proteins. Gonococcal lipopolysaccharide stimulates 
the production of tumor necrosis factor, which causes cell damage. Gonococci may 
disseminate via the bloodstream. Strains that cause disseminated infections are usu-
ally resistant to serum and complement. 
Host Defenses 
Infection stimulates inflammation and local immunity; however, it is not known 
whether the secretory immune response is protective. Serum antibodies also appear. 
Individuals with genetic defects in late-acting complement components are at in-
creased risk for disseminated infections. Protection, if it exists, may be strain specif-
ic. 
Epidemiology 
Gonorrhea is a sexually transmitted disease of worldwide importance. The highest 
attack rate in both men and women occurs between 15 and 29 years of age. Host-
related factors such as the number of sexual partners, contraceptive practices, sexual 
preference, and population mobility contribute to the incidence of gonorrhea. 
Diagnosis 
Gonorrhea cannot be diagnosed solely on clinical grounds. For men, a Gram-stained 
smear of urethral exudate showing intracellular Gram-negative diplococci is diagnos-
tic. For women, and for men when a direct smear is not definitive, culturing on selec-
tive medium is often required. N gonorrhoeae must be differentiated from other 
Neisseria species. Where appropriate, isolates should be examined for antibiotic re-
sistance. A non-amplified DNA probe test is commercially available. This test does 
not require viable organisms and is useful where maintenance of viability during 
specimen transport is a problem; however, it is not as sensitive as culture. Serologic 
tests are not recommended for uncomplicated infections. 
Control 
Recommended treatment for uncomplicated infections is a third-generation cephalo-
sporin or a fluoroquinolone plus an antibiotic (e.g., doxycycline) effective against 
possible coinfection with Chlamydia trachomatis. Sex partner(s) should be referred 
and treated. No effective vaccine yet exists. Condoms are effective in preventing 
gonorrhea. 
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Neisseria meningitidis 
Clinical Manifestations 
Infection with N meningitidis has two presentations, meningococcemia, character-
ized by skin lesions, and acute bacterial meningitis. Fulminant disease (with or with-
out meningitis) is characterized by multisystem involvement and high mortality. 
Structure 
Cell morphology is identical to that of N gonorrhoeae. The antiphagocytic polysac-
charide capsule is a prominent feature. 
Classification and Antigenic Types 
N meningitidis is grouped, on the basis of capsular polysaccharides, into 12 
serogroups, some of which are subdivided according to the presence of outer mem-
brane protein and lipopolysaccharide antigens. 
Pathogenesis 
Infection is by aspiration of infective particles, which attach to epithelial cells of the 
nasopharyngeal and oropharyngeal mucosa, cross the mucosal barrier, and enter the 
bloodstream. If not cleared blood-borne bacteria may enter the central nervous sys-
tem and cause meningitis. 
Host Defenses 
Meningococci establish systemic infections only in individuals who lack serum bac-
terial antibodies directed against the capsular or noncapsular antigens of the invading 
strain, or in patients deficient in the late-acting complement components. 
Epidemiology 
Asymptomatic carriage of meningococci in the nasopharynx provides a reservoir for 
infection but also enhances host immunity. Attack rates peak in infants 3 months to 1 
year old. Meningococcal meningitis occurs both sporadically (mainly groups B and 
C meningococci) and in epidemics (mainly group A meningococci), with the highest 
incidence during late winter and early spring. 
Diagnosis 
Symptoms are suggestive; diagnosis is confirmed by identifying N meningitidis in 
specimens of blood, cerebrospinal fluid, and nasopharyngeal secretions collected be-
fore antibiotic administration. 
Control 
Penicillin is the drug of choice. Household contacts require chemoprophylaxis with 
rifampin. Groups A, C, AC, and ACYW135 capsular polysaccharide vaccines are 
available. In children under 1 year old, antibody levels decline rapidly after immun-
ization. Routine vaccination is not recommended. 
Other Genera and Species 
Moraxella is an oxidase-positive bacterium, sometimes mistaken for Neisseria, that 
may be isolated from eye infections and respiratory tract infections. M catarrhalis 
causes lower respiratory infection in adults with chronic lung disease and is a com-
mon cause of otitis media, sinusitis, and conjunctivitis in children. Kingella and Eik-
enella species are short bacilli or coccoid bacteria that act as opportunistic pathogens. 
They are sometimes secondary invaders of damaged tissues.  
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INTRODUCTION 
The family Neisseriaceae comprises the genera Neisseria, Moraxella, Kingella, and 
Acinetobacter. The only significant human pathogens are N gonorrhoeae, the agent 
of gonorrhea, and N. meningitidis, an agent of acute bacterial meningitidis. N gonor-
rhoeae infections have a high prevalence and low mortality, whereas N meningitidis 
infections have a low prevalence and high mortality. 
Gonococcal infections are acquired by sexual contact and usually affect mucous 
membranes of the urethra in men and the endocervix in women, although the infec-
tion may disseminate to a variety of tissues. The pathogenic mechanism involves the 
attachment of the gonococci to nonciliated epithelial cells via pili (fimbriae) and the 
production of cytotoxic factors (endotoxin). Similarly, the lipopolysaccharide of me-
ningococci is highly toxic, but an additional virulence factor is the antiphagocytic 
capsule. Both pathogens produce proteases that cleave and inactivate human immu-
noglobulin A1 (IgA1), a major mucosal immunoglobulin of humans. Many normal 
individuals harbor meningococci, whereas gonococci are present only if sexual con-
tact with an infected person has occurred. Epidemics of meningococcal meningitis 
occur sporadically. Gonococcal infections occur frequently and affect large numbers 
of sexually active people. Other species in this genus are primarily parasites on mu-
cosal surfaces of humans and other animals. Human disease caused by these organ-
isms usually is associated with opportunistic infections in compromised patients.  
Nesseria gonorrhoeae 
Clinical Manifestations 
Gonorrheal infection is generally limited to superficial mucosal surfaces lined with 
columnar epithelium. The areas most frequently involved are the cervix, urethra, rec-
tum, pharynx, and conjunctiva (Fig. 14-1). Squamous epithelium, which lines the 
adult vagina, is not susceptible to infection by the gonococcus. However, the prepu-
bertal vaginal epithelium, which has not been keratinized under the influence of es-
trogen, may be infected. Hence, gonorrhea in young girls may present as vulvovagi-
nitis. Mucosal infections are usually characterized by a marked local neutrophilic re-
sponse (purulent discharge). 
The most common symptom of uncomplicated gonorrhea is a discharge that may 
range from a scanty, clear, or cloudy fluid to one that is copious and purulent. Dysu-
ria is often present. Men with asymptomatic urethritis are an important reservoir for 
transmission. In addition, such men and those who ignore their symptoms are at in-
creased risk for developing complications. 
Endocervical infection is the most common form of uncomplicated gonorrhea in 
women. Such infections are usually characterized by vaginal discharge and some-
times by dysuria (because of coexistent urethritis). The cervical os may be erythema-
tous and friable, with a purulent exudate. About 50 percent of women with cervical 
infections are asymptomatic. Local complications include abscesses in Bartholin's 
and Skene's glands. 
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FIGURE 14-1 Clinical manifestations of N gonorrhoeae infection. 
Rectal infections with N gonorrhoeae occur in about one-third of women with cervi-
cal infection. They most often result from autoinoculation with cervical discharge 
and are rarely symptomatic. Rectal infections in homosexual men usually result from 
anal intercourse and are more often symptomatic. The symptoms and signs of gono-
coccal proctitis range from mild burning on defecation to itching to severe tenesmus 
and from mucopurulent discharge to frank blood in the stools. 
Pharyngeal infections are diagnosed most often in women and homosexual men with 
a history of fellatio. Such infections may be a focal source of gonococcemia. 
Ocular infections can have serious consequences (corneal scarring or perforation); 
prompt diagnosis and treatment are therefore important. Ocular infections (ophthal-
mia neonatorum) occur most commonly in newborns who are exposed to infected 
secretions in the birth canal. Keratoconjunctivitis is occasionally seen in adults as a 
result of autoinoculation. 
Disseminated gonococcal infections result from gonococcal bacteremia. Asympto-
matic infections of the pharynx, urethra, or cervix often serve as focal sources for 
bacteremia. The most common form of disseminated gonococcal infection is the 
dermatitis-arthritis syndrome. It is characterized by fever, chills, skin lesions, and ar-
thralgias (usually involving the hands, feet, and elbows), which are due to periarticu-
lar inflammation of the tendon sheaths. Occasionally, a patient develops a septic 
joint with effusion. Skin lesions may be macular, pustular, centrally necrotic, or 
hemorrhagic. Rarely, disseminated gonococcal infection causes endocarditis or men-
ingitis. Gonococci may ascend from the endocervical canal through the endometrium 
to the fallopian tubes and ultimately to the pelvic peritoneum, resulting in endometri-
tis, salpingitis, and finally, peritonitis. Women usually present with pelvic and ab-
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dominal pain, fever, chills, and cervical motion tenderness. This complex of signs 
and symptoms is referred to as pelvic inflammatory disease (PID). This disease may 
also be caused by other sexually transmitted organisms (e.g., Chlamydia tracho-
matis) as well as by non-sexually transmitted bacteria that are part of the normal vag-
inal flora. Complications of pelvic inflammatory disease include tubo-ovarian ab-
scesses, pelvic peritonitis, or Fitz-Hugh and Curtis syndrome, which is an inflamma-
tion of Glisson's capsule of the liver. As many as 15 percent of women with uncom-
plicated cervical infections may develop pelvic inflammatory disease. The disease 
may have serious consequences, including an increased probability of infertility and 
ectopic pregnancy. 
Structure 
Neisseria species are Gram-negative cocci, 0.6 to 1.0 µm in diameter. The organisms 
are usually seen in pairs with the adjacent sides flattened. Pili, hairlike filamentous 
appendages extend several micrometers from the cell surface and have a role in ad-
herence. The outer membrane is composed of proteins, phospholipids, and lipopoly-
saccharide (LPS). Features that distinguish gonococcal LPS from enteric LPS are the 
highly branched basal oligosaccharide structure and the absence of repeating O-
antigen subunits. For these reasons gonococcal LPS, as well as that of other mucosal 
pathogens, is referred to as lipooligosaccharide (LOS). Gonococci characteristically 
release outer membrane fragments (blebs) during growth. These blebs contain LOS 
and may have a role in pathogenesis. 
Classification and Antigenic Types 
The gonococcus is an obligate human pathogen. It is one of two Neisseria species 
that cause significant human infections. The genus also includes several nonpatho-
genic species (Table 14-1), which may be part of the normal flora and therefore can 
be confused with N gonorrhoeae. Gonococcal strains can be characterized according 
to their nutritional requirements (auxotyping). A panel of monoclonal antibodies 
specific for epitopes on protein I have also been used to type strains. Strains exhibit-
ing specific reaction patterns are termed serovars. A combined auxotype-serovar 
classification provides greater resolution among gonococcal isolates and is useful in 
epidemiologic investigations. 
Pathogenesis 
Our knowledge of the molecular basis of gonococcal pathogenesis is incomplete 
(Fig. 14-2). Attachment of gonococci to mucosal cells is mediated in part by pili, alt-
hough nonspecific factors such as surface charge and hydrophobicity may be im-
portant. Pili undergo both phase and antigenic variation. Opa proteins (protein II), 
which are located in the outer membrane, are also involved in attachment to host 
cells. Gonococci attach only to microvilli of nonciliated columnar epithelial cells; 
attachment to ciliated cells is not observed. 
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FIGURE 14-2 Pathogenesis of uncomplicated gonorrhea. Gonococci can invade 
columnar epithelial cells, although they do not invade ciliated columnar epithelium 
of the genitourinary tract. 
Much of our knowledge of gonococcal invasion comes from studies with tissue cul-
ture cells and human fallopian tube organ culture. After gonococci attach to the non-
ciliated epithelial cells of the fallopian tube, they are surrounded by the microvilli, 
which draw them to the surface of the mucosal cell. The gonococci appear to enter 
the epithelial cells by a process called parasite-directed endocytosis. This process 
seems to be initiated by microbial factors because it does not occur unless the gono-
cocci are viable and because it involves host cells that are not normally phagocytic. 
An unidentified factor in serum enhances engulfment of gonococci. The process is 
inhibited by drugs that block the actions of the microtubule (demecolcine) and mi-
crofilament (cytochalasin B) systems. During endocytosis the membrane of the mu-
cosal cell retracts, pinching off a membrane-bound vacuole that contains gonococci; 
this vacuole is rapidly transported to the base of the cell, where gonococci are re-
leased by exocytosis into the subepithelial tissue. Gonococci are not destroyed within 
the phagocytic vacuole; it is not clear whether they replicate in the vacuoles. 
The major porin protein of the gonococcal outer membrane, Por (protein I), has been 
proposed as a candidate invasin (a substance that helps mediate invasion into a host 
cell). The insertion of Por into neutrophils treated with the chemotactic peptide, 
fMLP and leukotriene B4, inhibits degranulation but not the generation of the super-
oxide anion. The significance of these observations with respect to the pathogenesis 
of gonorrhea remains to be determined. Each gonococcal strain expresses only one 
type of Por; however, the Por of different strains may exhibit antigenic differences. 
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Gonococci can produce one or several outer membrane proteins called Opa proteins 
(proteins II). These proteins are subject to phase variation and are usually found on 
cells from colonies possessing an opaque phenotype (O+). At any one time, a gono-
coccus may express zero, one, or several different Opa proteins, though each strain 
has 10 or more genes for different Opas. Trypsin-like proteases present in cervical 
mucus may help select for protease-resistant transparent (O-) colony phenotypes. O+ 
colony phenotypes (protease sensitive) predominate in cultures taken during the 
middle portion of the menstrual cycle. Cervical proteases increase during the second 
half of the cycle, resulting in an increase in the O- phenotype. The O- colony types 
can be isolated from tubal as well as endocervical cultures; O+ colony phenotypes 
have been isolated more often from endocervical cultures than from tubal cultures. 
Rmp (Protein III) is an outer membrane protein found in all strains of N gonorrhoe-
ae. It does not undergo phase variation and is found in a complex with Por and LOS. 
It shares partial homology with the Omp A protein of Escherichia coli. Antibodies to 
Rmp, induced either by a neisserial infection or by colonization with E coli, block 
bactericidal antibodies directed against Por and LOS. Rmp antibodies may facilitate 
infection with N gonorrhoeae. 
LOS has a profound effect on the virulence and pathogenesis of N gonorrhoeae. 
Gonococci can express several antigenic types of LOS and can alter the type of LOS 
they express by an as yet unknown mechanism. Gonococcal LOS produces mucosal 
damage in fallopian tube organ cultures and brings about the release of enzymes, 
such as proteases and phospholipases, that may be important in pathogenesis. More 
recent evidence suggests that gonococcal LOS stimulates the production of tumor 
necrosis factor (TNF) in fallopian tube organ cultures; inhibition of tumor necrosis 
factor with specific antiserum prevents tissue damage. Thus, gonococcal LOS ap-
pears to have an indirect role in mediating tissue damage. Gonococcal LOS is also 
involved in the resistance of N gonorrhoeae to the bactericidal activity of normal 
human serum. Oligosaccharides containing epitopes defined by specific monoclonal 
antibodies are associated with a serum-resistant phenotype. 
Gonococci can utilize host-derived cytidine monophospho-N-acetylneuraminic acid 
(CMP-NANA) in vivo to sialylate the oligosaccharide component of its LOS, con-
verting a serum-sensitive organism to a serum-resistant one. When such organisms 
are grown in vitro without CMP-NANA, their resistance to killing by normal human 
serum is rapidly lost. Organisms with non-sialylated LOS are more invasive than 
those with sialylated LOS. There is antigenic similarity between neisserial LOS and 
antigens present on human erthyrocytes. This similarity to self may preclude an ef-
fective immune response to these LPS antigens. 
Gonococci are highly autolytic and release peptidoglycan fragments during growth. 
These fragments, released by bacterial and/or host peptidoglycan hydrolases, are tox-
ic for fallopian tube mucosa and may contribute to the intense inflammatory reac-
tions characteristic of gonococcal disease. 
N gonorrhoeae is highly efficient at utilizing transferrin-bound iron for in vitro 
growth; many strains can also utilize lactoferrin-bound iron. Gonococci (and menin-
gococci) bind only human transferrin and lactoferrin. This specificity is thought to be 
 44 
the reason these organisms are exclusively human pathogens. Nevertheless, the role 
of transferrin- and lactoferrin-bound iron in in vivo growth is unknown. Gonococci 
express several new proteins when grown under iron-restricted conditions similar to 
the conditions occurring in the host. Some of these proteins function as receptors for 
transferrin, lactoferrin, heme, and hemoglobin; others function in the transport of 
iron into the cell. Gonococci cannot grow anaerobically unless low concentrations of 
the alternative electron acceptor nitrite are present. Under these conditions they pro-
duce novel proteins. These proteins are apparently produced during an infection be-
cause antibodies against them are present in the serum specimens of patients with 
uncomplicated gonorrhea, disseminated gonococcal infection, or pelvic inflammato-
ry disease. These data suggest that some gonococci in the host are growing under an-
aerobic conditions. Further studies will determine the relevance of these proteins to 
pathogenesis. 
Strains of N gonorrhoeae (and N meningitidis) produce two distinct extracellular 
IgA1 proteases, which cleave the heavy chain of human immunoglobulin A1 (IgA1) 
at different points within the hinge region. Type 1 protease cleaves a prolyl-seryl 
peptide bond and type 2 protease cleaves a prolyl-threonyl bond in the hinge region 
of the heavy chain. This region is missing in human IgA2, and so this isotype is not 
susceptible to cleavage. Each gonococcal or meningococcal isolate elaborates only 
one of these two enzymes. Split products of IgA1 have been found in the genital se-
cretions of women with gonorrhea, suggesting that the gonococcal IgA1 protease is 
present and active during genital infection. Fab fragments of IgA1 may bind to the 
gonococcal cell surface and block the Fc-mediated functions of intact immunoglobu-
lins. 
Host Defenses 
Not everyone exposed to N gonorrhoeae acquires the disease. This may be due to 
variations in the size or virulence of the inoculum, to nonspecific resistance, or to 
specific immunity. A 50 percent infective dose (ID50) of about 1,000 organisms has 
been established, based on the experimental urethral inoculation of male volunteers. 
There is no reliable ID50 for women, although it is assumed to be similar. 
Nonspecific factors have been implicated in natural resistance to gonococcal infec-
tion. In women, changes in the genital pH and hormones may increase resistance to 
infection at certain times of the menstrual cycle. Urinary solutes exhibit bactericidal 
and bacteriostatic activity of N gonorrhoeae. Factors in urine that seem to be im-
portant are pH, osmolarity, and the concentration of urea. The variability in the sus-
ceptibility of gonococcal strains to the bactericidal and bacteriostatic properties of 
urine is thought to be one of the reasons some men do not develop a gonococcal in-
fection when exposed. 
Most uninfected individuals have serum antibodies that react with gonococcal anti-
gens. These antibodies probably result from colonization or infection with various 
Gram-negative bacteria that possess cross-reactive antigens. These "natural" antibod-
ies differ, both qualitatively and quantitatively, from person to person, but may be 
important in an individual's natural resistance or susceptibility to infection. 
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Infection with N gonorrhoeae stimulates both mucosal and systemic antibodies to a 
variety of gonococcal antigens. Mucosal antibodies are primarily IgA and IgG. In 
genital secretions, antibodies have been identified that react with Por, Opa and LOS, 
and some of the iron-regulated proteins. Vaccine trials have suggested that antipilus 
antibodies inhibit the pilus-mediated attachment of the homologous gonococcal 
strain. Complement is present in endocervical secretions, but in a much lower con-
centration than in blood. However, there is little evidence to support a role for a 
complement-mediated bactericidal defense mechanism on the genital mucosa. In 
general, the IgA response is brief and declines rapidly after treatment; IgG levels de-
cline more slowly. 
More information is available about the function of systemic humoral immune 
mechanisms in gonococcal infection. Gonococcal antigens such as pili, Por, Opa, 
Rmp, and LOS elicit a serum antibody response during an infection. Antipilus anti-
body levels tend to be higher in women than in men and are related to the number of 
previous infections. The predominant IgG subclass that reacts with a variety of gon-
ococcal antigens is IgG3, followed by IgG1 and IgG4. IgG2 is minimal, suggesting 
that polysaccharides are not important in the immune response to gonococcal infec-
tion. Anti-Por antibodies may be bactericidal for the gonococcus. IgG that reacts 
with Rmp blocks the bactericidal activity of antibodies directed against Por and 
LOS. Genital infection with N gonorrhoeae stimulates a serum antibody response 
against the LOS of the infecting strain. Disseminated gonococcal infection results in 
higher levels of anti-LOS antibody than do genital infections. 
Strains that cause uncomplicated genital infections usually are killed by normal hu-
man serum and are termed serum sensitive. This bactericidal activity is mediated by 
IgM and IgG that recognize sites on the LOS. Strains that cause disseminated infec-
tions are not killed by most normal human serum and are referred to as serum re-
sistant. Resistance is mediated, in part, by IgA that blocks the IgG-mediated bacteri-
cidal activity of the serum. Serum specimens from convalescent patients with dis-
seminating infections contain bactericidal IgG to the LOS of the infecting strain. 
Individuals with inherited complement deficiencies have a markedly increased risk 
of acquiring systemic neisserial infections and are subject to recurring episodes of 
systemic gonococcal and meningococcal infections, indicating that the complement 
system is important in host defense.Gonococci activate complement by both the clas-
sic and alternative pathways. Complement activation by gonococci leads to the for-
mation of the C5b-9 complex (membrane attack complex) on the outer membrane. In 
normal human serum, similar numbers of C5b-9 complexes are deposited on serum-
sensitive and serum-resistant organisms, but the membrane attack complex is not 
functional on serum-resistant organisms. Other complement-mediated functions, 
such as opsonophagocytosis and chemotaxis, are more efficient with serum-sensitive 
than with serum-resistant gonococci. This may be a significant factor in the patho-
genesis of disseminated gonococcal infection and probably contributes to the relative 
lack of genital symptoms observed with this disease. 
Normal human serum contains opsonic anti-Por IgG. Antibodies to various surface-
exposed antigens are also present in cervical and urethral secretions of patients with 
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gonorrhea and probably contribute to the opsonophagocytosis of the organism. Opa 
is important in gonococcus-neutrophil interactions. Gonococci expressing certain 
Opas interact with neutrophils in the absence of antibodies. Once phagocytosed, 
gonococci are killed by both oxygen-dependent and oxygen-independent mecha-
nisms. The survival of gonococci within neutrophils has been the subject of consid-
erable controversy, with no clear-cut answer yet available. The opsonization and 
phagocytosis of gonococci are comparatively more important in mucosal infections 
than in protection from systemic gonococcal (and meningococcal) infections. 
Epidemiology 
The only natural host for N gonorrhoeae is the human. Gonorrhea has all but disap-
peared in Scandinavia and several other European countries. In the United States, 
gonorrhea remains the most frequently reported infectious disease. Between 1977 
and 1993, the number of reported cases decreased 56 percent, from 1 million to 
439,673 cases per year. The Centers for Disease Control (CDC) estimates that there 
are two unreported cases for every reported case of gonorrhea. Gonorrhea is trans-
mitted almost exclusively by sexual contact. The highest rates occur in women be-
tween the ages of 15 and 19 years and in men 20 and 24 years of age. Persons who 
have multiple sex partners are at highest risk. Rates of gonorrhea are higher in males 
and in minority and inner-city populations. 
Gonorrhea is usually contracted from a sex partner who is either asymptomatic or 
has only minimal symptoms. It is estimated that the efficiency of transmission after 
one exposure is about 35 percent from an infected woman to an uninfected man and 
50 to 60 percent from an infected man to an uninfected woman. More than 90 per-
cent of men with urethral gonorrhea will develop symptoms within 5 days; fewer 
than 50 percent of women with anogenital gonorrhea will do so. Women with 
asymptomatic infections are at higher risk of developing pelvic inflammatory disease 
and disseminated gonococcal infection. 
Diagnosis 
Gonococcal infection produces several common clinical syndromes that have multi-
ple causes or that mimic other conditions. Laboratory tests are often required to dif-
ferentiate among the etiologic agents causing urethritis or cervicitis. The etiologic 
diagnosis of salpingitis and pelvic peritonitis is quite difficult because mixed infec-
tions are common and laparoscopy is required to obtain appropriate cultures. Gono-
coccal perihepatitis may mimic acute cholecystitis. All of the above syndromes are 
also caused by C trachomatis, a sexually transmitted bacterium that causes more in-
fections in the United States than N gonorrhoeae. The gonococcal arthritis-dermatitis 
syndrome, must be, differentiated from meningococcemia and Reiter syndrome, in 
particular, and from other causes of septic arthritis. 
Customarily, the laboratory diagnosis of gonorrhea is made presumptively and then 
confirmed; the latter process involves identifying characteristics that distinguish N 
gonorrhoeae from other Neisseria spp. that may be present in the specimen. Non-
pathogenic Neisseria are normal inhabitants of the oropharynx and nasopharynx and 
occasionally are isolated from other sites infected by N gonorrhoeae. A presumptive 
diagnosis of gonorrhea may be made from Gram-stained smears of urethral, cervical, 
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and rectal specimens if Gram-negative diplococci are observed within leukocytes; it 
is equivocal if only extracellular Gram-negative diplococci are seen and negative if 
no Gram-negative diplococci are seen. Gram stain diagnosis has a sensitivity and 
specificity of >95 percent in men with symptomatic urethritis. The specificity of 
Gram stain diagnosis in women is also high if the cervix is wiped clean to remove 
cervical secretions before collecting the specimen; however, the sensitivity is only 
about 50 percent. The sensitivity and specificity of the Gram stain for rectal speci-
mens are lower than with cervical specimens. 
Specimens for the laboratory diagnosis of gonorrhea should be collected before treat-
ing the patient. Ideally, specimens should be inoculated onto appropriate media and 
incubated immediately after collection at 35 to 36.5°C in a CO2-enriched atmos-
phere, which can be obtained by using a candle extinction jar or a CO2 incubator. 
Urethral specimens are normally obtained from heterosexual men; urethral, rectal, 
and pharyngeal specimens are normally obtained from homosexual men; and cervi-
cal and rectal specimens are normally obtained from women. Specimens are collect-
ed with cotton, polyester, or calcium alginate swabs. When appropriate, specimens 
may also be obtained from the urethra and from Bartholin's and Skene's glands of in-
fected women. Blood cultures should be performed for patients with suspected dis-
seminated infection. Synovial fluid cultures should be performed for patients with 
septic arthritis. 
Urethral, cervical, and pharyngeal specimens are inoculated onto selective medium 
such as modified Thayer-Martin, Martin-Lewis, or NYC medium. These are com-
plex media that contain antimicrobial and antifungal agents to inhibit the growth of 
unwanted organisms. Rectal specimens should be inoculated onto modified Thayer-
Martin medium which contains trimethoprim lactate to inhibit the growth and 
swarming of Proteus species. Specimens collected from normally sterile sites such as 
blood, synovial fluid, and conjunctivae may be inoculated onto a nonselective medi-
um such as chocolate agar. 
The combination of oxidase-positive colonies and Gram-negative diplococci pro-
vides a presumptive identification of N gonorrhoeae. Fluorescent-antibody staining, 
coagglutination, specific biochemical tests, and DNA probes may be used for con-
firmation. DNA probes have also been used to detect gonococci in urethral and cer-
vical specimens. A commercial test based on this approach is available. Serologic 
tests for uncomplicated gonorrhea have not proved satisfactory. 
Control 
There is no effective vaccine to prevent gonorrhea. Candidate vaccines consisting of 
pilus protein or Por are of little benefit. The development of an effective vaccine has 
been hampered by the lack of a suitable animal model and the fact that an effective 
immune response has never been demonstrated. Condoms are effective in preventing 
the transmission of gonorrhea. 
Contact tracing to identify source contacts (i.e., those who infected the index patient) 
has been useful in identifying asymptomatic individuals or those with ignored symp-
toms. Contact tracing has also been used to identify contacts who were exposed to 
the index patient and who may have become infected. 
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The evolution of antimicrobial resistance in N gonorrhoeae may ultimately affect the 
control of gonorrhea. Strains with multiple chromosomal resistance to penicillin, tet-
racycline, erythromycin, and cefoxitin have been identified in the United States and 
most other parts of the world. Sporadic high-level resistance to spectinomycin and 
fluoroquinolones have been reported. 
Penicillinase-producing strains of N gonorrhoeae were first described in 1976. Five 
related ß-lactamase plasmids of different sizes have been identified in these strains. 
The strains cause more than one-half of all gonococcal infections in parts of Africa 
and Asia. Their prevalence has increased dramatically in the United States since 
1984 and has affected nearly every major metropolitan area. 
Plasmid-mediated high-level resistance of N gonorrhoeae to tetracycline was first 
described in 1986 and has now been reported in most parts of the world. This re-
sistance is due to the presence of the streptococcal tetM determinant on a gonococcal 
conjugative plasmid. 
The current CDC Treatment Guidelines recommend treatment of all gonococcal in-
fections with antibiotic regimens effective against resistant strains. The recommend-
ed antimicrobial agents are ceftriaxone, cefixime, ciprofloxacin, or oflaxacin. Since a 
significant proportion of patients with gonorrhea are also infected with C tracho-
matis, doxycycline or erythromycin has been added to treat this concomitant infec-
tion. 
Neisseria meningitidis 
Clinical Presentation 
N meningitidis infection results from the bloodborne dissemination (meningococ-
cemia) of the meningococcus, usually following an asymptomatic or mildly symp-
tomatic nasopharyngeal carrier state or a mild rhinopharyngitis (Fig. 14-3). The 
mildest form is a transient bacteremic illness characterized by a fever and malaise; 
symptoms resolve spontaneously in 1 to 2 days. Acute meningococcemia is more se-
rious and is often complicated by meningitis. The manifestations of meningococcal 
meningitis are similar to acute bacterial meningitis caused by organisms such as 
Streptococcus pneumoniae, Haemophilus influenzae, and E coli. The manifestations 
result from both infection and increased intracranial pressure. Chills, fever, malaise, 
and headache are the usual manifestations of infection; headache, vomiting, and rare-
ly, papilledema may result from increased intracranial pressure. Signs of meningeal 
inflammation are also present. The onset of meningococcal meningitis may be abrupt 
or insidious. 
Infants with meningococcal meningitis rarely display signs of meningeal irritation. 
Irritability and refusal to take food are typical; vomiting occurs early in the disease 
and may lead to dehydration. Fever is typically absent in children younger than 2 
months of age. Hypothermia is more common in neonates. As the disease progresses, 
apneic episodes, seizures, disturbances in motor tone, and coma may develop. 
In older children and adults, specific symptoms and signs are usually present, with 
fever and altered mental status the most consistent findings. Headache is an early, 
prominent complaint and is usually very severe. Nausea, vomiting, and photophobia 
are also common symptoms. 
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FIGURE 14-3 Clinical manifestations of N meningitidis infection. 
Neurologic signs are common; approximately one-third of patients have convulsions 
or coma when first seen by a physician. Signs of meningeal irritation such as cervical 
rigidity (Brudzinski sign), thoracolumbar rigidity, hamstring spasm (Kernig sign), 
and exaggerated reflexes are common. 
Petechiae (minute hemorrhagic spots in the skin) or purpura (hemorrhages into the 
skin) occurs from the first to the third day of illness in 30 to 60 percent of patients 
with meningococcal disease, with or without meningitis. The lesions may be more 
prominent in areas of the skin subjected to pressure, such as the axillary folds, the 
belt line, or the back. 
Fulminant meningococcemia (Waterhouse-Friderichsen syndrome) occurs in 5 to 15 
percent of patients with meningococcal disease and has a high mortality rate. It be-
gins abruptly with sudden high fever, chills, myalgias, weakness, nausea, vomiting, 
and headache. Apprehension, restlessness, and frequently, delirium occur within the 
next few hours. Widespread purpuric and ecchymotic skin lesions appear suddenly. 
Typically, no signs of meningitis are present. Pulmonary insufficiency develops 
within a few hours, and many patients die within 24 hours of being hospitalized de-
spite appropriate antibiotic therapy and intensive care. 
Structure 
The only distinguishing structural feature between N meningitidis and N gonorrhoe-
ae is the presence of a polysaccharide capsule in the former. The capsule is antipha-
gocytic and is an important virulence factor. 
Classification and Antigenic Types 
Meningococcal capsular polysaccharides provide the basis for grouping these organ-
isms. Twelve serogroups have been identified (A, B, C, H, I, K, L, X, Y, Z, 29E, and 
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W135). The most important serogroups associated with disease in humans are A, B, 
C, Y, and W135. The chemical composition of these capsular polysaccharides, 
where known, is listed in Table 14-2. The prominent outer membrane proteins of N 
meningitidis have been designated class 1 through class 5. The class 2 and 3 proteins 
function as porins and are analogous to gonococcal Por. The class 4 and 5 proteins 
are analogous to gonococcal Rmp and Opa, respectively. Serogroup B and C menin-
gococci have been further subdivided on the basis of serotype determinants located 
on the class 2 and 3 proteins. A few serotypes are associated with most cases of me-
ningococcal disease, whereas other serotypes within the same serogroup rarely 
caused disease. All known group A strains have the same protein serotype antigens 
in the outer membrane. Another serotyping system is based on the antigenic diversity 
of meningococcal LOS. The LOS types are independent of the protein serotypes, alt-
hough certain combinations frequently occur together. 
Pathogenesis 
The human nasopharynx is the only known reservoir of N meningitidis. Meningo-
cocci are spread via respiratory droplets, and transmission requires aspiration of in-
fective particles. Meningococci attach to the nonciliated columnar epithelial cells of 
the nasopharynx. Attachment is mediated by pili and possibly by other outer mem-
brane components. Invasion of the mucosal cells occurs by a mechanism similar to 
that observed with gonococci. However, once internalized, meningococci remain in 
an apical location within the epithelial cell; the route by which they gain access to 
the subepithelial space remains unclear. Trimers of class 2 and 3 proteins have the 
ability to translocate from intact cells and insert into eukaryotic cell membranes to 
form voltage-dependent channels. This process may be important in invasion. 
Purified meningococcal LOS is highly toxic and is as lethal for mice as the LOS 
from E coli or Salmonella typhimurium; however, meningococcal LOS is 5 to 10 
times more effective than enteric LPS in eliciting a dermal Shwartzman reaction in 
rabbits. Meningococcal LPS suppresses leukotriene B4 synthesis in human polymor-
phonuclear leukocytes. The loss of leukotriene B4 deprives the leukocytes of a 
strong chemokinetic and chemotactic factor. 
The events after bloodstream invasion are unclear. Relatively little information is 
known about how the meningococcus enters the central nervous system. 
Host Defenses 
The integrity of the pharyngeal and respiratory epithelium may be important in pro-
tection from invasive disease. Chronic irritation of the mucosa due to dust or low 
humidity, or damage to the mucosa resulting from a concurrent viral or mycoplasmal 
upper respiratory infection, may be predisposing factors for invasive disease. 
The presence of serum bactericidal IgG and IgM is probably the most important host 
factor in preventing invasive disease. These antibodies are directed against both cap-
sular and noncapsular surface antigens. The antibodies are produced in response to 
colonization with carrier strains of N meningitidis, N lactamica, or other nonpatho-
genic Neisseria species. Protective antibodies are also stimulated by cross-reacting 
antigens on other bacterial species. The role of bactericidal antibodies in prevention 
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of invasive disease explains why high attack rates are seen in infants from 6 to 9 
months old, the age at which maternally acquired antibodies are being lost. 
The immunity conferred by specific antibody may not be absolute. Illness has been 
documented in individuals with levels of antibodies considered to be protective. It 
has been postulated that the activity of the bactericidal antibodies might be blocked 
by IgA, induced by other meningococcal strains, or by cross-reacting antigens on en-
teric or other respiratory bacteria. Since IgA does not bind complement, it may block 
binding sites for the bactericidal IgG and IgM. Persons with complement deficien-
cies (C5, C6, C7, or C8) may develop meningococcemia despite protective antibody. 
This underscores the importance of the complement system in protection from me-
ningococcal disease. 
Epidemiology 
The meningococcus usually inhabits the human nasopharynx without causing detect-
able disease. This carrier state may last for a few days to months and is important 
because it not only provides a reservoir for meningococcal infection but also enhanc-
es host immunity. Between 5 and 30 percent of normal individuals are carriers at any 
given time, yet few develop meningococcal disease. Even during epidemics of me-
ningococcal meningitis in military recruits, when the carrier rate may reach 95 per-
cent, the incidence of systemic disease is less than 1 percent. Meningococcal carriage 
rates are highest in older children and young adults, but the attack rates are higher in 
children, peaking at 5 years of age (group B) and 4 to 14 years of age (group C). The 
low incidence of disseminated disease following colonization suggests that host ra-
ther than bacterial factors play an important determining role. 
Meningococcal meningitis occurs sporadically and in epidemics, with the highest in-
cidence during late winter and early spring. Most epidemics are caused by group A 
strains, but small outbreaks have occurred with group B and C strains. Sporadic cas-
es generally are caused by group B, C, and Y strains. Whenever group A strains be-
come prevalent in the population, the incidence of meningitis increases markedly. 
Diagnosis 
The most characteristic manifestation of meningococcemia is the skin rash, which is 
essential for its recognition. Petechiae are the most common type of skin lesion. Ill-
defined pink macules and maculopapular lesions also occur. Lesions are sparsely dis-
tributed over the body. They tend to occur in crops and on any part of the body; 
however, the face is usually spared and involvement of the palms and soles is less 
common. The skin rash may progress from a few ill-defined lesions to a widespread 
eruption within a few hours. 
Acute bacterial meningitis has characteristic signs and symptoms. Except in epidem-
ic situations, it is difficult to identify the causative agent without laboratory tests. 
In cases of suspected meningococcal disease, specimens of blood, cerebrospinal flu-
id, and nasopharyngeal secretions should be collected before administration of any 
antimicrobial agents and examined for the presence of N meningitidis. Success in 
isolation is reduced by prior therapy; however, the microscopic diagnosis is not sig-
nificantly affected. The cerebrospinal fluid should be concentrated by centrifugation 
and a portion of the sediment cultured on chocolate or blood agar. The plates should 
 52 
be incubated in a candle jar or CO2 incubator. The presence of oxidase-positive col-
onies and Gram-negative diplococci provides a presumptive identification of N men-
ingitidis. Production of acid from glucose and maltose but not sucrose, lactose, or 
fructose may be used for confirmation (Table 14-1). The serologic group may be de-
termined by a slide agglutination test, using first polyvalent and then monovalent an-
tisera. 
Nasopharyngeal specimens must be obtained from the posterior nasopharyngeal wall 
behind the soft palate and then should be inoculated onto a selective medium such as 
Thayer-Martin medium and processed as above. 
Blood specimens are inoculated in 10- to 15-ml aliquots onto each of three blood 
bottles to give a final concentration of 10% (vol/vol). Evacuated bottles should be 
vented. Some strains of N meningitidis are inhibited by the sodium polyanethol-
sulfonate contained in blood medium. Toxicity may be overcome by the addition of 
gelatin. Sodium amylosulfate is not toxic for the meningococcus. Blood cultures are 
subcultured blindly onto chocolate or blood agar for confirmation. 
Gram-stained smears of cerebrospinal fluid may be diagnostic; however, finding 
neisseriae in these smears is often more difficult than finding the strains that cause 
pneumococcal meningitis. Quellung tests may be of value. 
Control 
Group A, C, Y, and W135 capsular polysaccharide vaccines are available and can be 
used to control outbreaks due to the meningococcal serogroups covered by the vac-
cine. The A, C, AC, and ACYW135 polysaccharide formulations are currently li-
censed in the United States. The polysaccharide vaccines are ineffective in young 
children, and the duration of protection is limited in children vaccinated at 1 to 4 
years of age. Routine vaccination of the civilian population in industrialized coun-
tries is not currently recommended because the risk of infection is low and most en-
demic disease occurs in young children. The group B capsular polysaccharide is a 
homopolymer of sialic acid and is not immunogenic in humans. A group B meningo-
coccal vaccine consisting of outer membrane protein antigens has recently been de-
veloped but is not licensed in the United States. 
Meningococcal disease arises from association with infected individuals, as evi-
denced by the 500- to 800-fold greater attack rate among household contacts than 
among the general population. Because such household members are at high risk, 
they require chemoprophylaxis. Sulfonamides were the chemoprophylactic agent of 
choice until the emergence of sulfonamide-resistant meningococci. At present, ap-
proximately 25 percent of clinical isolates of N meningitidis in the United States are 
resistant to sulfonamides; rifampin is therefore the chemoprophylactic agent of 
choice. 
Penicillin is the drug of choice to treat meningococcemia and meningococcal menin-
gitis. Although penicillin does not penetrate the normal blood-brain barrier, it readily 
penetrates the blood-brain barrier when the meninges are acutely inflamed. Either 
chloramphenicol or a third-generation cephalosporin such as cefotaxime or ceftriax-
one is used in persons allergic to penicillins. 
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Salmonella 
General Concepts 
Clinical Manifestations 
Salmonellosis ranges clinically from the common Salmonella gastroenteritis (diar-
rhea, abdominal cramps, and fever) to enteric fevers (including typhoid fever) which 
are life-threatening febrile systemic illness requiring prompt antibiotic therapy. Focal 
infections and an asymptomatic carrier state occur. The most common form of sal-
monellosis is a self-limited, uncomplicated gastroenteritis.  
Structure, Classification, and Antigenic Types 
Salmonella species are Gram-negative, flagellated facultatively anaerobic bacilli 
characterized by O, H, and Vi antigens. There are over 1800 known serovars which 
current classification considers to be separate species.  
Pathogenesis 
Pathogenic salmonellae ingested in food survive passage through the gastric acid 
barrier and invade the mucosa of the small and large intestine and produce toxins. 
Invasion of epithelial cells stimulates the release of proinflammatory cytokines 
which induce an inflammatory reaction. The acute inflammatory response causes di-
arrhea and may lead to ulceration and destruction of the mucosa. The bacteria can 
disseminate from the intestines to cause systemic disease.  
Host Defenses 
Both nonspecific and specific host defenses are active. Non-specific defenses consist 
of gastric acidity, intestinal mucus, intestinal motility (peristalsis), lactoferrin, and 
lysozyme. Specific defenses consist of mucosal and systemic antibodies and genetic 
resistance to invasion. Various factors affect susceptibility. 
Epidemiology 
Non-typhoidal salmonellosis is a worldwide disease of humans and animals. Ani-
mals are the main reservoir, and the disease is usually food borne, although it can be 
spread from person to person. The salmonellae that cause Typhoid fever and other 
enteric fevers spread mainly from person-to-person via the fecal-oral route and have 
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no significant animal reservoirs. Asymptomatic human carriers ("typhoid Marys") 
may spread the disease.  
Diagnosis 
Salmonellosis should be considered in any acute diarrheal or febrile illness without 
obvious cause. The diagnosis is confirmed by isolating the organisms from clinical 
specimens (stool or blood). 
Control 
Effective vaccines exist for typhoid fever but not for non-typhoidal salmonellosis. 
Those diseases are controlled by hygienic slaughtering practices and thorough cook-
ing and refrigeration of food.  
INTRODUCTION 
Salmonellae are ubiquitous human and animal pathogens, and salmonellosis, a dis-
ease that affects an estimated 2 million Americans each year, is common throughout 
the world. Salmonellosis in humans usually takes the form of a self-limiting food 
poisoning (gastroenteritis), but occasionally manifests as a serious systemic infection 
(enteric fever) which requires prompt antibiotic treatment. In addition, salmonellosis 
causes substantial losses of livestock.  
Clinical Manifestations 
Some infectious disease texts recognize three clinical forms of salmonellosis: (1) 
gastroenteritis, (2) septicemia, and (3) enteric fevers. This chapter focuses on the two 
extremes of the clinical spectrumgastroenteritis and enteric fever. The septicemic 
form of salmonella infection can be an intermediate stage of infection in which the 
patient is not experiencing intestinal symptoms and the bacteria cannot be isolated 
from fecal specimens. The severity of the infection and whether it remains localized 
in the intestine or disseminates to the bloodstream may depend on the resistance of 
the patient and the virulence of the Salmonella isolate. 
The incubation period for Salmonella gastroenteritis (food poisoning) depends on the 
dose of bacteria. Symptoms usually begin 6 to 48 hours after ingestion of contami-
nated food or water and usually take the form of nausea, vomiting, diarrhea, and ab-
dominal pain. Myalgia and headache are common; however, the cardinal manifesta-
tion is diarrhea. Fever (38oC to 39oC) and chills are also common. At least two-thirds 
of patients complain of abdominal cramps. The duration of fever and diarrhea varies, 
but is usually 2 to 7 days. 
Enteric fevers are severe systemic forms of salmonellosis. The best studied enteric 
fever is typhoid fever, the form caused by S typhi, but any species of Salmonella 
may cause this type of disease. The symptoms begin after an incubation period of 10 
to 14 days. Enteric fevers may be preceded by gastroenteritis, which usually resolves 
before the onset of systemic disease. The symptoms of enteric fevers are nonspecific 
and include fever, anorexia, headache, myalgias, and constipation. Enteric fevers are 
severe infections and may be fatal if antibiotics are not promptly administered.  
Structure, Classification, and Antigenic Types 
Salmonellae are Gram-negative, flagellated, facultatively anaerobic bacilli pos-
sessing three major antigens: H or flagellar antigen; O or somatic antigen; and Vi an-
tigen (possessed by only a few serovars). H antigen may occur in either or both of 
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two forms, called phase 1 and phase 2. The organisms tend to change from one phase 
to the other. O antigens occur on the surface of the outer membrane and are deter-
mined by specific sugar sequences on the cell surface. Vi antigen is a superficial an-
tigen overlying the O antigen; it is present in a few serovars, the most important be-
ing S typhi.  
Antigenic analysis of salmonellae by using specific antisera offers clinical and epi-
demiological advantages. Determination of antigenic structure permits one to identi-
fy the organisms clinically and assign them to one of nine serogroups (A-I), each 
containing many serovars. H antigen also provides a useful epidemiologic tool with 
which to determine the source of infection and its mode of spread. 
As with other Gram-negative bacilli, the cell envelope of salmonellae contains a 
complex lipopolysaccharide (LPS) structure that is liberated on lysis of the cell and, 
to some extent, during culture. The lipopolysaccharide moiety may function as an 
endotoxin, and may be important in determining virulence of the organisms. This 
macromolecular endotoxin complex consists of three components, an outer O-
polysaccharide coat, a middle portion (the R core), and an inner lipid A coat. Lipo-
polysaccharide structure is important for several reasons. First, the nature of the re-
peating sugar units in the outer O-polysaccharide chains is responsible for O antigen 
specificity; it may also help determine the virulence of the organism. Salmonellae 
lacking the complete sequence of O-sugar repeat units are called rough because of 
the rough appearance of the colonies; they are usually avirulent or less virulent than 
the smooth strains which possess a full complement of O-sugar repeat units. Second, 
antibodies directed against the R core (common enterobacterial antigen) may protect 
against infection by a wide variety of Gram-negative bacteria sharing a common core 
structure or may moderate their lethal effects. Third, the endotoxin component of the 
cell wall may play an important role in the pathogenesis of many clinical manifesta-
tions of Gram-negative infections. Endotoxins evoke fever, activate the serum com-
plement, kinin, and clotting systems, depress myocardial function, and alter lympho-
cyte function. Circulating endotoxin may be responsible in part for many of the man-
ifestations of septic shock that can occur in systemic infections. 
Pathogenesis 
Salmonellosis includes several syndromes (gastroenteritis, enteric fevers, septicemia, 
focal infections, and an asymptomatic carrier state) (Fig. 1). Particular serovars show 
a strong propensity to produce a particular syndrome (S typhi, S paratyphi-A, and S 
schottmuelleri produce enteric fever; S choleraesuis produces septicemia or focal in-
fections; S typhimurium and S enteritidis produce gastroenteritis); however, on occa-
sion, any serotype can produce any of the syndromes. In general, more serious infec-
tions occur in infants, in adults over the age of 50, and in subjects with debilitating 
illnesses. 
Most non-typhoidal salmonellae enter the body when contaminated food is ingested 
(Fig. 2). Person-to-person spread of salmonellae also occurs. To be fully pathogenic, 
salmonellae must possess a variety of attributes called virulence factors. These in-
clude (1) the ability to invade cells, (2) a complete lipopolysaccharide coat, (3) the 
ability to replicate intracellularly, and (4) possibly the elaboration of toxin(s). After  
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Figure 21-1 Pathogenesis of salmonellosis. 
 
Figure 21-2 Scheme of the Pathogenesis of Salmonella enterocolitis and diar-
rhea. 
ingestion, the organisms colonize the ileum and colon, invade the intestinal epitheli-
um, and proliferate within the epithelium and lymphoid follicles. The mechanism by 
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which salmonellae invade the epithelium is partially understood and involves an ini-
tial binding to specific receptors on the epithelial cell surface followed by invasion. 
Invasion occurs by the organism inducing the enterocyte membrane to undergo "ruf-
fling" and thereby to stimulate pinocytosis of the organisms (Fig. 3). Invasion is de-
pendent on rearrangement of the cell cytoskeleton and probably involves increases in 
cellular inositol phosphate and calcium. Attachment and invasion are under distinct 
genetic control and involve multiple genes in both chromosomes and plasmids.  
 
 
Figure 21-3 Invasion of intestinal mucosa by Salmonella. 
After invading the epithelium, the organisms multiply intracellularly and then spread 
to mesenteric lymph nodes and throughout the body via the systemic circulation; 
they are taken up by the reticuloendothelial cells. The reticuloendothelial system 
confines and controls spread of the organism. However, depending on the serotype 
and the effectiveness of the host defenses against that serotype, some organisms may 
infect the liver, spleen, gallbladder, bones, meninges, and other organs (Fig. 1). For-
tunately, most serovars are killed promptly in extraintestinal sites, and the most 
common human Salmonella infection, gastroenteritis, remains confined to the intes-
tine. 
After invading the intestine, most salmonellae induce an acute inflammatory re-
sponse, which can cause ulceration. They may elaborate cytotoxins that inhibit pro-
tein synthesis. Whether these cytotoxins contribute to the inflammatory response or 
to ulceration is not known. However, invasion of the mucosa causes the epithelial 
cells to synthesize and release various proinflammatory cytokines, including: IL-1, 
IL-6, IL-8, TNF-2, IFN-U, MCP-1, and GM-CSF. These evoke an acute inflammato-
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ry response and may also be responsible for damage to the intestine. Because of the 
intestinal inflammatory reaction, symptoms of inflammation such as fever, chills, 
abdominal pain, leukocytosis, and diarrhea are common. The stools may contain 
polymorphonuclear leukocytes, blood, and mucus.  
Much is now known about the mechanisms of Salmonella gastroenteritis and diar-
rhea. Figures 2 and 3 summarize the pathogenesis of Salmonella enterocolitis and 
diarrhea. Only strains that penetrate the intestinal mucosa are associated with the ap-
pearance of an acute inflammatory reaction and diarrhea (Fig. 4); the diarrhea is due 
to secretion of fluid and electrolytes by the small and large intestines. The mecha-
nisms of secretion are unclear, but the secretion is not merely a manifestation of tis-
sue destruction and ulceration. Salmonella penetrate the intestinal epithelial cells but, 
unlike Shigella and invasive E. coli, do not escape the phagosome. Thus, the extent 
of intercellular spread and ulceration of the epithelium is minimal. Salmonella es-
cape from the basal side of epithelial cells into the lamina propria. Systemic spread 
of the organisms can occur, giving rise to enteric fever. Invasion of the intestinal 
mucosa is followed by activation of mucosal adenylate cyclase; the resultant increase 
in cyclic AMP induces secretion. The mechanism by which adenylate cyclase is 
stimulated is not understood; it may involve local production of prostaglandins or 
other components of the inflammatory reaction. In addition, Salmonella strains elab-
orate one or more enterotoxin-like substances which may stimulate intestinal secre-
tion. However, the precise role of these toxins in the pathogenesis of Salmonella en-
terocolitis and diarrhea has not been established. 
Host Defenses 
Various host defenses are important in resisting intestinal colonization and invasion 
by Salmonella (Table 2). Normal gastric acidity (pH < 3.5) is lethal to salmonellae. 
In healthy individuals, the number of ingested salmonellae is reduced in the stomach, 
so that fewer or no organisms enter the intestine. Normal small intestinal motility al-
so protects the bowel by sweeping ingested salmonellae through quickly. The normal 
intestinal microflora protects against salmonellae, probably through anaerobes, 
which liberate short-chain fatty acids that are thought to be toxic to salmonellae. Al-
teration of the anaerobic intestinal flora by antibiotics renders the host more suscep-
tible to salmonellosis. Secretory or mucosal antibodies also protect the intestine 
against salmonellae. Animal strains genetically resistant to intestinal invasion by 
salmonellae have been described. When these host defenses are absent or blunted, 
the host becomes more susceptible to salmonellosis; factors that render the host more 
susceptible to salmonellosis are listed in Table 3. For example, in AIDS, Salmonella 
infection is common, frequently persistent and bacteremic, and often resistant to 
even prolonged antibiotic treatment. Relapses are common. The role of host defenses 
in salmonellosis is extremely important, and much remains to be learned.  
Epidemiology 
Contaminated food is the major mode of transmission for non-typhoidal salmonellae 
because salmonellosis is a zoonosis and has an enormous animal reservoir. The most 
common animal reservoirs are chickens, turkeys, pigs, and cows; dozens of other 
domestic and wild animals also harbor these organisms. Because of the ability of 
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salmonellae to survive in meats and animal products that are not thoroughly cooked, 
animal products are the main vehicle of transmission. The magnitude of the problem 
is demonstrated by the following recent yields of salmonellae: 41% of turkeys exam-
ined in California, 50% of chickens cultured in Massachusetts, and 21% of commer-
cial frozen egg whites examined in Spokane, WA. 
The epidemiology of typhoid fever and other enteric fevers primarily involves per-
son-to-person spread because these organisms lack a significant animal reservoir. 
Contamination with human feces is the major mode of spread, and the usual vehicle 
is contaminated water. Occasionally, contaminated food (usually handled by an indi-
vidual who harbors S typhi) may be the vehicle. Plasmid DNA fingerprinting and 
bacteria phage lysotyping of Salmonella isolates are powerful epidemiologic tools 
for studying outbreaks of salmonellosis and tracing the spread of the organisms in 
the environment. 
In typhoid fever and non-typhoidal salmonellosis, two other factors have epidemio-
logic significance. First, an asymptomatic human carrier state exists for the agents of 
either form of the disease. Approximately 3% of persons infected with S typhi and 
0.1% of those infected with non-typhoidal salmonellae become chronic carriers. The 
carrier state may last from many weeks to years. Thus, human as well as animal res-
ervoirs exist. Interestingly, children rarely become chronic typhoid carriers. Second, 
use of antibiotics in animal feeds and indiscriminant use of antibiotics in humans in-
crease antibiotic resistance in salmonellae by promoting transfer of R factors. 
Salmonellosis is a major public health problem because of its large and varied ani-
mal reservoir, the existence of human and animal carrier states, and the lack of a 
concerted nationwide program to control salmonellae. 
Diagnosis 
The diagnosis of salmonellosis requires bacteriologic isolation of the organisms from 
appropriate clinical specimens. Laboratory identification of the genus Salmonella is 
done by biochemical tests; the serologic type is confirmed by serologic testing. Fe-
ces, blood, or other specimens should be plated on several nonselective and selective 
agar media (blood, MacConkey, eosin-methylene blue, bismuth sulfite, Salmonella-
Shigella, and brilliant green agars) as well as intoenrichment broth such as selenite or 
tetrathionate. Any growth in enrichment broth is subsequently subcultured onto the 
various agars. The biochemical reactions of suspicious colonies are then determined 
on triple sugar iron agar and lysine-iron agar, and a presumptive identification is 
made. Biochemical identification of salmonellae has been simplified by systems that 
permit the rapid testing of 10-20 different biochemical parameters simultaneously. 
The presumptive biochemical identification of Salmonella then can be confirmed by 
antigenic analysis of O and H antigens using polyvalent and specific antisera. Fortu-
nately, approximately 95% of all clinical isolates can be identified with the available 
group A-E typing antisera. Salmonella isolates then should be sent to a central or 
reference laboratory for more comprehensive serologic testing and confirmation. 
Control 
Salmonellae are difficult to eradicate from the environment. However, because the 
major reservoir for human infection is poultry and livestock, reducing the number of 
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salmonellae harbored in these animals would significantly reduce human exposure. 
In Denmark, for example, all animal feeds are treated to kill salmonellae before dis-
tribution, resulting in a marked reduction in salmonellosis. Other helpful measures 
include changing animal slaughtering practices to reduce cross-contamination of an-
imal carcasses; protecting processed foods from contamination; providing training in 
hygienic practices for all food-handling personnel in slaughterhouses, food pro-
cessing plants, and restaurants; cooking and refrigerating foods adequately in food 
processing plants, restaurants, and homes; and expanding of governmental enteric 
disease surveillance programs. 
Recently, The U.S. Department of Agriculture has approved the radiation of poultry 
to reduce contamination by pathogenic bacteria, e.g. salmonella and campylobacter. 
Unfortunately, radiation pasteurization has not yet been widely accepted in the U.S. 
Adoption and implementation of this technology would greatly reduce the magnitude 
of the salmonella problem.  
Vaccines are available for typhoid fever and are partially effective, especially in 
children. No vaccines are available for non-typhoidal salmonellosis. Continued re-
search in this area and increased understanding of the mechanisms of immunity to 
enteric infections are of great importance.  
General salmonellosis treatment measures include replacing fluid loss by oral and 
intravenous routes, and controlling pain, nausea, and vomiting. Specific therapy con-
sists of antibiotic administration. Typhoid fever and enteric fevers should be treated 
with antibiotics. Antibiotic therapy of non-typhoidal salmonellosis should be re-
served for the septicemic, enteric fever, and focal infection syndromes. Antibiotics 
are not recommended for uncomplicated Salmonella gastroenteritis because they do 
not shorten the illness and they significantly prolong the fecal excretion of the organ-
isms and increase the number of antibiotic-resistant strains. 
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Shigella 
General Concepts 
Clinical Manifestations 
Symptoms of shigellosis include abdominal pain, tenesmus, watery diarrhea, and/or 
dysentery (multiple scanty, bloody, mucoid stools). Other signs may include ab-
dominal tenderness, fever, vomiting, dehydration, and convulsions. 
Structure, Classification, and Antigenic Types 
Shigellae are Gram-negative, nonmotile, facultatively anaerobic, non-spore-forming 
rods. Shigella are differentiated from the closely related Escherichia coli on the basis 
of pathogenicity, physiology (failure to ferment lactose or decarboxylate lysine) and 
serology. The genus is divided into four serogroups with multiple serotypes: A (S 
dysenteriae, 12 serotypes); B (S flexneri, 6 serotypes); C (S boydii, 18 serotypes); 
and D (S sonnei, 1 serotype). 
Pathogenesis 
Infection is initiated by ingestion of shigellae (usually via fecal-oral contamination). 
An early symptom, diarrhea (possibly elicited by enterotoxins and/or cytotoxin), may 
occur as the organisms pass through the small intestine. The hallmarks of shigellosis 
are bacterial invasion of the colonic epithelium and inflammatory colitis. These are 
interdependent processes amplified by local release of cytokines and by the infiltra-
tion of inflammatory elements. Colitis in the rectosigmoid mucosa, with concomitant 
malabsorption, results in the characteristic sign of bacillary dysentery: scanty,. un-
formed stools tinged with blood and mucus. 
Host Defenses 
Inflammation, copious mucus secretion, and regeneration of the damaged colonic ep-
ithelium limit the spread of colitis and promote spontaneous recovery. Serotype-
specific immunity is induced by a primary infection, suggesting a protective role of 
antibody recognizing the lipopolysaccharide (LPS) somatic antigen. Other Shigella 
antigens include enterotoxins, cytotoxin, and plasmid-encoded proteins that induce 
bacterial invasion of the epithelium. The protective role of immune responses against 
these antigens is unclear. 
 62 
Epidemiology 
Shigellosis is endemic in developing countries were sanitation is poor. Typically 10 
to 20 percent of enteric disease, and 50% of the bloody diarrhea or dysentery of 
young children, can be characterized as shigellosis, and the prevalence of these in-
fections decreases significantly after five years of life. In developed countries, sin-
gle-source, food or water-borne outbreaks occur sporadically, and pockets of endem-
ic shigellosis can be found in institutions and in remote areas with substandard sani-
tary facilities. 
Diagnosis 
Shigellosis can be correctly diagnosed in most patients on the basis of fresh blood in 
the stool. Neutrophils in fecal smears is also a strongly suggestive sign. Nonetheless, 
watery, mucoid diarrhea may be the only symptom of many S sonnei infections, and 
any clinical diagnosis should be confirmed by cultivation of the etiologic agent from 
stools. 
Control 
Prevention of fecal-oral transmission is the most effective control strategy. Severe 
dysentery is treated with ampicillin, trimethoprim-sulfamethoxazole, or, in patients 
over 17 years old, a 4-fluorquinolone such as ciprofloxacin. Vaccines are not cur-
rently available, but some promising candidates are being developed. 
INTRODUCTION 
Gram-negative, facultative anaerobes of the genus Shigella are the principal agents 
of bacillary dysentery. This disease differs from profuse watery diarrhea, as is com-
monly seen in choleraic diarrhea or in enterotoxigenic Escherichia coli diarrhea, in 
that the dysenteric stool is scant and contains blood, mucus, and inflammatory cells. 
In some individuals suffering from shigellosis, however, moderate volume diarrhea 
is a prodrome or the sole manifestation of the infection. Bacillary dysentery consti-
tutes a significant proportion of acute intestinal disease in the children of developing 
countries, and this infection is a major contributor to stunted growth of these chil-
dren. Shigellosis also presents a significant risk to travelers from developed countries 
when visiting in endemic areas, and sporadic food or water-borne outbreaks occur in 
developed countries. 
The pathogenic mechanism of shigellosis is complex, involving a possible enterotox-
ic and/or cytotoxic diarrheal prodrome, cytokine-mediated inflammation of the co-
lon, and necrosis of the colonic epithelium. The underlying physiological insult that 
initiates this inflammatory cascade is the invasion of Shigella into the colonic epithe-
lium and the lamina propria. The resulting colitis and ulceration of the mucosa result 
in bloody, mucoid stools, and/or febrile diarrhea. 
Clinical Presentation 
Shigellosis has two basic clinical presentations: (1) watery diarrhea associated with 
vomiting and mild to moderate dehydration, and (2) dysentery characterized by a 
small volume of bloody, mucoid stools, and abdominal pain (cramps and tenesmus) 
(Table 22-1). Volunteer challenge studies show that shigellosis can be evoked by an 
extremely small inoculum (10-100 organisms), and the time of onset of symptoms is 
somewhat influenced by the size of the challenge. The salient point is that shigellosis 
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is an acute infection with onset of symptoms usually occurring within 24-48 hours of 
ingestion of the etiologic agent. The average duration of symptoms in untreated 
adults is 7 days, and the organism may be cultivated from stools for 30 days or long-
er. 
The clinical features of shigellosis are summarized in Figure 22-1. Watery diarrhea 
occurs as a prodrome, or as the sole clinical manifestation, in a majority of patients 
infected with S sonnei. Diarrhea is often a prodome of the dysentery characterizing 
infection with other species of Shigella. Recently discovered enterotoxins secreted 
by S flexneri may contribute to the diarrheal phase as the etiologic agents traverse 
the small intestine. However, diarrhea is most common in patients who have colitis 
involving the transverse colon or cecum. These patients evidence net water secretion 
and impaired absorption in the inflamed colon. In patients experiencing dysentery, 
involvement is most severe in the distal colon, and the resulting inflammatory colitis 
is evidenced in frequent scanty stools reflecting the ileocecal fluid flow. Dysentery is 
also characterized by the daily loss of 200-300 ml of serum protein into the feces. 
This loss of serum proteins results in depletion of nitrogen stores that exacerbates 
malnutrition and growth stunting. Depletion of immune factors also increases the 
risk of concurrent, unrelated infectious disease and contributes to substantial mortali-
ty. 
 
FIGURE 22-1 Pathogenesis of shigellosis in humans. 
Possible complications of shigellosis include bacteremia, convulsions and other neu-
rological complications, reactive arthritis, and hemolytic-uremic syndrome. Bacte-
remia occasionally accompanies S dysenteriae serotype 1 infections in malnourished 
infants, but this complication is uncommon in otherwise healthy individuals. Con-
vulsions have been reported in up to 25% of Shigella infections involving children 
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under the age of 4 years. Both high fever and a family history of seizures are risk 
factors for a convulsive episode. Ekiri syndrome, an extremely rare, fatal encephalo-
pathy has also been described in Japanese children with S sonnei or S flexneri infec-
tions. Reactive arthritis, a self-limiting sequela of S flexneri infection, occurs in an 
incidence as high as 2% in individuals expressing the HLA-B27 histocompatibility 
antigen. Hemolytic-uremic syndrome, characterized by a triad of microangiopathic 
hemolytic anemia, thrombocytopenia, and acute renal failure, is a rare complication 
in children infected with S dysenteriae serotype 1. 
Structure, Classification, and Antigenic Types 
Organisms of the genus Shigella belong to the tribe Escherichia in the family Enter-
obacteriaceae. In DNA hybridization studies, Escherichia coli and Shigella species 
cannot be differentiated on the polynucleotide level; however, the virulence pheno-
type of the latter species is a distinctive distinguishing feature. Enteroinvasive E coli 
(EIEC), are very similar to shigellae biochemically and they also evoke diarrhea 
and/or dysentery. Some EIEC are also serologically related to shigellae. For exam-
ple, EIEC serotype O124 agglutinates in S dysenteriae serotype 3 antiserum. 
The genus Shigella is differentiated into four species: S dysenteriae (serogroup A, 
consisting of 12 serotypes); S flexneri (serogroup B, consisting of 6 serotypes); S. 
boydii (serogroup C, consisting of 18 serotypes); and S sonnei (serogroup D, consist-
ing of a single serotype). Serogoups A, B, and C are very similar physiologically 
while S. sonnei can be differentiated from the other serogroups by positive b-D-
galactosidase and ornithine decarboxylase biochemical reactions. The identification 
of shigellae by species in the clinical laboratory is usually accomplished by slide ag-
glutination using commercially available, absorbed rabbit antisera. 
Pathogenesis 
Pathology 
The rectosigmoidal lesions of shigellosis resemble those of ulcerative colitis. With 
frequencies indicated in Figure 22-2, there is proximal extension of erythema, ede-
ma, loss of vascular pattern, focal hemorrhage, and adherent layers of purulent exu-
date. Biopsy specimens from affected areas are typically edematous, with capillary 
congestion, focal hemorrhage, crypt hyperplasia, goblet cell depletion, mononuclear 
and polymorphonuclear (PMN) cell infiltration, shedding of epithelial cells and 
erythrocytes, and microulcerations. 
The pathogenic mechanism that underlies these pathological manifestations is dia-
grammed in Figure 22-3. This cartoon incorporates experimental observations from 
tissue cultures and from animal models of shigellosis such as rabbit ligated ileal 
loops injected with virulent organisms. In the latter model, Shigella infection is initi-
ated at the membranous (M) cells that are associated with macroscopic lymphoid fol-
licles (Peyer's patches). Biopsy studies in rhesus monkeys suggest that shigellae also 
infect microscopic lymphoid follicles of the primate colon. During the early stages of 
infection, bacteria are transcytosed through the M cells into the subepithelial space. 
In the subepithelial space, the organisms are phagocytosed by resident macrophages.  
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FIGURE 22-2 Gross pathology of shigellosis. 
However, virulent shigellae are not killed and digested in the macrophage phagoly-
some. The bacteria lyse the phagosome and initiate apoptosis (programmed cell 
death). During this process, the infected macrophage releases the inflammatory cyto-
kine IL-1, which elicits infiltration of PMN. 
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FIGURE 22-3 Histopathology of acute colitis following peroral infection with 
shigellae. The organisms are initially ingested by membranous (M) cells that are as-
sociated with lymphoid microfollicles in the colon. After transcytosis through the M 
cell, the bacteria are deposited into the subepithelial space where they are phagocy-
tosed by macrophages. The macrophage phagosome is subsequently degraded, and 
the intracellular shigellae cause release of IL-1 that evokes an influx of polymorpho-
nuclear leukocytes (PMN). Eventually the infected macrophages undergo apoptosis 
(programmed cell death), and the bacteria are released onto the basolateral surface of 
adjacent colonic enterocytes. In addition, PMN transmigration through the epitheli-
um disrupts tight junctions, allowing shigellae to migrate into the subepithelial 
space. The bacteria infect enterocytes by induced endocytosis, and the endocytic 
vacuoles are subsequently degraded. The intercellular shigellae attach to actin in the 
enterocyte junctional complex, multiply, and spread to contiguous enterocytes by in-
duced actin polymerization. Ultimately, the infected enterocytes die, and the result-
ing necrosis of the epithelium, in conjunction with the continuing inflammatory re-
sponse, constitutes the lesions of shigellosis. 
Transmigration of infiltrating PMNs through the tight junctions of local epithelial 
cells and into the intestinal lumen allows the reverse migration of shigellae from the 
lumen into the subepithelial spaces. These organisms then infect the columnar epi-
thelial cells by inducing endocytic uptake at the basolateral surface. Immediately af-
ter infection of enterocytes, intracellular shigellae lyse endocytic vacuoles and attach 
to the actin cytoskeleton in the area of the junctional complex. As these organisms 
multiply within the enterocyte cytoplasm, occasional daughter cells induce polar nu-
cleation of filamentous actin resulting in a "tail" that propels the shigellae into pro-
trusions impinging on contiguous enterocytes. Plasma membranes enveloping the 
organisms are again lysed, and the organisms are deposited within the contiguous 
host cell resulting in intercellular bacterial spread. 
In summary, shigellosis can be characterized as an acute inflammatory bowel disease 
initiated by the uptake of only a few organisms into lymphoid follicles. Intracellular 
replication and intercellular spread leads to an amplified inflammatory cascade at the 
initial site of entry, and as this inflammation persists and expands, the infiltration of 
PMN facilitates the entry of additional bacteria into the epithelium. The inflammato-
ry infiltrate can also cause detachment of sheets of epithelial cells in areas devoid of 
lymphoid structures or bacterial cells. 
Genetics of Virulence 
Shigella are exquisitely adapted for reproduction within the colonic epithelium of the 
human host. Many of the bacterial virulence determinants that mediate the complex 
interactions between these bacteria and mammalian host cells have been identified 
by genetic and immunological means. These virulence determinants are encoded by 
large extra-chromosomal elements (plasmids) that are functionally identical in all 
Shigella species and in EIEC. A complex of two plasmid-encoded determinants, des-
ignated Invasion Plasmid Antigens (Ipa) B and C, is recognized by antibody in the 
sera of convalescent patients. Ipa proteins are maximally expressed in conditions ap-
proximating the intestinal lumen (e.g., bile salts, high osmolarity, and human body 
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temperature), and release of the IpaBC complex is triggered by contact with the 
mammalian host cell. This complex induces the endocytic uptake of shigellae by M 
cells, epithelial cells, and macrophages. IpaB also mediates lysis of endocytic vacu-
oles in epithelial cells or macrophages. In the latter case, Ipa proteins also cause re-
lease of the IL-1 cytokine and macrophage apoptosis. Another plasmid-encoded 
virulence determinant is secreted at the poles of Shigella daughter cells as these or-
ganisms multiply within the cytoplasm of infected host cells. This InterCellular 
Spread (IcsA) protein elicits polymerization of filamentous actin. Formation of this 
actin tail provides a motive force for shigellae impinging on the plasma membrane of 
the infected cell. The resulting protrusions deform the plasma membrane of contigu-
ous cells. The IcsB plasmid-encoded protein then lyses the plasma membranes, re-
sulting in intercellular bacterial spread. Biochemical characterization of the interac-
tion between these Shigella virulence determinants and host cell components is a re-
maining research challenge. Characterizing and enhancing the neutralizing potential 
of antibody recognizing these protein virulence determinants is also an important re-
search goal. 
Toxins 
Spent medium from S flexneri or EIEC cultures elicits fluid accumulation in rabbit 
ligated ileal loops and ion secretion in isolated ileal tissue. Using these assays, enter-
otoxins designated ShET1 and ShET2 have been identified, and the genetic loci en-
coding these toxins have been localized to the chromosome and plasmid, respective-
ly. ShET1 is neutralized by convalescent sera from volunteers challenged with S 
flexneri 2a, suggesting that this toxic moiety is expressed by shigellae growing in the 
human intestine. The ShET1 locus is present on the chromosome of S flexneri 2a, 
but it is only occasionally found in other serotypes. In contrast, ShET2 is more wide-
spread and detectable in 80% of shigellae representing all four species. These entero-
toxins may elicit the diarrheal prodrome that often precedes bacillary dysentery; 
however, their role in the disease process remains to be defined by controlled chal-
lenge studies using toxin-negative mutants. 
S dysenteriae serotype 1 expresses Shiga toxin, an extremely potent, ricin-like, cyto-
toxin that inhibits protein synthesis in susceptible mammalian cells. This toxin also 
has enterotoxic activity in rabbit ileal loops, but its role in human diarrhea is unclear, 
since shigellae apparently express a number of enterotoxins. Experimental infection 
of rhesus monkeys with S dysenteriae 1, and with a Shiga toxin-negative mutant, 
suggests that this cytotoxin causes capillary destruction and focal hemorrhage that 
exacerbates dysentery (see Table 22-1). More importantly, Shiga toxin is associated 
with the hemolytic-uremic syndrome, a complication of infections with S dysenteriae 
1. Closely related toxins are expressed by enterohemorrhagic E coli (EHEC) includ-
ing the potentially lethal, food-borne O157-H7 serotype. 
Host Defense 
Shigellae are remarkably infectious enteric pathogenes that can cause disease after 
the ingestion of as few as 10 organisms. Nonetheless, shigellosis is normally an 
acute, self-limiting disease that exemplifies the regenerative capacity of the intestinal 
epithelium. Shigella virulence probably reflects both the efficient uptake by the folli-
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cle associated epithelium (M cells) and the amplifying effect of the inflammatory 
cascade generated by apoptic macrophages. Tenesmus and evacuation of mucus by 
intestinal goblet cells may effectively eliminate both extracellular shigellae and in-
fected enterocytes from the intestinal lumen, but this defensive response, in conjunc-
tion with PMN infiltration, also constitutes the definitive sign of bacillary dysentery. 
In endemic areas, shigellosis is essentially a childhood disease, and the incidence de-
creases drastically in the indigenous population over 5 years of age. Controlled vol-
unteer challenge studies in North American adults also indicate that prior infection 
with S flexneri protects against reinfection with the homologous serotype (70% effi-
cacy). Serotype-specific immune protection against shigellosis suggests that anti-
body recognizing the O-polysaccharide of LPS protects against clinical symptoms. 
Ingested bovine colostrum containing antibody recognizing the O-polysaccharide of 
S flexneri 2a passively protects volunteers challenged with the homologous Shigella 
serotype. These observations have encouraged the development of a number of par-
enteral and mucosally administered O-polysaccharide vaccines that are currently in 
safety and/or efficacy trials. These vaccines offer the possibility of effective control 
of shigellosis independent of the needed improvements in the public health infra-
structure of developing countries, but licensure and delivery of practical Shigella 
vaccines remains a distant prospect. 
Epidemiology 
Humans are the primary reservoir of Shigella species, with captive subhuman pri-
mates as accidental hosts. In developing countries with prevailing conditions of in-
adequate sanitation and overcrowded housing, the infection is transmitted most often 
by the excreta of infected individuals via direct fecal-oral contamination. Flies may 
contribute to spread from feces to food. The most common species, S dysenteriae 
and S flexneri, are also the most virulent. In developed countries, sporadic common-
source outbreaks, predominantly involving S sonnei, are transmitted by uncooked 
food or contaminated water. The latter outbreaks usually involve semipublic water 
systems such as those found in camps, trailer parks, and Indian reservations. Direct 
fecal-oral spread can also occur in institutional environments such as child day-care 
centers. mental hospitals, and nursing homes. Homosexual men are also at increased 
risk for direct transmission of Shigella flexneri infections, and chronic, recrudescent 
illness complicating HIV infection has been reported. 
Diagnosis 
Clinical 
Patients presenting with watery diarrhea and fever should be suspected of having 
shigellosis. The diarrheal stage of the infection cannot be distinguished clinically 
from other bacterial, viral, and protozoan infections. Nausea and vomiting can ac-
company Shigella diarrhea, but these symptoms are also observed during infections 
with nontyphoidal salmonellae and enterotoxigenic E coli. Bloody, mucoid stools are 
highly indicative of shigellosis, but the differential diagnosis should include EIEC, 
Salmonella enteritidis, Yersinia enterocolitica, Campylobacter species, and Enta-
moeba histolytica. Although blood is common in the stools of patients with amebia-
sis, it is usually dark brown rather than bright red, as in Shigella infections. Micro-
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scopic examination of stool smears from patients with amebiasis should reveal 
erythrophagocytic trophozoites in the absence of PMN, whereas bacillary dysentery 
is characterized by sheets of PMN. Sigmoidoscopic examination of a shigellosis pa-
tient reveals a diffusely erythematous mucosal surface with small ulcers, whereas 
amebiasis is characterized by discrete ulcers in the absence of generalized inflamma-
tion. 
Laboratory 
Although clinical signs may evoke the suspicion of shigellosis, diagnosis is depend-
ent upon the isolation and identification of Shigella from the feces. Positive cultures 
are most often obtained from blood-tinged plugs of mucus in freshly passed stool 
specimens obtained during the acute phase of disease. Rectal swabs may also be used 
to culture shigellae if the specimen is processed rapidly or is deposited in a buffered 
glycerol saline holding solution. Isolation of shigellae in the clinical laboratory typi-
cally involves an initial streaking for isolation on differential/selective media with 
aerobic incubation to inhibit the growth of the anaerobic normal flora. Commonly 
used primary isolation media include MacConkey, Hektoen Enteric Agar, and Sal-
monella-Shigella (SS) Agar. These media contain bile salts to inhibit the growth of 
other Gram-negative bacteria and pH indicators to differentiate lactose fermenters 
(Coliforms) from non-lactose fermenters such as shigellae. A liquid enrichment me-
dium (Hajna Gram-negative broth) may also be inoculated with the stool specimen 
and subcultured onto the selective/differential agarose media after a short growth pe-
riod. Following overnight incubation of primary isolation media at 37° C, colorless, 
non-lactose-fermenting colonies are streaked and stabbed into tubed slants of 
Kligler's Iron Agar or Triple Sugar Iron Agar. In these differential media, Shigella 
species produce an alkaline slant and an acid butt with no bubbles of gas in the agar. 
This reaction gives a presumptive identification, and slide agglutination tests with 
antisera for serogroup and serotype confirm the identification. 
Some E coli biotypes of the normal intestinal flora closely resemble Shigella species 
(i.e. they are nonmotile, delayed lactose fermenters). These coliforms can usually be 
differentiated from shigellae by the ability to decarboxylate lysine. However, some 
coliforms cause enteroinvasive disease because they carry the Shigella-like virulence 
plasmid, and these pathogens are conventionally identified by laborious serological 
screening for EIEC serotypes. Sensitive and rapid methodology for identification of 
both EIEC and Shigella species utilizes DNA probes that hybridize with common 
virulence plasmid genes or DNA primers that amplify plasmid genes by polymerase 
chain reaction (PCR). Enzyme-linked immunosorbent assay (ELISA) using antise-
rum or monoclonal antibody recognizing Ipa proteins can also be used to screen 
stools for enteroinvasive pathogens. These experimental diagnostic techniques are 
useful for epidemiological studies of enteroinvasive infections, but they are probably 
too specialized for routine use in the clinical laboratory. 
Treatment 
Although severe dehydration is uncommon in shigellosis, the first consideration in 
treating any diarrheal disease is correction of abnormalities that result from isotonic 
dehydration, metabolic acidosis, and significant potassium loss. The oral rehydration 
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treatment developed by the World Health Organization has proven effective and safe 
in the treatment of acute diarrhea, provided that the patient is not vomiting or in 
shock from severe dehydration. In the latter case, intravenous fluid replacement is 
required until initial fluid and electrolyte losses are corrected. With proper hydration, 
shigellosis is generally a self-limiting disease, and the decision to prescribe antibiot-
ics is predicated on the severity of disease, the age of the patient, and the likelihood 
of further transmission of the infection. Effective antibiotic treatment reduces the av-
erage duration of illness from approximately 5-7 days to approximately 3 days and 
also reduces the period of Shigella excretion after symptoms subside. Absorbable 
drugs such as ampicillin (2 g/day for 5 days) are likely to be effective when the iso-
late is sensitive. Trimethoprim (8 mg/kg/day) and sulfamethoxazole (40 mg/kg/day) 
will eradicate sensitive organisms quickly from the intestine, but resistance to this 
agent is increasing. Ciprofloxacin (1 g/day for 3 days) is effective against multiple 
drug resistant strains, but this antibiotic is not approved by the United States Food 
and Drug Administration for use in children less than 17 years of age because there 
is a theoretical risk of cartilage damage. Opiates, such as paregoric, induce intestinal 
stasis and may promote bacterial invasion, prolonging the febrile state. 
Control 
As is the case with other intestinal infections, the most effective methods for control-
ling shigellosis are provision of safe and abundant water and effective feces disposal. 
These public health measures are, at best, long range strategies for control of enteric 
infections in developing countries. The estimated five million deaths annually at-
tributed to diarrheal disease in these countries, in addition to the malabsorption and 
growth stunting among survivors, require more immediate and practical approaches. 
The most effective intervention strategy to minimize morbidity and mortality would 
involve comprehensive media and personal outreach programs consisting of the fol-
lowing components: (1) education of all residents to actively avoid fecal contamina-
tion of food and water and to encourage hand washing after defecation; (2) encour-
age mothers to breast-feed infants; (3) promote the use of oral rehydration therapy to 
offset the effects of acute diarrhea; (4) encourage mothers to provide convalescent 
nutritional care in the form of extra food for children recovering from diarrhea or 
dysentery. 
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Campylobacter and Helicobacter 
General Concepts 
Campylobacter Jejuni and other Enteric Campylobacters 
Clinical Manifestations 
Campylobacter species cause acute gastroenteritis with diarrhea, abdominal pain, fe-
ver, nausea, and vomiting. Recently, Campylobacter infections have been identified 
as the most common antecedent to an acute neurological disease, the Guillain-Barré 
syndrome. 
Structure 
Campylobacter species are Gram-negative, microaerophilic, non-fermenting, motile 
rods with a single polar flagellum; they are oxidase-positive and grow optimally at 
37° or 42°C. 
Classification and Antigenic Types 
Campylobacter species have many serogroups, based on lipopolysaccharide (O) and 
protein (H) antigens. However, only a few serogroups account for most human iso-
lates in a given geographic region. C jejuni possesses several common surface-
exposed antigens, including porin protein and flagellin. 
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Pathogenesis 
The bacteria colonize the small and large intestines, causing inflammatory diarrhea 
with fever. Stools contain leukocytes and blood. The role of toxins in pathogenesis is 
unclear. C jejuni antigens that cross-react with one or more neural structures may be 
responsible for triggering the Guillian-Barre syndrome. 
Host Defenses 
Nonspecific defenses such as gastric acidity and intestinal transit time are important. 
Specific immunity, involving intestinal immunoglobulin (IgA) and systemic antibod-
ies, develops. Persons deficient in humoral immunity develop severe and prolonged 
illnesses. 
Epidemiology 
C jejuni and C coli infections are endemic worldwide and hyperendemic in develop-
ing countries. Infants and young adults are most often infected. Disease incidence 
peaks in the summer. Domestic and wild animals are the reservoirs for the organ-
isms. Outbreaks are associated with contaminated animal products or water. 
Diagnosis 
Observation of darting motility in fresh fecal specimens or of vibrio forms on Gram 
stain permit presumptive diagnosis; definitive diagnosis is established by stool cul-
ture, and occasionally by blood culture. 
Control 
Control depends on measures to prevent transmission from animal reservoirs to hu-
mans. 
Helicobacter Pylori and other Gastric Helicobacter-like Organisms 
Clinical Manifestations 
Helicobacter pylori is associated with chronic superficial gastritis (stomach inflam-
mation) and plays a role in the pathogenesis of peptic ulcer disease. Increasing evi-
dence indicates that H pylori infection is important in causing gastric carcinoma and 
lymphoma. Acute infection may cause vomiting and upper gastrointestinal pain; hy-
pochlorhydria and intense gastritis develop. Chronic infection usually is asympto-
matic. 
Structure 
This Gram-negative curved or spiral rod is distinguished by multiple, sheathed 
flagellae and abundant urease. 
Classification and Antigenic Types 
The antigenic structures are not completely defined and no universal typing scheme 
has been developed; strains may be differentiated by genotypic methods including 
restriction endonuclease analysis, and polymerase chain reaction (PCR). 
Pathogenesis 
Helicobacter pylori is sheltered from gastric acidity in the mucus layer and a small 
proportion of cells adheres to the gastric epithelium. The microorganism does not 
appear to invade tissue. Production of urease, a vacuolating cytotoxin, and the cagA-
encoded protein is associated with injury to the gastric epithelium. 
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Host Defenses 
Local and systemic humoral immune responses are essentially universal, but are not 
able to clear infection. 
Epidemiology 
H pylori infection has a worldwide distribution; about 1/3 of the world's population 
is infected. The prevalence of infection increases with age. The major, if not exclu-
sive, reservoir is humans but the exact modes of transmission are not known. H pylo-
ri has now been isolated from feces and dental plaque. 
Diagnosis 
Examination of gastric biopsy or stained smears allows presumptive diagnosis; de-
finitive diagnosis is made by culture. Recently, non-invasive techniques such as the 
urea breath test and serologic tests have been developed to diagnose H pylori infec-
tion, with accuracy exceeding 95 percent. 
Control 
Several indications have emerged for the use of antimicrobial therapies that eradicate 
H pylori infection. No vaccine is yet available. 
Other Pathogenic Camplyobacter and Helicobacter Species 
Campylobacter fetus causes bacteremia in compromised hosts and self-limited diar-
rhea in previously healthy individuals. Helicobacter cinaedi and H fennelliae cause 
enteric and extraintestinal diseases and are more common in homosexual men and in 
travelers. 
INTRODUCTION 
Campylobacter and Helicobacter are Gram-negative microaerophilic bacteria that are 
widely distributed in the animal kingdom. They have been known as animal patho-
gens for nearly 100 years. However, because they are fastidious and slow-growing in 
culture, they have been recognized as human gastrointestinal pathogens only during 
the last 20 years. They can cause diarrheal illnesses, systemic infection, chronic su-
perficial gastritis, peptic ulcer disease, and can lead to gastric carcinoma. 
Table 23-1 lists the Campylobacter species known to be pathogenic for humans. 
Campylobacter jejuni, and, less often, C coli and C lari are the most common bacte-
rial causes of acute diarrheal illnesses in developed countries. Helicobacter pylori 
(formerly known as Campylobacter pylori), which was first cultured from gastric bi-
opsy tissues in 1982, causes chronic superficial gastritis and is associated with the 
pathogenesis of peptic ulcer disease and gastric cancer. Campylobacter fetus subspe-
cies fetus occasionally causes systemic illnesses in compromised hosts. 
Campylobacter Jejuni and other Enteric Campylobacters 
Clinical Manifestations 
The symptoms and signs of Campylobacter enteritis are not distinctive enough to dif-
ferentiate it from illness caused by many other enteric pathogens. Symptoms range 
from mild gastrointestinal distress lasting 24 hours to a fulminating or relapsing coli-
tis that mimics ulcerative colitis or Crohn's disease (Figure 23-1). The predominant 
symptoms experienced by individuals in developed countries are diarrhea, abdominal 
pain, fever, nausea, and vomiting. A history of grossly bloody stools is common, and 
many patients have at least one day with eight or more bowel movements; fecal leu-
 74 
kocytes are usually present. A cholera-like illness with massive watery diarrhea may 
also occur. Campylobacter enteritis usually is self-limiting with gradual improve-
ment in symptoms over several days. Most patients recover within a week, but 10%-
20% experience relapse or a prolonged severe illness. Toxic megacolon, pseudo-
membranous colitis, and massive lower gastrointestinal hemorrhage also have been 
described. Mesenteric adenitis and appendicitis have been reported in children and 
young adults. Bacteremia is uncommon (<1%) in immunocompetent patients with C 
jejuni infection. 
 
Figure 23-1 Pathogenesis of Campylobacter and Helicobacter infection in hu-
mans. 
Among populations in developing countries, infection by C jejuni and closely related 
organisms is associated with much milder illness, without bloody diarrhea, fever or 
fecal leukocytes. Asymptomatic infection is much more common than in the devel-
oped countries, especially in older children and adults. However, when travelers 
from developed countries acquire C jejuni infections in developing countries, the 
symptoms are those associated with an inflammatory process. This indicates that or-
ganisms in the developing countries are fully pathogenic. Guillain-Barré syndrome is 
an uncommon consequence of C jejuni infection that is present 2-3 weeks after the 
diarrheal illness. However, because of the high incidence of Campylobacter infec-
tion, it has been estimated to be the trigger of 20 to 40 percent of all cases of Guil-
lain-Barré syndrome. 
Structure 
Campylobacter jejuni, like all Campylobacter species, is a microaerophilic, non-
fermentative Gram-negative organism. The name Campylobacter, meaning "curved 
rod," describes the appearance of the organisms (Figure 23-2). In young cultures, or-
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ganisms are comma shaped, spiral, S shaped, or gull-winged shaped; as cultures age 
or are subjected to atmospheric or temperature stresses, round or coccoid forms ap-
pear. 
C jejuni, which is structurally similar to other Gram-negative bacilli, is motile, with a 
single flagellum at one or both poles of the cell. The cell envelope has an inner bipo-
lar lipid cell membrane, a thin peptidoglycan layer, an outer bipolar lipid layer with 
the lipid moiety of a lipopolysaccharide layer embedded in it, and the carbohydrate 
portion extending to the surface of the cell. Interspersed in the outer membrane layer 
are membrane proteins, some of which are exposed to the surface and are antigenic 
for infected hosts. Many Campylobacter species contain surface proteins that are ex-
ternal to the outer membrane. Campylobacter lipopolysaccharide has endotoxin ac-
tivity similar to that of other Gram-negative bacteria. 
All Campylobacter species except H pylori are similar in structure and appearance. 
The Campylobacter and Helicobacter species and subspecies may be differentiated 
by biochemical markers. 
Classification and Antigenic Types 
Based on heat-labile antigens, at least 108 serogroups of both C jejuni and C coli 
have been described. In addition, 47 and 18 different heat-stable somatic (O) anti-
gens have been described among isolates of C jejuni and C coli organisms, respec-
tively. Although geographic differences in the prevalence of serogroups exist, 10 O-
groups account for about 70% of human infections. Similarly, only a few serogroups 
account for most human isolates in any geographic region. Serotyping has been of 
value in numerous epidemiologic investigations. 
Despite the antigenic diversity of these organisms, C jejuni possesses several com-
mon surface-exposed antigens which have been used for development of serological 
tests. Major antigens include the porin protein (Mr 45,000), flagellin (Mr 63,000), 
and a group of proteins around Mr 30,000 that appear important in adhesion. The 
flagellar proteins undergo antigenic phase variation. 
Pathogenesis 
As with other enteric pathogens, the attack rate of C jejuni varies with the ingested 
dose. In outbreaks of Campylobacter enteritis, the incubation period has ranged from 
1-7 days, with most illness developing 2-4 days after infection. Infection leads to 
multiplication of organisms in the intestines. Patients shed 106 to 109 Campylobac-
ter per gram of feces, concentrations similar to those shed in Salmonella and Shigella 
enteric infections. The sites of tissue injury include the small and large intestines, 
and the lesions show an acute exudative and hemorrhagic inflammation. Patients fre-
quently have colonic involvement consisting of inflammation of the lamina propria 
with neutrophils, eosinophils, and mononuclear cells. Destruction of epithelial glands 
with crypt abscess formation occurs in severe cases (Figure 23-3). The pathologic 
lesions seen in Campylobacter colitis are difficult to distinguish from those in ulcera-
tive colitis. Therefore, before ulcerative colitis can be diagnosed, infection by Cam-
pylobacter and related organisms should be ruled out. 
The mechanisms by which C jejuni causes illness are uncertain. Cellular infiltration 
in colonic biopsy specimens of patients with Campylobacter infections and the occa-
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sional presence of bacteremia suggest that these organisms may be invasive. That 
most Campylobacter enteritis in developed countries is associated with fever and the 
presence of fecal leukocytes and blood in the stool also is consistent with the inva-
sive characteristics of the organisms. C jejuni is invasive in vitro in chicken embryo 
cells and causes bacteremia in experimentally infected mice, rabbits, calves, chickens 
and monkeys. 
Some C jejuni isolates elaborate very low levels of cytotoxins similar to Shiga toxin. 
Some isolates have been reported to elaborate an enterotoxin similar to cholera toxin. 
Enterotoxin production has been more frequently observed in isolates from develop-
ing countries, where infection by C jejuni has been associated with watery diarrhea. 
However, the clinical significance of the toxigenicity of these organisms is still un-
clear. Strains lacking detectable enterotoxin production and with low level in vitro 
cytotoxin production were fully virulent in volunteers. Campylobacter jejuni may 
adhere in vitro in several tissue culture lines. This may be important in intestinal col-
onization or may enhance tissue invasion. A superficial antigen (PEB1) that appears 
to be the major adhesin is conserved among C jejuni strains. However, the actual in 
vivo significance of adherence remains undefined. 
Host Defenses 
C jejuni and related organisms are capable of infecting healthy persons as well as 
immunocompromised patients. The minimal infection-causing dose of C jejuni is not 
known, although volunteers who have ingested as few as 800 organisms have be-
come ill. Campylobacter jejuni can be killed by hydrochloric acid, suggesting that 
normal gastric acidity may be an important barrier against infection. 
Neutrophils often are observed in the feces of patients infected with C jejuni, and co-
lonic biopsy specimens from patients with Campylobacter colitis have shown 
marked infiltration with neutrophils, suggesting that these cells may be important in 
host defense. In mice, macrophages are important for clearance of bacteremia, and, 
in vitro, C jejuni antigens stimulate a T-cell response. 
Acutely infected persons frequently develop elevated specific serum Immunoglobu-
lin A (IgA), IgG, and IgM titers, which may persist for several weeks. Experimental-
ly infected animals and humans manifest specific intestinal IgA production. Whether 
the antibody response eliminates the infection or protects against reinfection is not 
known. However, upon challenge with C jejuni, human volunteers with elevated 
specific serum IgA levels were likely to develop asymptomatic infection with only a 
brief duration of pathogen excretion. In contrast, hypogammaglobulinemic persons 
and those with acquired immune deficiency syndrome (AIDS) are at increased risk 
for severe, recurrent or bacteremic infections. C jejuni isolates are usually suscepti-
ble to complement-mediated killing by normal serum. Regardless of the exact host 
defense mechanisms involved, most C jejuni infections resolve spontaneously. 
Epidemiology 
In developed countries, C jejuni is an important cause of diarrhea, particularly in 
children and young adults (Figure 23-4). Between 3 and 14 percent of patients with 
diarrhea who seek medical attention are infected with C jejuni. Prolonged asympto-
matic carriage is rare. The attack rate is highest in children less than 1 year old, and 
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gradually decreases throughout childhood. A second peak occurs in young adults (18 
to 29 years old). Although C jejuni enteritis occurs throughout the year, the highest 
isolation rates occur in summer, as with other enteric pathogens. In contrast, up to 40 
percent of healthy children in developing countries may carry the organism at any 
time. This is an age-related phenomenon, with the highest excretion rates in very 
young children. Case-to-infection ratios decline with age, which probably is indica-
tive of acquisition of immunity due to recurrent exposure. 
Diagnosis 
Campylobacter enteritis is hard to distinguish from enteritis caused by other patho-
gens. The presence of neutrophils or blood in the feces of patients with acute diar-
rheal illnesses is an important clue to Campylobacter infection. Darting motility in a 
fresh fecal specimen observed by dark-field or phase-contrast microscopy or charac-
teristic vibrio forms visible after Gram staining permit a presumptive diagnosis. The 
diagnosis is confirmed by isolating the organism from a fecal culture or, rarely, from 
a blood culture (Figure 23-5). Because of its growth requirement for microaerobic 
atmosphere, special laboratory methods are needed to isolate C jejuni. Plating meth-
ods must be selective to inhibit the growth of competing microorganisms in the fecal 
flora. The traditional approach to isolating C jejuni has been to use media that con-
tain antibiotics to which C jejuni is resistant but most members of the usual flora are 
susceptible. However, owing to their motility and small diameter, Campylobacter 
organisms have been isolated by filtration methods that do not use antibiotic-
containing media. Use of filters (pore size 0.6µm) in conjunction with non-selective 
media improves stool culture yields of both C jejuni and the atypical enteric Cam-
pylobacters. Polymerase chain reaction (PCR)-based techniques have been devel-
oped for rapid detection, culture confirmation and for typing of C jejuni strains. 
 
Figure 23-5 Detection of C jejuni and related enteric bacteria. 
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Because Campylobacter is microaerophilic, cultures must be incubated in an envi-
ronment with reduced oxygen, optimally between 5 and 10 percent. The optimal 
temperature for growth is 42°C for C jejuni, and 37°C for many of the other enteric 
Campylobacters. When selective methods are used, suspicious colonies can be readi-
ly identified by their spreading character, mucoid appearance, and grayish color. The 
series of biochemical reactions outlined in Table 23-2 can differentiate the Campylo-
bacter species. Serologic methods for diagnosis are only research tools at the present. 
A non-radioactive gene probe is available for rapid identification of C jejuni and C 
coli from isolated colonies. 
Control 
Control of Campylobacter enteritis depends largely on interrupting the transmission 
of the organism to humans from farm and domestic animals, food of animal origin, 
or contaminated water. Individuals can reduce the risk of Campylobacter infection 
by properly cooking and storing meat and dairy products, avoiding contaminated 
drinking water and unpasteurized milk, and washing their hands after contact with 
animals or animal products. 
Fluid and electrolyte replacement are the cornerstones for treatment. Specific treat-
ment with antimicrobial agents indicated for persons with severe or prolonged symp-
toms. However, for mild infections, the efficacy of treatment with antimicrobial 
agents has not yet been demonstrated. When treatment is required, erythromycin or 
ciprofloxacin appear to be the agents of choice. The presence of several surface-
exposed, broadly specific proteins may permit vaccine development. 
Other Pathogenic Campylobacter Species 
Campylobacter fetus subsp fetus, well known as an animal pathogen, may cause bac-
teremia and other extraintestinal infections in compromised hosts, as well as an un-
common self-limited diarrheal illness in previously healthy persons. Recognized 
complications of C fetus infection include meningitis, endocarditis, pneumonia, 
thrombophlebitis, septicemia, arthritis, and peritonitis. 
Virtually all C fetus isolates from humans possess lipopolysaccharide molecules with 
long polysaccharide side chains. Two major serogroups, A and B, have been identi-
fied. A microcapsule of high molecular-weight, antigenically related surface-array 
proteins has been associated with serum and phagocytosis resistance. These proteins 
apparently mediate serum resistance by inhibiting the binding of complement com-
ponent C3b, thereby conferring to the organism a significant survival advantage. C 
fetus can undergo antigenic variation, switching the particular S-layer protein ex-
pressed. 
Helicobacter Pylori and other Gastric Helicobacter-Like Organisms 
Clinical Manifestations 
Helicobacter pylori has repeatedly been shown to be associated with chronic superfi-
cial gastritis (CSG), which involves the antrum and the fundus of the stomach (Fig-
ure 23-1). Essentially all infected persons develop chronic superficial gastritis and it 
has clearly been shown worldwide that H pylori is the major cause of this lesion. 
Most of the patients with H pylori-induced chronic superficial gastritis are asympto-
matic. The organisms are present on the luminal surface of mucus-secreting cells and 
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within gastric pits, but do not invade tissue. Colonization of the affected areas of the 
gastric mucosa may be patchy (heavily colonized areas may be adjacent to those with 
no colonization). Organisms are generally not present over areas of intestinal meta-
plasia in the gastric mucosa. This CSG is nearly always present in patients with ei-
ther gastric or duodenal ulcers. Essentially all patients with duodenal ulcers harbor H 
pylori in the duodenum. In duodenal ulcer disease, H pylori is associated with gastric 
metaplasia, but not with normal duodenal mucosa. The association of H pylori infec-
tion and gastric metaplasia is highly associated with active duodenitis. 
H pylori causes the most common form of chronic gastritis (CSG), and chronic gas-
tritis is a well known risk factor for the development of gastric carcinoma. The epi-
demiologic characteristics of H pylori infection are similar to those observed in the 
epidemiology of adenocarcinoma of the stomach. In addition, the development of in-
testinal metaplasia and atrophic gastritis, two risk factors for gastric cancer, are asso-
ciated with H pylori infection. All these data and prospective epidemiologic studies 
indicate that infection of humans with H pylori is causally associated with the risk of 
developing gastric cancer. H pylori infection also is associated with risk of develop-
ing gastric lymphoma. 
Structure 
H pylori differs genetically from members of the genus Campylobacter, and has been 
reclassified from Campylobacter (where it was initially placed) to the separate genus 
Helicobacter. H pylori organisms are microaerophilic, nonsporulating, Gram-
negative curved rods, 3.5 µm long and 0.5 to 1 µm wide, with a spiral periodicity in 
fresh cultures and spherical (coccoid) forms present in older cultures. H pylori fur-
ther differs from Campylobacter species in having multiple polar sheathed flagellae 
(Figure 23-6), a unique composition of cell wall fatty acids, and a smooth surface. 
Most Campylobacter species contain either unipolar or bipolar single unsheathed 
flagellae and have a wrinkled surface. Unlike most campylobacters, H pylori produc-
es urease and does not grow when incubated below 30°C. Growth is best on choco-
late or blood agar plates after incubation for 2 to 5 days; for liquid media, either a 
blood or a hemin source appears essential. 
Classification and Antigenic Types 
The antigenic nature of H pylori has not been completely defined. The whole-cell 
and outer-membrane profiles of all H pylori isolates have major similarities and are 
substantially different from those of C jejuni and C fetus. However, H pylori has 
strain-specific protein and lipopolysaccharide antigens, so it may be possible to type 
the organism. Simple systems for biotyping and serotyping H pylori are not yet 
available, but strains can be differentiated by genotypic-based techniques such as re-
striction endonuclease analysis, polymerase chain reaction, and restriction fragment 
length polymorphism (RFLP). 
Pathogenesis 
Helicobacter pylori are readily killed by brief exposure to hydrochloric acid solu-
tions with pH below 4.0. This is paradoxical for an organism whose primary resi-
dence is the gastric lumen. However, several factors may explain this phenomenon. 
Firstly, H pylori lives in the mucus layer overlaying the gastric mucosa, a niche pro-
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tected against gastric acid. This mucus is relatively thick and viscous and maintains a 
pH gradient from approximately pH 2 adjacent to the gastric lumen to pH 7.4 imme-
diately above the epithelial cells. Secondly, H pylori is among the most efficient 
producers of urease. An important effect of this metabolic activity is the release of 
ammonia, which buffers acidity. Third, H pylori is highly motile even in very vis-
cous mucus. This motility may allow organisms to migrate to the most favorable pH 
gradient. Finally, acute H pylori infection is associated with hypochlorhydria. H py-
lori only overlays gastric-type but not intestinal-type epithelial cells; a proportion of 
the bacterial cells are adherent. 
Inflammatory infiltrates with polymorphonuclear leukocytes, eosinophils, and an in-
creased number of lymphocytes are observed in the epithelium and lamina propria 
(Figure 23-7). The exact mechanism by which H pylori causes tissue injury is un-
known. At present there is little evidence for direct tissue invasion by H pylori. For 
pathogenic organisms that do not invade tissue, the lesions are likely to reflect a re-
sponse to extracellular products such as exotoxins. An 87kDa cytotoxin that induces 
vacuolation of eukaryotic cells is expressed in vitro by about 50% of strains. Howev-
er, vacA, the gene encoding this toxin, is present in all strains but has substantial var-
iability. Strains from patients with ulcers are more often toxin-producing than are 
strains from patients with gastritis only. H pylori also appears to affect the gastric 
mucus layer in which it resides. Isolates cultured in vitro produce an extracellular 
protease. This proteolytic activity affects the ability of mucus to retard diffusion of 
hydrogen ions. Mucus depletion over inflamed tissues is characteristic of H pylori-
associated gastritis. Ammonia, produced by urease, is known to be toxic to eukaryot-
ic cells and may potentiate mucosal injury. H pylori strains from patients with duo-
denal ulceration more frequently express a highly antigenic protein of 120-128kDa 
than H pylori strains from patients with gastritis. The gene encoding this protein, 
termed cagA, only is present in about 60% of H pylori strains. 
Host Defenses 
Although gastric acid plays an important role in protection against many enteric or-
ganisms, it is not a sufficient barrier to prevent colonization of the gastric mucosa by 
H pylori. Infected persons develop high titers of serum and local IgA and IgG anti-
bodies to H pylori. Longitudinal serologic studies show that H pylori can persist for 
years or longer despite these high antibody levels. It is not known whether these spe-
cific antibodies play any protective role, such as inhibiting adherence or promoting 
opsonophagocytosis. The role of cell-mediated immunity to these persistent patho-
gens has only been explored in recent years. Activation of mononuclear cells by H 
pylori induces production of tumor necrosis factor a, Interleukin-1 and other cyto-
kines. Differences among infected hosts in cell-mediated immunity are possible de-
terminants of outcome variability. 
Epidemiology 
H pylori is found worldwide and affects persons from diverse socioeconomic strata. 
The prevalence of these infections, as documented by both histologic and serologic 
studies, rises with age, as does gastritis. Person-to-person transmission is the major, 
if not exclusive, source of infection. H pylori has been isolated from dental plaque, 
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and DNA products may be detected in saliva by PCR. H pylori has been isolated 
from feces. These data indicate potential routes of transmission of H pylori. H pylori 
is frequently isolated from asymptomatic persons who have no dyspeptic or ulcer-
related symptoms. H pylori infection is more common among populations from de-
veloping areas than in more industrialized countries. Moreover, high prevalence of 
infection has been observed among persons in settings where sanitary conditions are 
suboptimal suggesting that fecal-oral transmission occurs. Infection, defined by se-
ropositivity, persists for years and possibly for life. The annual incidence of infection 
in adult populations in developed countries is approximately 1 percent. On occasion, 
transmission occurs from person to person via contaminated endoscopes. 
Other gastric Helicobacter-like organisms have now been observed in a variety of 
animals, including rodents, primates, swine, and ferrets, but with the exception of 
primates and possibly cats, these isolates are clearly different from human isolates. 
Human exposure to non-human primates is not sufficiently frequent to explain the 
wide prevalence of H pylori infection in humans. Food-borne transmission would not 
be unusual for an enteric pathogen, but no other environmental reservoirs of H pylori 
have been identified. 
Diagnosis 
H pylori can be presumptively identified in freshly prepared gastric biopsy smears by 
phase-contrast microscopy, based on the characteristic motility of the microorgan-
isms, and by staining histologic sections from gastric biopsies with Gram (carbol 
fuchsin counterstain), Warthin-Starry silver, Giemsa, or acridine orange stains. Or-
ganisms also can be seen directly in fixed tissue stained with hematoxylin and eosin. 
H pylori may be isolated from gastric tissue or from biopsies of esoageal or duodenal 
tissue containing gastric metaplasia (Figure 23-8) using nonselective media, such as 
chocolate agar, or antibiotic-containing selective media, such as those of Skirrow or 
Goodwin. Spiral organisms that are oxidase-, catalase-, and urease-positive can be 
identified as H pylori. Culture allows determination of antimicrobial susceptibilities. 
In gastric biopsies, H pylori also can be diagnosed presumptively, on the basis of the 
presence of preformed urease. DNA probe and PCR methodologies have been devel-
oped as well. 
All of the above tests require endoscopy and biopsy. A non-invasive technique 
known as the urea breath test has been developed to diagnose H pylori infection. In-
fection can also be diagnosed accurately by detecting serum antibodies to H pylori 
antigens. These methods may be more sensitive than diagnostic methods involving 
biopsies. These non-invasive methods will greatly facilitate diagnosis in individual 
patients, aid studies of the epidemiology of this infection, and be useful for evalua-
tion of the efficacy of antimicrobial therapy. A number of kits now are commercially 
available. 
Control 
Antimicrphobial therapy for treatment of this infection has emerged as the most im-
portant means to resolve H pylori infection. Antimicrobial therapy is now one of the 
primary therapies for duodenal ulceration. Studies to identify the best combinations 
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of antibiotics are being done. However, for most cases of H pylori-associated non-
ulcer dyspepsia, data related to efficacy of antimicrobial therapy are not clear.  
 
Figure 23-8 Detection methods for H pylori 
Other Pathogenic Helicobacter Species 
Helicobacter cinaedi and Helicobacter fennelliae are two newly recognized Helico-
bacter species, formerly identified as Campylobacter species which have been asso-
ciated with enteric and extraintestinal diseases; they are more common in homosexu-
al men, and in travelers to developing countries. 
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Cholera, Vibrio cholerae O1 and O139, and Other 
Pathogenic Vibrios  
Cholera and Vibrio cholerae 
Clinical Manifestations 
Cholera is a potentially epidemic and life-threatening secretory diarrhea character-
ized by numerous, voluminous watery stools, often accompanied by vomiting, and 
resulting in hypovolemic shock and acidosis. It is caused by certain members of the 
species Vibrio cholerae which can also cause mild or inapparent infections. Other 
members of the species may occasionally cause isolated outbreaks of milder diarrhea 
whereas othersthe vast majorityare free-living and not associated with disease. 
Structure, Classification, and Antigenic Types 
Vibrios are Gram-negative, highly motile curved rods with a single polar flagellum. 
They tolerate alkaline media that kill most intestinal commensals, but they are sensi-
tive to acid. Numerous free-living vibrios are known, some potentially pathogenic. 
Until 1992, cholera was caused by only two serotypes, Inaba (AC) and Ogawa (AB), 
and two biotypes, classical and El Tor, of toxigenic O group 1 V cholerae. These or-
ganisms may be identified by agglutination in O group 1-specific antiserum directed 
against the lipopolysaccharide component of the cell wall and by demonstration of 
their enterotoxigenicity. In 1992, cholera caused by serogroup O139 (synonym 
"Bengal"; the 139th and latest serogroup of V cholerae to be identified) emerged in 
epidemic proportions in India and Bangladesh. This serovar is identified by 1) ab-
sence of agglutination in O group 1 specific antiserum; 2) by agglutination in O 
group 139 specific antiserum; and 3) by the presence of a capsule. 
Pathogenesis 
Cholera is transmitted by the fecal-oral route. Vibrios are sensitive to acid, and most 
die in the stomach. Surviving virulent organisms may adhere to and colonize the 
small bowel, where they secrete the potent cholera enterotoxin (CT, also called 
"choleragen"). This toxin binds to the plasma membrane of intestinal epithelial cells 
and releases an enzymatically active subunit that causes a rise in cyclic adenosine 
51-monophosphate (cAMP) production. The resulting high intracellular cAMP level 
causes massive secretion of electrolytes and water into the intestinal lumen. 
Host Defenses 
Gastric acid, mucus secretion, and intestinal motility are the prime nonspecific de-
fenses against V cholerae. Breastfeeding in endemic areas is important in protecting 
infants from disease. Disease results in effective specific immunity, involving pri-
marily secretory immunoglobulin (IgA), as well as IgG antibodies, against vibrios, 
somatic antigen, outer membrane protein, and/or the enterotoxin and other products. 
Epidemiology 
Cholera is endemic or epidemic in areas with poor sanitation; it occurs sporadically 
or as limited outbreaks in developed countries. In coastal regions it may persist in 
shellfish and plankton. Long-term convalescent carriers are rare. Enteritis caused by 
the halophile V parahaemolyticus is associated with raw or improperly cooked sea-
food. 
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Diagnosis 
The diagnosis is suggested by strikingly severe, watery diarrhea. For rapid diagnosis, 
a wet mount of liquid stool is examined microscopically. The characteristic motility 
of vibrios is stopped by specific antisomatic antibody. Other methods are culture of 
stool or rectal swab samples on TCBS agar and other selective and nonselective me-
dia; the slide agglutination test of colonies with specific antiserum; fermentation 
tests (oxidase positive); and enrichment in peptone broth followed by fluorescent an-
tibody tests, culture, or retrospective serologic diagnosis. More recently the poly-
merase chain reaction (PCR) and additional genetically-based rapid techniques have 
been recommended for use in specialized laboratories. 
Control 
Control by sanitation is effective but not feasible in endemic areas. A good vaccine 
has not yet been developed. A parenteral vaccine of whole killed bacteria has been 
used widely, but is relatively ineffective and is not generally recommended. An ex-
perimental oral vaccine of killed whole cells and toxin B-subunit protein is less than 
ideal. Living attenuated genetically engineered mutants are promising, but such 
strains can cause limited diarrhea as a side effect. Antibiotic prophylaxis is feasible 
for small groups over short periods. 
Other Vibrio Infections 
Other serogroups of V cholerae may cause diarrheal disease and other infections but 
are not associated with epidemic cholera. Vibrio parahaemolyticus is an important 
cause of enteritis associated with the ingestion of raw or improperly prepared sea-
food. Other Vibrio species, including V vulnificus, can cause infections of humans 
and other animals including fish. Campylobacter species (formerly included with 
vibrios) can cause enteritis. C pylori, now known as Helicobacter pylori, is associat-
ed with gastric and duodenal ulcers (see Ch. 23). 
INTRODUCTION 
Vibrios are highly motile, gram-negative, curved or comma-shaped rods with a sin-
gle polar flagellum. Of the vibrios that are clinically significant to humans, Vibrio 
cholerae O group 1, the agent of cholera, is the most important. Vibrio cholerae was 
first isolated in pure culture by Robert Koch in 1883, although it had been seen by 
other investigators, including Pacini, who is credited with describing it first in Flor-
ence, Italy, in 1854. 
Cholera is a life-threatening secretory diarrhea induced by an enterotoxin secreted by 
V cholerae. Cholera and the cholera enterotoxin are increasingly recognized as the 
prototypes for a wide variety of non-invasive diarrheal diseases, collectively known 
as the enterotoxic enteropathies; of these, diarrhea due to enterotoxigenic strains of 
Escherichia coli (see Ch. 26) is the most important. Cholera remains a major epidem-
ic disease. There have been seven great pandemics. The latest, which started in 1961, 
invaded the Western Hemisphere (for the first time this century) with a massive out-
break in Peru in 1991. There have since been more than a million cases in Central 
and South America as well as a few imported cases in the U.S. and Canada. V chol-
erae serogroup O139, which arose in October of 1992 in India and Bangladesh, may 
become the cause of the 8th great pandemic of cholera. 
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Other vibrios may also be clinically significant in humans, and some are known to 
cause diseases in domestic animals. Nonpathogenic vibrios are widely distributed in 
the environment, particularly in estuarine waters and seafoods. For this reason, isola-
tion of a vibrio from a patient with diarrheal disease does not necessarily indicate an 
etiologic relationship. 
Vibrio Cholerae 
Clinical Manifestations 
Following an incubation period of 6 to 48 hours, cholera begins with the abrupt onset 
of watery diarrhea (Fig. 24-1). The initial stool may exceed 1 L, and several liters of 
fluid may be secreted within hours, leading to hypovolemic shock. Vomiting usually 
accompanies the diarrheal episodes. Muscle cramps may occur as water and electro-
lytes are lost from body tissues. Loss of skin turgor, scaphoid abdomen, and weak 
pulse are characteristic of cholera. Various degrees of fluid and electrolyte loss are 
observed, including mild and subclinical cases. The disease runs its course in 2 to 7 
days; the outcome depends upon the extent of water and electrolyte loss and the ade-
quacy of water and electrolyte repletion therapy. Death can occur from hypovolemic 
shock, metabolic acidosis, and uremia resulting from acute tubular necrosis. 
 
FIGURE 24-1 Pathophysiology of cholera. 
Structure, Classification, and Antigenic Types 
The cholera vibrios are Gram-negative, slightly curved rods whose motility depends 
on a single polar flagellum. Their nutritional requirements are simple. Fresh isolates 
are prototrophic (i.e., they grow in media containing an inorganic nitrogen source, a 
utilizable carbohydrate, and appropriate minerals). In adequate media, they grow rap-
idly with a generation time of less than 30 minutes. Although they reach higher pop-
ulation densities when grown with vigorous aeration, they can also grow anaerobi-
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cally. Vibrios are sensitive to low pH and die rapidly in solutions below pH 6; how-
ever, they are quite tolerant of alkaline conditions. This tolerance has been exploited 
in the choice of media used for their isolation and diagnosis. 
Until 1992, the vibrios that caused epidemic cholera were subdivided into two bio-
types: classical and El Tor. Classical V cholerae was first isolated by Koch in 1883. 
Subsequently, in the early 1900s, some vibrios resembling V cholerae were isolated 
from Mecca-bound pilgrims at the quarantine station at El Tor, in the Sinai peninsu-
la, that had been established to try to control cholera associated with pilgrimages to 
Mecca. These vibrios resembled classical V cholerae in many ways but caused lysis 
of goat or sheep erythrocytes in a test known as the Greig test. Because the pilgrims 
from whom they were isolated did not have cholera, these hemolytic El Tor vibrios 
were regarded as relatively insignificant except for the possibility of confusion with 
true cholera vibrios. In the 1930s, similar hemolytic vibrios were associated with rel-
atively restricted outbreaks of diarrheal disease, called paracholera, in the Celebes. In 
1961, cholera caused by El Tor vibrios erupted in Hong Kong and spread virtually 
worldwide. Although in the course of this pandemic most V cholerae biotype El Tor 
strains lost their hemolytic activity, a number of ancillary tests differentiate them 
from vibrios of the classical biotype. 
The operational serology of the cholera vibrios which belong in O antigen group 1 is 
relatively simple. Both biotypes (El Tor and classical) contain two major serotypes, 
Inaba and Ogawa (Fig. 24-2). These serotypes are differentiated in agglutination and 
vibriocidal antibody tests on the basis of their dominant heat-stable lipopolysaccha-
ride somatic antigens. The cholera group has a common antigen, A, and the sero-
types are differentiated by the type-specific antigens, B (Ogawa) and C (Inaba). An 
additional serotype, Hikojima, which has both specific antigens, is rare. V cholerae 
O139 appears to have been derived from the pandemic El Tor biotype but has lost 
the characteristic O1 somatic antigen; it has gained the ability to produce a polysac-
charide capsule; it produces the same cholera enterotoxin; and it seems to have re-
tained the epidemic potential of O1 strains. 
 
FIGURE 24-2 Vibrio cholerae (O group 1 antigen). 
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Other antigenic components of the vibrios, such as outer membrane protein antigens, 
have not been extensively studied. The cholera vibrios also have common flagellar 
antigens. Cross-reactions with Brucella and Citrobacter species have been reported. 
Because of DNA relatedness and other similarities, other vibrios formerly called 
"nonagglutinable" are now classified as V cholerae. The term nonagglutinable is a 
misnomer because it implies that these vibrios are not agglutinable; in fact, they are 
not agglutinable in antisera against the O antigen group 1 cholera vibrios, but they 
are agglutinable in their own specific antisera. More than 139 serotypes are now rec-
ognized. Some strains of non-O group 1 V cholerae cause diarrheal disease by means 
of an enterotoxin related to the cholera enterotoxin and, perhaps, by other mecha-
nisms, but these strains have not been associated with devastating outbreaks like 
those caused by the true cholera vibrios. Recently, vibrio strains that agglutinate in 
some O group 1 cholera diagnostic antisera but not in others have been isolated from 
environmental sources. Volunteer feeding experiments have shown that these atypi-
cal O group 1 vibrios are not enteropathogenic in humans. Recent studies using spe-
cific toxin gene probes indicate that these environmental isolates not only are 
nontoxigenic, but also do not possess any of the genetic information encoding chol-
era toxin, although some isolates from diarrheal stools do. 
The cholera vibrios cause many distinctive reactions. They are oxidase positive. The 
O group 1 cholera vibrios almost always fall into the Heiberg I fermentation pattern; 
that is, they ferment sucrose and mannose but not arabinose, and they produce acid 
but not gas. Vibrio cholerae also possesses lysine and ornithine decarboxylase, but 
not arginine dihydrolase. Freshly isolated agar-grown vibrios of the El Tor biotype, 
in contrast to classical V cholerae, produce a cell-associated mannose-sensitive he-
magglutinin active on chicken erythrocytes. This activity is readily detected in a rap-
id slide test. In addition to hemagglutination, numerous tests have been proposed to 
differentiate the classical and El Tor biotypes, including production of a hemolysin, 
sensitivity to selected bacteriophages, sensitivity to polymyxin, and the Voges-
Proskauer test for acetoin. El Tor vibrios originally were defined as hemolytic. They 
differed in this characteristic from classical cholera vibrios; however, during the 
most recent pandemic, most El Tor vibrios (except for the recent isolates from Texas 
and Louisiana) had lost the capacity to express the hemolysin. Most El Tor vibrios 
are Voges-Proskauer positive and resistant to polymyxin and to bacteriophage IV, 
whereas classical vibrios are sensitive to them. As both biotypes cause the same dis-
ease, these characteristics have only epidemiologic significance. Strains of the El Tor 
biotype, however, produce less cholera enterotoxin, but appear to colonize intestinal 
epithelium better than vibrios of the classical variety. Also, they seem some what 
more resistant to environmental factors. Thus, El Tor strains have a higher tendency 
to become endemic and exhibit a higher infection-to-case ratio than the classical bio-
type. 
Pathogenesis 
Recent studies with laboratory animal models and human volunteers have provided a 
detailed understanding of the pathogenesis of cholera. Initial attempts to infect 
healthy American volunteers with cholera vibrios revealed that the oral administra-
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tion of up to 1011 living cholera vibrios rarely had an effect; in fact, the organisms 
usually could not be recovered from stools of the volunteers. After the administration 
of bicarbonate to neutralize gastric acidity, however, cholera diarrhea developed in 
most volunteers given 104 cholera vibrios. Therefore, gastric acidity itself is a pow-
erful natural resistance mechanism. It also has been demonstrated that vibrios admin-
istered with food are much more likely to cause infection. 
Cholera is exclusively a disease of the small bowel. To establish residence and mul-
tiply in the human small bowel (normally relatively free of bacteria because of the 
effective clearance mechanisms of peristalsis and mucus secretion), the cholera vib-
rios have one or more adherence factors that enable them to adhere to the microvilli 
(Fig. 24-3). Several hemagglutinins and the toxin-coregulated pili have been sug-
gested to be involved in adherence but the actual mechanism has not been defined. In 
fact, there may be multiple mechanisms. The motility of the vibrios may affect viru-
lence by enabling them to penetrate the mucus layer. They also produce mucinolytic 
enzymes, neuraminidase, and proteases. The growing cholera vibrios elaborate the 
cholera enterotoxin (CT or choleragen), a polymeric protein (Mr 84,000) consisting 
of two major domains or regions. The A region (Mr 28,000), responsible for biologic 
activity of the enterotoxin, is linked by noncovalent interactions with the B region 
(Mr 56,000), which is composed of five identical noncovalently associated peptide 
chains of Mr 11,500. The B region, also known as choleragenoid, binds the toxin to 
its receptors on host cell membranes. It is also the immunologically dominant por-
tion of the holotoxin. The structural genes that encode the synthesis of CT reside on 
a transposon-like element in the V cholerae chromosome, in contrast to those for the 
heat-labile enterotoxins (LTs) of E coli (Ch. 25), which are encoded by plasmids. 
The amino acid sequences of these structurally, functionally, and immunologically 
related enterotoxins are very similar. Their differences account for the differences in 
physicochemical behavior and the antigenic distinctions that have been noted. There 
are at least two antigenically related but distinct forms of cholera enterotoxin, called 
CT-1 and CT-2. Classical O1 V cholerae and the Gulf Coast El Tor strains produce 
CT-1 whereas most other El Tor strains and O139 produce CT-2. Vibrio cholerae 
exports its enterotoxin, whereas the E coli LTs occur primarily in the periplasmic 
space. This may account for the reported differences in severity of the diarrheas 
caused by these organisms.  
Studies in adult American volunteers have shown that 5µ g of CT, administered oral-
ly with bicarbonate, causes 1 to 6 L of diarrhea; 25µg causes more than 20 L. 
The molecular events in these diarrheal diseases involve an interaction between the 
enterotoxins and intestinal epithelial cell membranes (Fig. 24-4). The toxins bind 
through region B to a glycolipid, the GM1 ganglioside, which is practically ubiqui-
tous in eukaryotic cell membranes. Following this binding, the A region, or a major 
portion of it known as the A1 peptide (Mr 21,000), penetrates the host cell and en-
zymatically transfers ADP-ribose from nicotinamide adenine dinucleotide (NAD) to 
a target protein, the guanosine 5'-triphosphate (GTP)-binding regulatory protein as-
sociated with membrane-bound adenylate cyclase. Thus, CT (and LT) resembles 
diphtheria toxin in causing transfer of ADP-ribose to a substrate. With diphtheria 
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toxin, however, the substrate is elongation factor 2 and the result is cessation of host 
cell protein synthesis. With CT, the ADP-ribosylation reaction essentially locks ade-
nylate cyclase in its "on mode" and leads to excessive production of cyclic adenosine 
51-monophosphate (cAMP). Pertussis toxin, another ADP-ribosyl transferase, also 
increases cAMP levels, but by its effect on another G-protein, Gi (Fig. 24-5). The 
subsequent cAMP-mediated cascade of events has not yet been delineated, but the 
final effect is hypersecretion of chloride and bicarbonate followed by water, resulting 
in the characteristic isotonic voluminous cholera stool. In hospitalized patients, this 
can result in losses of 20 L or more of fluid per day. The stool of an actively purging, 
severely ill cholera patient can resemble rice waterthe supernatant of boiled rice. Be-
cause the stool can contain 108 viable vibrios per ml, such a patient could shed 2 X 
1012 cholera vibrios per day into the environment. Perhaps by production of CT, the 
cholera vibrios thus ensure their survival by increasing the likelihood of finding an-
other human host. Recent evidence suggests that prostaglandins may also play a role 
in the secretory effects of cholera enterotoxin. Recent studies in volunteers using ge-
netically-engineered Tox- strains of V cholerae have revealed that the vibrios have 
putative mechanisms in addition to CT for causing (milder) diarrheal disease. These 
include Zot (for Zonula occludens toxin) and Ace (for accessory cholera enterotox-
in), and perhaps others, but their role has not been established conclusively. Certain-
ly CT is the major virulence factor and the act of colonization of the small bowel 
may itself elicit an altered host response (e.g., mild diarrhea), perhaps by a trans-
membrane signaling mechanism. 
 
FIGURE 24-4 Mechanism of action of cholera enterotoxin. Cholera toxin ap-
proaches target cell surface. B subunits bind to oligosaccharide of GM1 ganglioside. 
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Conformational alteration of holotoxin occurs, allowing the presentation of the A 
subunit to cell surface. The A subunit enters the cell. The disulfide bond of the A 
subunit is reduced by intracellular glutathione, freeing A1 and A2. NAD is hydro-
lyzed by A1, yielding ADP-ribose and nicotinamide. One of the G proteins of ade-
nylate cyclase is ADP-ribosylated, inhibiting the action of GTPase and locking ade-
nylate cyclase in the "on" mode (Modified from Fishman PH: Mechanism of action 
of cholera toxin: events on the cell surface. p. 85. In Field M, Fordtran JS, Schultz 
SG (eds): Secretory Diarrhea. Waverly Press, Baltimore, 1980, with permission.)  
 
FIGURE 24-5 Comparison of activities of cholera enterotoxin (CT) with pertus-
sis toxin (PT). The a-subunits of Gs and Gi, with GTP-binding sites, are ADP-
ribosylated, respectively, by A1 peptide of CT or by the A subunit of PT, preventing, 
respectively, the hydrolysis of Gs-GTP to GDP or the responsiveness of Gi to inhibi-
tory hormones, both effectively producing increases in adenylate cyclase activity. 
(Modified from Gill DM, Woolkalis M: Toxins which activate adenylate cyclase. 
CIBA Found Symp 112:57, 1985, with permission.) 
Various animal models have been used to investigate pathogenic mechanisms, viru-
lence, and immunity. Ten-day-old suckling rabbits develop a fulminating diarrheal 
disease after intraintestinal inoculation with virulent V cholerae or CT. Adult rabbits 
are relatively resistant to colonization by cholera vibrios; however, they do respond, 
with characteristic out pouring of fluid, to the intraluminal inoculation of live vibrios 
or enterotoxin in surgically isolated ileal loops. Suckling mice are susceptible to in-
tragastric inoculation of vibrios and to orally administered toxin. Adult conventional 
mice are also susceptible to orally administered toxin, but resist colonization except 
in isolated intestinal loops. Interestingly, however, germ-free mice can be colonized 
for months with cholera vibrios. They rarely show adverse effects, although they are 
susceptible to cholera enterotoxin. Dogs have been used experimentally, although 
they are relatively refractory and require enormous inocula to elicit choleraic mani-
festations. Chinchillas also are susceptible to diarrhea following intraintestinal inocu-
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lation with moderate numbers of cholera vibrios. Infections initiated by extraintesti-
nal routes of inoculation (e.g., intraperitoneal) largely reflect the toxicity of the lipo-
polysaccharide endotoxin. The intraperitoneal infection in mice has been used to as-
say the protective effect of conventional killed vibrio vaccines (no longer widely 
used). 
Various animals, including humans, rabbits, and guinea pigs, also respond to intra-
dermal inoculation of relatively minute amounts of CT with a characteristic delayed 
(maximum response at 24 hours), sustained (visible up to 1 week or more), erythem-
atous, edematous induration associated with a localized alteration of vascular perme-
ability. In laboratory animals, this response can be measured after injecting a protein-
binding dye, such as trypan blue, that extravasates to produce a zone of bluing at the 
site of intracutaneous inoculation of toxin. This observation has been exploited in the 
assay of CT and its antibody and in the detection of other enterotoxins. 
In addition, because of the broad spectrum of activity of CT on cells and tissues that 
it never contacts in nature, various in vitro systems can be used to assay the entero-
toxin and its antibody. In each, the toxin causes a characteristically delayed, but sus-
tained, activation of adenylate cyclase and increased production of cAMP, and it 
may cause additional, readily recognizable, morphologic alterations of certain cul-
tured cell lines. The cells most widely used for this purpose are Chinese hamster 
ovary (CHO) cells, which elongate in response to picogram doses of the toxin, and 
mouse Y-l adrenal tumor cells, which round up. Cholera toxin has become an ex-
tremely valuable experimental probe to identify other cAMP-mediated responses. It 
also activates adenylate cyclase in pigeon erythrocytes, a procedure that was used by 
D. Michael Gill to define its mode of action. 
These assays and models also have been applied in the study of an expanding num-
ber of CT-related and unrelated enterotoxins. These include the LTs of E coli, which 
are structurally and immunologically similar to it and are effective in any model that 
is responsive to CT. The family of small molecular weight heat-stable enterotoxins 
(ST) of E coli, which activate guanylate cyclase, and which are rapidly active in the 
infant mouse and certain other intestinal models, are clearly unrelated to CT. CT-
related enterotoxins have been reported from certain nonagglutinable (non-O group 
I) Vibrio strains and a Salmonella enterotoxin was shown to be related immunologi-
cally to CT. CT-like factors from Shigella and V parahaemolyticus have thus far 
been demonstrated only in sensitive cell culture systems. Other enterotoxins and en-
terocytotoxins, which elicit cytotoxic effects on intestinal epithelial cells, also have 
been described from Escherichia, Klebsiella, Enterobacter, Citrobacter, Aeromonas, 
Pseudomonas, Shigella, V parahaemolyticus, Campylobacter, Yersinia enterocoliti-
ca, Bacillus cereus, Clostridium perfringens, C difficile, and staphylococci. Esche-
richia coli, some vibrio strains, and some other enteric bacteria produce cytotoxins 
that, like Shiga toxin of Shigella dysenteriae, act on Vero (African green monkey 
kidney) cells in vitro. These toxins have been called Shiga-like toxins, Shiga toxin-
like toxins, Vero toxins, and Vero cytotoxins. The classic staphylococcal enterotox-
ins perhaps should more properly be called neurotoxins, as they seem to affect the 
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central nervous system rather than the gut directly to cause fluid secretion or histo-
pathologic effects. 
Host Defenses 
Infection with cholera vibrios results in a spectrum of responses. These range from 
no observed manifestations except perhaps a serologic response ( the most common) 
to acute purging, which must be treated by hospitalization and fluid replacement 
therapy; this is the classic response. The reasons for these differences are not entirely 
clear, although it is known that individuals differ in gastric acidity and that hypo-
chlorhydric individuals are most prone to cholera. Whether individuals differ in the 
availability of intestinal receptors for cholera vibrios or for their toxin has not been 
established. Prior immunologic experience of subjects at risk is certainly a major fac-
tor. For example, in heavily endemic regions such as Bangladesh, the attack rate is 
relatively low among adults in comparison with children. In neoepidemic areas, 
cholera is more frequent among the working adult population. Resistance is related 
to the presence of circulating antibody and, perhaps more importantly, local immu-
noglobulin A (IgA) antibody against the cholera bacteria or the cholera enterotoxin 
or both. Intestinal IgA antibody can prevent attachment of the vibrios to the mucosal 
surface and neutralize or prevent binding of the cholera enterotoxin. For reasons that 
are not clear, individuals of blood group O are slightly more susceptible to cholera. 
Breastfeeding is highly recommended as a means of increasing immunity of infants 
to this and other diarrheal disease agents. 
Recovery from cholera probably depends on two factors: elimination of the vibrios 
by antibiotics or the patient's own immune response, and regeneration of the poi-
soned intestinal epithelial cells. Treatment with a single 200-mg dose of doxycycline 
has been recommended. As studies in volunteers demonstrated conclusively, the dis-
ease is an immunizing process. Patients who have recovered from cholera are solidly 
immune for at least 3 years. 
Cholera vaccines consisting of killed cholera bacteria administered parenterally have 
been used since the turn of the century. However, recent controlled field studies in-
dicate that little, if any, effective immunity is induced in immunologically virgin 
populations by such vaccines, although they do stimulate preexisting immunity in the 
adult population in heavily endemic regions. Controlled studies have likewise shown 
that a cholera toxoid administered parenterally was ineffective in preventing cholera. 
Probably the natural disease should be simulated to induce truly effective immunity 
although a parenterally administered conjugate vaccine consisting of the polysaccha-
ride of the vibrio LPS covalently linked to cholera toxin has given promising results 
in preliminary studies. Studies in volunteers have shown that orally administered, 
chemically mutagenized or genetically engineered mutants which do not produce CT 
or produce only its B subunit protein can induce immunity against subsequent chal-
lenge. However, most of these candidate vaccines also produce unacceptable side ef-
fectsprimarily mild to moderate diarrhea. An exception is strain CVD103-HgR (a 
mercury resistant A-B+ derivative of classical biotype Inaba serotype strain 569B). 
This strain has minimal reactogenicity but does not colonize well and therefore has 
to be given in higher doses. Field studies with this strain are in progress. Combined 
 93 
preparations of bacterial somatic antigen and toxin antigen have been reported to act 
synergistically in stimulating immunity in laboratory animals; that is, the combined 
protective effect is closer to the product than to the sum of the individual protective 
effects. However, a large field study evaluating such nonviable oral vaccines in 
Bangladesh revealed that neither the whole-cell bacterin nor the killed vibrios sup-
plemented with the B-subunit protein of the cholera enterotoxin induced sufficient 
long term protection, especially in children, to justify their recommendation for pub-
lic health use. No clear-cut advantage of the inclusion of the B-subunit was demon-
strated. 
In any case, even if these vaccines were effective, the requirement for large and re-
peated doses would make them too expensive for use in the developing areas that are 
usually afflicted with epidemic cholera. Moreover, they were clearly less effective in 
childrenthe primary target population in heavily endemic areas. Neither the killed 
whole cell vaccine nor strain CVD103-HgR could be expected to protect against the 
new O139 serovar. 
Epidemiology 
Humans apparently are the only natural host for the cholera vibrios. Cholera is ac-
quired by the ingestion of water or food contaminated with the feces of an infected 
individual. Previously, the disease swept the world in six great pandemics and later 
receded into its ancestral home in the Indo-Pakistani subcontinent. In 1961, the El 
Tor biotype (a subset distinguished by physiologic characteristics) of V cholerae, not 
previously implicated in widespread epidemics, emerged from the Celebes (now Su-
lawesi), causing the seventh great cholera pandemic. In the course of their migration, 
the El Tor biotype cholera vibrios virtually replaced V cholerae of the classic biotype 
that formerly was responsible for the annual cholera epidemics in India and East Pa-
kistan (now Bangladesh). The pandemic that began in 1961 is now heavily seeded in 
Southeast Asia and in Africa. It has also invaded Europe, North America, and Japan, 
where the outbreaks have been relatively restricted and self-limited because of more 
highly developed sanitation. Several new cases were reported in Texas in 1981 and 
sporadic cases have since been reported in Louisiana and other Gulf Coast areas. 
This now endemic focus appears to be due to a clone which is unique from the pan-
demic strain. In 1991, the pandemic strain hit Peru with massive force and has since 
spread through most of the Western Hemisphere, causing more than a million cases. 
Fortunately, mortality has been less than 1 percent because of the effectiveness of 
oral rehydration therapy. The vibrios surprised us again, in 1992, with the emergence 
of O139 in India and Bangladesh. For a while it appeared that O139 would replace 
O1 (both classical and El Tor) but it has exhibited quiescent periods when O1 
reemerges. 
Cholera appears to exhibit three major epidemiologic patterns: heavily endemic, ne-
oepidemic (newly invaded, cholera-receptive areas), and, in developed countries 
with good sanitation, occasional limited outbreaks. These patterns probably depend 
largely on environmental factors (including sanitary and cultural aspects), the prior 
immune status or antigenic experience of the population at risk, and the inherent 
properties of the vibrios themselves, such as their resistance to gastric acidity, ability 
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to colonize, and toxigenicity. In the heavily endemic region of the Indian subconti-
nent, cholera exhibits some periodicity; this may vary from year to year and season-
ally, depending partly on the amount of rain and degree of flooding. Because humans 
are the only reservoirs, survival of the cholera vibrios during interepidemic periods 
probably depends on a relatively constant availability of low-level undiagnosed cases 
and transiently infected, asymptomatic individuals. Long-term carriers have been re-
ported but are extremely rare. The classic case occurred in the Philippines, where 
"cholera Dolores" harbored cholera vibrios in her gallbladder for 12 years after her 
initial attack in 1962. Her carrier state resolved spontaneously in 1973; no secondary 
cases had been associated with her well-marked strain. Recent studies, however, 
have suggested that cholera vibrios can persist for some time in shellfish, algae or 
plankton in coastal regions of infected areas and it has been claimed that they can ex-
ist in "a viable but nonculturable state." 
During epidemic periods, the incidence of infection in communities with poor sanita-
tion is high enough to frustrate the most vigorous epidemiologic control efforts. Alt-
hough transmission occurs primarily through water contaminated with human feces, 
infection also may be spread within households and by contaminated foods. Thus, in 
heavily endemic regions, adequate supplies of pure water may reduce but not elimi-
nate the threat of cholera. 
In neoepidemic cholera-receptive areas, vigorous epidemiologic measures, including 
rapid identification and treatment of symptomatic cases and asymptomatically in-
fected individuals, education in sanitary practices, and interruption of vehicles of 
transmission (e.g., by water chlorination), may be most effective in containing the 
disease. In such situations, spread of cholera usually depends on traffic of infected 
human beings, although spread between adjacent communities can occur through 
bodies of water contaminated by human feces. John Snow was credited with stop-
ping an epidemic in London, England, by the simple expedient of removing the han-
dle of the "Broad Street pump" (a contaminated water supply) in 1854, before ac-
ceptance of the "germ theory" and before the first isolation of the "Kommabacillus" 
by Robert Koch. 
In such developed areas as Japan, Northern Europe, and North America, cholera has 
been introduced repeatedly in recent years, but has not caused devastating outbreaks; 
however, Japan has reported secondary cases and, in 1978, the United State experi-
enced an outbreak of about 12 cases in Louisiana. In that outbreak, sewage was in-
fected, and infected shellfish apparently were involved. Interestingly, the hemolytic 
vibrio strain implicated was identical to one that caused an unexplained isolated case 
in Texas in 1973. 
Diagnosis 
Rapid bacteriologic diagnosis offers relatively little clinical advantage to the patient 
with secretory diarrhea, because essentially the same treatment (fluid and electrolyte 
replacement) is employed regardless of etiology. Nevertheless, rapid identification of 
the agent can profoundly affect the subsequent course of a potential epidemic out-
break. Because of their rapid growth and characteristic colonial morphology, V chol-
erae can be easily isolated and identified in the bacteriology laboratory, provided, 
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first, that the presence of cholera is suspected and, second, that suitable specific di-
agnostic antisera are available. The vibrios are completely inhibited or grow some-
what poorly on usual enteric diagnostic media (MacConkey agar or eosin-methylene 
blue agar). An effective selective medium is thiosulfate-citrate-bile salts-sucrose 
(TCBS) agar, on which the sucrose-fermenting cholera vibrios produce a distinctive 
yellow colony. However, the usefulness of this medium is limited because serologic 
testing of colonies grown on it occasionally proves difficult, and different lots vary 
in their productivity. This medium is also useful in isolating V parahaemolyticus. 
They can also be isolated from stool samples or rectal swabs from cholera cases on 
simple meat extract (nutrient) agar or bile salts agar at slightly alkaline pH values. 
Following observation of characteristic colonial morphology with a stereoscopic mi-
croscope using transmitted oblique illumination, microorganisms can be confirmed 
as cholera vibrios by a rapid slide agglutination test with specific antiserum. Classic 
and El Tor biotypes can be differentiated at the same time by performing a direct 
slide hemagglutination test with chicken erythrocytes: all freshly isolated agar-grown 
El Tor vibrios exhibit hemagglutination; all freshly isolated classic vibrios do not. In 
practice, this can be accomplished with material from patients as early as 6 hours af-
ter streaking the specimen in which the cholera vibrios usually predominate. Howev-
er, to detect carriers (asymptomatically infected individuals) and to isolate cholera 
vibrios from food and water, enrichment procedures and selective media are recom-
mended. Enrichment can be accomplished by inoculating alkaline (pH 8.5) peptone 
broth with the specimen and then streaking for isolation after an approximate 6-hour 
incubation period; this process both enables the rapidly growing vibrios to multiply 
and suppresses much of the commensal microflora.  
The classic case of cholera, which includes profound secretory diarrhea and should 
evoke clinical suspicion, can be diagnosed within a few minutes in the prepared la-
boratory by finding rapidly motile bacteria on direct, bright-field, or dark-field mi-
croscopic examination of the liquid stool. The technician can then make a second 
preparation to which a droplet of specific anti-V cholerae O group 1 antiserum is 
added. This quickly stops vibrio motility. Another rapid technique is the use of fluo-
rescein isothiocyanate-labeled specific antiserum (fluorescent antibody technique) 
directly on the stool or rectal swab smear or on the culture after enrichment in alka-
line peptone broth. For cultural diagnosis, both nonselective and selective (TCBS) 
media may be used. Although demonstration of typical agglutination essentially con-
firms the diagnosis, additional conventional tests such as oxidase reaction, indole re-
action, sugar fermentation reactions, gelatinase, lysine, arginine, and ornithine de-
carboxylase reactions may be helpful. Tests for chicken cell hemagglutination, he-
molysis, polymyxin sensitivity, and susceptibility to phage IV are useful in differen-
tiating the El Tor biotype from classic V cholerae. Tests for toxigenesis may be indi-
cated. 
Diagnosis can be made retrospectively by confirming significant rises in specific se-
rum antibody titers in convalescents. For this purpose, conventional agglutination 
tests, tests for rises in complement-dependent vibriocidal antibody, or tests for rises 
in antitoxic antibody can be employed. Convenient microversions of these tests have 
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been developed. Passive hemagglutination tests and enzyme-linked immunosorption 
assays (ELISAs) have also been proposed. 
Cultures that resemble V cholerae but fail to agglutinate in diagnostic antisera (non-
agglutinable or non-O group 1 vibrios) present more of a problem and require addi-
tional tests such as oxidase, decarboxylases, inhibition by the vibriostatic pteridine 
compound 0/129, and the "string test." The string test demonstrates the property, 
shared by most vibrios and relatively few other genera, of forming a mucus-like 
string when colony material is emulsified in 0.5 percent aqueous sodium deoxycho-
late solution. Additional tests for enteropathogenicity and toxigenesis may be useful. 
Genetically based tests such as PCR are increasingly being used in specialized labor-
atories. 
Control 
Treatment of cholera consists essentially of replacing fluid and electrolytes. Former-
ly, this was accomplished intravenously, using costly sterile pyrogen-free intrave-
nous solutions. The patient's fluid losses were conveniently measured by the use of 
buckets, graduated in half-liter volumes, kept underneath an appropriate hole in an 
army-type cot on which the patient was resting. Antibiotics such as tetracycline, to 
which the vibrios are generally sensitive, are useful adjuncts in treatment. They 
shorten the period of infection with the cholera vibrios, thus reducing the continuous 
source of cholera enterotoxin; this results in a substantial saving of replacement flu-
ids and a markedly briefer hospitalization. Note, however, that fluid and electrolyte 
replacement is all-important; patients who are adequately rehydrated and maintained 
will virtually always survive, and antibiotic treatment alone is not sufficient. 
Recently it has been recognized that almost all cholera patients and others with simi-
lar severe secretory diarrheal disease can be maintained by fluids given orally if the 
solutions contain a usable energy source such as glucose. Because of this discovery, 
packets containing appropriate salts are distributed by such organizations as WHO 
and UNICEF to cholera-afflicted areas, where they are dissolved in water as needed. 
One such formulation, called ORS for oral rehydration salts, contains NaCl, 3.5 g; 
KCl,1.5 g; NaHCO3, 2.5 g (or trisodium citrate, 2.9 g); and glucose, 20.0 g. This 
mixture is dissolved in 1 L of water and taken orally in increments. Flavoring may be 
added. Improved versions of ORS, including rice-based formulations that reduce 
stool output and can be made at home, have been recommended. Unfortunately, this 
technique, which will save countless millions of lives in developing countries, has 
not yet been widely accepted by practicing physicians in developed countries. 
The possibility of pharmacologic intervention (e.g., a pill that will stop choleraic di-
arrhea after it has started), has been considered. Two drugs, chlorpromazine and nic-
otinic acid, have been effective in experimental animals, although the precise mech-
anism of action has yet to be defined. 
Like smallpox and typhoid, choleraunder natural circumstancesappears to affect only 
humans; therefore, V cholerae as an etiologic entity could conceivably disappear 
with the last human infection. Nevertheless, the spectrum of cholera-like diarrheal 
diseases probably will persist for some time. 
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Cholera is essentially a disease associated with poor sanitation. The simple applica-
tion of sanitary principlesprotecting drinking water and food from contamination 
with human feceswould go a long way toward controlling the disease. However, at 
present, this is not feasible in the underdeveloped areas that are afflicted with epi-
demic cholera or are considered to be cholera receptive. Meanwhile, development of 
a vaccine that would effectively prevent colonization and manifestations of cholera 
would be extremely helpful. As indicated above, such vaccines are presently being 
tested. Antibiotic or chemotherapeutic prophylaxis is feasible and may be indicated 
under certain circumstances. It also should be mentioned that the incidence of chol-
era is significantly higher in formula-fed than in breast-fed babies. 
Present information indicates that V parahaemolyticus enteritis could be almost 
completely prevented by applying appropriate procedures to prevent multiplication 
of the organisms in contaminated seafood, such as keeping it refrigerated continual-
ly. 
Other Vibrio Infections 
Other vibrios may be clinically significant also. These include non-O group 1 V 
cholerae. Vibrio parahaemolyticus, a halophilic (salt-loving) vibrio associated with 
enteritis is acquired by ingestion of raw or improperly cooked seafoods. Another 
halophilic vibrio, which ferments lactose and for this reason was called the L + vib-
rio, has recently been identified as V vulnificus. It has been associated with wound 
infections as well as fatal septicemias. Other groups of vibrios, previously referred to 
as group F and EF-6, have recently been classified into species: V fluvialis, V holli-
sae, V furnissia, and V damsela. Vibrio mimicus is a recently described sucrose-
negative species. Vibrio fetus, a group of anaerobic to microaerophilic spirally 
curved rods associated with venereally transmitted infertility and abortion in domes-
tic animals, is now called Campylobacter jejuni and is considered to belong in the 
family Spirillaceae rather than in the family Vibrionaceae. Campylobacter jejuni has 
been associated with dysentery-like gastroenteritis, duodenal and gastric ulcers, as 
well as with other types of infection, including bacteremic and central nervous sys-
tem infections in humans (see Ch. 23). Another vibrio-like organism, Helicobacter 
pylori (formerly known as C pylori) causes gastritis and predisposes to duodenal ul-
cers and gastric cancer. Although some similarities in habitat and other properties 
occur, members of the family Vibrionaceae are separated taxonomically from mem-
bers of the family Enterobacteriaceae. The oxidase test (vibrios are usually oxidase 
positive) is particularly useful. Other vibrios exist, and some of these may be respon-
sible for diseases in fish and other lower animals. As vibrios are widely distributed in 
the environment, particularly in estuarine waters and in seafoods, reports of their iso-
lation from patients with diarrheal disease do not necessarily always imply an etio-
logic relationship. 
Cholera-like vibrios have been reported in Maryland's Chesapeake Bay but have not 
been associated with any human cases despite more than 15 years of extensive sur-
veillance. These vibrios are probably nonpathogenic nonagglutinable (non-O group 
1) vibrios, or the atypical O group 1 vibrios mentioned above, which do not contain 
the genes for toxin production, do not colonize, and are avirulent. 
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Relatively little is known about the epidemiology of nonagglutinable vibrios. When 
sought, these vibrios have been found widely in brackish surface waters (sewers, 
marshes, bogs, and coastal areas), and are generally more numerous in warmer 
months. They appear to be free-living aquatic organisms; whether particular subsets 
are potential pathogens is not yet clear. Strains isolated from humans with diarrheal 
disease more frequently give positive responses in assays for enterotoxins or entero-
pathogenicity, but the pathogenic mechanism of other isolates associated with shell-
fish remains undefined.An epidemiologic pattern is more evident with V parahaemo-
lyticus, which is clearly part of the normal flora of coastal and estuarine waters 
throughout the world. Although originally recognized in Japan, V parahaemolyticus 
enteritis has been reported virtually worldwide within the last decade. Its reported 
frequency varies widely, partly because of inherent differences in distribution and 
partly because many laboratories do not use the appropriate culture medium (TCBS) 
to isolate these organisms. Two types of clinical syndromes, both usually self-
limited, have been observed. The most common is a watery diarrhea, perhaps with 
associated abdominal cramps, nausea, vomiting, and fever, with a modal incubation 
period of 15 hours. A dysenteric syndrome with a short incubation period of 2 1/2 
hours also has been described. In Japan, about 24 percent of reported cases of food 
poisoning are attributed to V parahaemolyticus. The disease occurs primarily during 
summer, possibly reflecting the increased presence of the organism in the marine en-
vironment during those months, as well as the enhanced opportunity for it to multi-
ply in unrefrigerated foods. It appears to be transmitted exclusively by food, primari-
ly raw or improperly prepared seafood. As growth of this organism is inhibited at 
temperatures below 15° C, rapid cooling and refrigeration of seafoods that are eaten 
raw would vastly reduce the incidence of disease. The organisms are killed by heat-
ing to 65° C for 10 minutes; therefore, properly handled cooked seafood should pre-
sent no problem. The role played in virulence and pathogenesis by the thermostable 
direct hemolysin, which is responsible for the positive Kanagawa phenomenon (a 
hemolytic reaction around colonies growing on a particular blood agar medium), is 
not yet fully defined. This hemolysin is clearly associated with pathogenicity, but 
whether it is merely an associated marker or intimately involved in the disease pro-
cess awaits further research. Be this as it may, only strains that possess the Kanaga-
wa hemolysin are considered pathogenic. In laboratory studies, the isolated hemoly-
sin has been reported to be cytotoxic, cardiotoxic, and lethal. 
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Escherichia, Klebsiella, Enterobacter,Serratia, Citrobac-
ter, and Proteus 
General Concepts 
Clinical Manifestations 
The genera Escherichia, Klebsiella, Enterobacter, Serratia, and Citrobacter (collec-
tively called the coliform bacilli) and Proteus include overt and opportunistic patho-
gens responsible for a wide range of infections. Many species are members of the 
normal intestinal flora. Escherichia coli (E coli) is the most commonly isolated or-
ganism in the clinical laboratory.  
Enteric Infections: E coli is a major enteric pathogen, particularly in developing 
countries. The principal groups of this organism responsible for enteric disease in-
clude the classical enteropathogenic serotypes (EPEC), enterotoxigenic (ETEC), en-
teroinvasive (EIEC), enterohemorrhagic (EHEC), and enteroggregative (EAEC) 
strains which are described in detail in Chapter 25.  
Nosocomial Infections: Coliform and Proteus bacilli currently cause 29 percent of 
nosocomial (hospital-acquired) infections in the United States. In order of decreasing 
frequency, the major sites of nosocomial infection are the urinary tract, surgical sites, 
bloodstream, and pneumonias. This group of nosocomial pathogens are responsible 
for 46% of urinary tract and 24% of surgical site infections, 17% of the bacteremias, 
and 30% of the pneumonias. E coli is the premier nosocomial pathogen.  
Community-Acquired Infections: E coli is the major cause of urinary tract infec-
tions, including prostatitis and pyelonephritis; Proteus, Klebsiella, and Enterobacter 
species are also common urinary tract pathogens. Proteus mirabilis is the most fre-
quent cause of infection-related kidney stones. Klebsiella pneumoniae causes a se-
vere pneumonia; K rhinoscleromatis causes rhinoscleroma; and K ozaenae is associ-
ated with ozena, an atrophic disease of the nasal mucosa.  
Structure, Classification, and Antigenic Types 
The coliforms and Proteus are Gram negative bacilli. All genera except Klebsiella 
are flagellated. Some strains produce capsules. Virulence often depends on the pres-
ence of attachment pili (which can be characterized by specific hemagglutinating re-
actions). Sex pili also may be present. The major classes of antigens used in defining 
strains are H (flagellar), O (somatic), and K (capsular).  
Pathogenesis 
E coli enteropathogens have diverse mechanisms for disease production which in-
clude different toxins and colonization factors (see Ch. 25 ). Specific serotypes of 
coliforms and Proteus with particular virulence factors often preferentially infect 
specific extraintestinal sites. E coli bacilli in extraintestinal infections have soluble 
and cell-bound hemolysins, siderophores, capsules, and adherence pili.  
Host Defenses 
Coliforms and Proteus species rarely cause extraintestinal disease unless host de-
fenses are compromised. Disruption of the normal intestinal flora by antibiotic thera-
py may allow resistant nosocomial strains to colonize or overgrow. The skin and 
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mucosae may be breached by disease, trauma, operation, venous catheterization, tra-
cheal intubation, etc. Immunosuppressive therapy also increases the risk of infection.  
Epidemiology 
The epidemiology of coliform and Proteus infections involves many reservoirs and 
modes of transmission. The infecting organism may be endogenous or exogenous. 
Transmission may be direct or indirect; vehicles include hospital food and equip-
ment, intravenous solutions, and the hands of hospital personnel. Nosocomial strains 
progressively colonize the intestine and pharynx with increasing length of hospital 
stay, resulting in an increased risk of infection.  
Diagnosis 
The clinical picture depends on the site of infection; diagnosis relies on culturing the 
organism and on biochemical and/or serologic identification. A variety of phenotypic 
(i.e., biotyping, serotyping, antibiograms, bacteriocin and phage typing) and geno-
typic (i.e., plasmid analysis, RFLP, ribotyping, and PCR) methods are used for epi-
demiological investigations.  
Control 
The most effective way to reduce transmission of nosocomial organisms is for all 
hospital personnel to wash hands meticulously after attending to each patient. Vac-
cines and hyperimmune sera are not currently available. Various antibiotics are the 
backbone of treatment; drug resistance (often multiple) due to conjugative plasmids 
is a major problem.  
INTRODUCTION 
The Gram-negative bacilli of the genera Escherichia, Klebsiella, Enterobacter, Serra-
tia, Citrobacter, and Proteus (Table 26- 1) are members of the normal intestinal flora 
of humans and animals and may be isolated from a variety of environmental sources. 
With the exception of Proteus, they are sometimes collectively referred to as the coli-
form bacilli because of shared properties, particularly the ability of most species to 
ferment the sugar lactose. 
Many of these microorganisms used to be dismissed as harmless commensals. To-
day, they are known to be responsible for major health problems worldwide. A lim-
ited number of species, including E coli, K pneumoniae, Enterobacter aerogenes, En-
terobacter cloacae, S marcescens, and P mirabilis, are responsible for most infections 
produced by this group of organisms. The increasing incidence of the coliforms, Pro-
teus, and other Gram-negative organisms in diseases reflects in part a better under-
standing of their pathogenic potential but more importantly the changing ecology of 
bacterial disease. The widespread and often indiscriminate use of antibiotics has cre-
ated drug-resistant Gram-negative bacilli that readily acquire multiple resistance 
through transmission of drug resistance plasmids (R factors). Also, development of 
new surgical procedures, health support technology, and therapeutic regimens has 
provided new portals of entry and compromised many host defenses.  
Clinical Manifestations 
As opportunistic pathogens, the coliforms and Proteus take advantage of weakened 
host defenses to colonize and elicit a variety of disease states (Fig. 26-1). Together, 
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the many disease syndromes produced by these organisms are among the most com-
mon infections in humans requiring medical intervention.  
 
FIGURE 26-1 Sites of colonization and extraintestinal disease production by the 
coliforms and Proteus. 
Enteric Infections 
The role of E coli as a major enteric pathogen, particularly in developing countries, 
is discussed in detail in Ch. 25. However, the different types of E coli associated 
with enteric infections and which are classified into five groups according to their 
virulence properties are briefly described here: Enteropathogenic (EPEC) serotypes 
in the past were associated with serious outbreaks of diarrhea in newborn nurseries 
in the US. They remain an important cause of acute infantile diarrhea in developing 
countries. Disease is rare in adults. Enteroinvasive (EIEC) types produce disease re-
sembling shigellosis in adults and children. Enterotoxigenic (ETEC) types are a ma-
jor cause of traveler's diarrhea, and of infantile diarrhea in developing countries. En-
terohemorrhagic E. coli (EHEC) occur largely as a single serotype (O157:H7) caus-
ing sporadic cases and outbreaks of hemorrhagic colitis characterized by bloody diar-
rhea. EHEC also may cause hemolytic uremic syndrome (HUS), an association of 
hemolytic anemia, thrombocytopenia, and acute renal failure. Enteroaggregative 
(EAEC) types exhibit a characteristic aggregative pattern of adherence and produce 
persistent gastroenteritis and diarrhea in infants and children in developing countries.  
Nosocomial Infections 
The etiology of nosocomial infections has markedly changed during past decades. 
Streptococci were the major nosocomial pathogens in the preantibiotic era. However, 
following the introduction and use of sulfonamides and penicillin, Staphylococcus 
aureus became the predominant pathogen in the 1950's. Aerobic gram negative rods 
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gained prominence as nosocomial pathogens with widespread use of aminoglyco-
sides and first generation cephalosporins through the early 1970's. Subsequent wide-
spread use of broad spectrum cephalosporins was associated with changes in the fre-
quency and etiology of nosocomial infections into the 1980's with the trend towards 
certain gram-positive pathogens. For example, in nosocomial bloodstream infections 
from 1980 to 1989 marked increases in the incidence of coagulase-negative staphy-
lococci, S. aureus, enterococci, and Candida albicans infections occurred.  
The coliforms and Proteus were responsible for 29 percent of nosocomial (hospital-
acquired) infections in the United States from 1990 through 1992 based on data from 
hospitals participating in the National Nosocomial Infections Survey (NNIS) (Table 
26-2). Estimates of nosocomial infections in US hospitals suggest that about 5 per-
cent of the estimated 40 million annual admissions, or 2 million patients, had at least 
one nosocomial infection. Thus, the coliforms and Proteus probably are responsible 
for hospital-acquired infections in approximately 600,000 patients each year. Aside 
from the enormous cost measured in human life, nosocomial infections prolong the 
duration of hospitalization by an average of 4 days and increase the cost of medical 
care by $4.5 billion a year in 1992 dollars.  
The highest numbers of nosocomial infections in the NNIS occur in surgical and 
medicine services. Among surgical patients, highest rates of nosocomial infections 
occur with surgery on the stomach (21%) and bowel (19%), craniotomies (18%), 
coronary artery bypass graft procedures (11%) and other cardiac surgery (10%). 
High rates also are observed with burn (15%) and high-risk nursery patients (14%). 
In order of decreasing frequency, the major sites of nosocomial infection are the uri-
nary tract, surgical sites, bloodstream, and lower respiratory tracts. The coliforms 
and Proteus were responsible for 46% of urinary tract and 24% of surgical site infec-
tions, 17% of the bacteremias, and 30% of the pneumonias from 1990 through 1992. 
Escherichia coli, the predominant nosocomial pathogen, is the major cause of infec-
tion in the urinary tract and is common in other body sites. Staphylococcus aureus 
and Pseudomonas aeruginosa are currently the most common pathogens in nosocom-
ial pneumonias, followed by Enterobacter and Klebsiella. Coagulase-negative staph-
ylococci have replaced E coli as the predominant pathogen in primary bloodstream 
infections. The major causes of surgical site infections are S aureus, coagulase- nega-
tive staphylococci, and enterococci.  
Other coliform bacilli and Proteus have been incriminated in various hospital-
acquired infections. Klebsiella, Enterobacter, and Serratia species are frequent causes 
of bacteremia at some medical centers and also are frequently involved in infections 
associated with respiratory tract manipulations, such as tracheostomy and procedures 
using contaminated inhalation therapy equipment. Klebsiella and Serratia species 
commonly cause infections following intravenous and urinary catheterization and in-
fections complicating burns. Proteus species frequently cause nosocomial infections 
of the urinary tract, surgical wounds, and lower respiratory tract. Less frequently, 
Proteus species cause bacteremia, most often in elderly patients. A series of nation-
wide outbreaks of bacteremia (1970 to 1971 and 1973), caused by contaminated 
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commercial fluids for intravenous injections, involved Enterobacter cloacae, Entero-
bacter agglomerans, and C freundii. 
The role of Citrobacter species in human disease is not as great as that of the other 
coliforms and Proteus. Citrobacter freundii and C diversus (C koseri) have been iso-
lated predominantly as superinfecting agents from urinary and respiratory tract infec-
tions. Citrobacter septicemia may occur in patients with multiple predisposing fac-
tors; Citrobacter species also cause meningitis, septicemia, and pulmonary infections 
in neonates and young children. Neonatal meningitis produced by C diversus, while 
uncommon, is associated with a very high frequency of brain abscesses, death, and 
mental retardation in survivors. Although E coli and group B streptococci cause most 
cases of neonatal meningitis, the most common cause of brain abscesses in neonatal 
meningitis is P mirabilis. 
Immunocompromised patients often develop non-hospital-acquired infections with 
coliforms. For example, group B streptococci and E coli are responsible for most 
cases of neonatal meningitis, with the latter accounting for about 40 percent of cases. 
Infections seen in cancer patients with solid tumors or malignant blood diseases fre-
quently are caused by E coli, Klebsiella, Serratia, and Enterobacter species. Such in-
fections often have lethal course. Individuals who are immunosuppressed by therapy 
(e.g., cancer patients or transplant recipients) or by congenital defects of the immune 
system may develop Klebsiella, Enterobacter, and Serratia infections. Many addi-
tional factors such as diabetes, trauma, and chronic lung disease may predispose to 
infection by coliforms and other microbes.  
Community-Acquired Infections 
The coliform organisms and Proteus species are major causes of diseases acquired 
outside the hospital; many of these diseases eventually require hospitalization. Esch-
erichia coli causes approximately 85 percent of cases of urethrocystitis (infection of 
the urethra and bladder), about 80 percent of cases of chronic bacterial prostatitis, 
and up to 90 percent of cases of acute pyelonephritis (inflammation of the renal pel-
vis and parenchyma). Approximately one half of females have had a urinary tract in-
fection by their late twenties due to E coli from their fecal flora. Proteus, Klebsiella, 
and Enterobacter species are among the other organisms most frequently involved in 
urinary tract infections. Proteus, particularly P mirabilis, is believed to be the most 
common cause of infection-related kidney stones, one of the most serious complica-
tions of unresolved or recurrent bacteriuria.  
Klebsiella was first recognized clinically as an agent of pneumonia. Klebsiella 
pneumoniae accounts for a small percentage of pneumonia cases; however, extensive 
damage produced by the organism results in high case fatality rates (up to 90 percent 
in untreated patients). Klebsiella rhinoscleromatis is the agent of rhinoscleroma, a 
chronic destructive granulomatous disease of the respiratory tract that is endemic in 
Eastern Europe and Central America. Klebsiella ozaenae, a rare cause of serious in-
fection, is classically associated only with ozena, an atrophy of nasal mucosal mem-
branes with a mucopurulent discharge that tends to dry into crusts; however, recent 
studies indicate that the organism may cause various other diseases including infec-
tions of the urinary tract, soft tissue, middle ear, and blood.  
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Distinctive Properties 
Structure and Antigens 
The generalized structure and antigenic composition of coliform bacilli, as well as of 
Proteus and other members of the family Enterobacteriaceae, are depicted schemati-
cally in Figure 26-2. A more detailed figure of the structure is presented in Chapter 
2. The major antigens of coliforms are referred to as H, K, and O antigens. The coli-
forms and Proteus are divided into serotypes on the basis of combinations of these 
antigens; different serotypes may have different virulence properties or may prefer-
entially colonize and produce disease in particular body habitats. The H antigen de-
terminants are flagellar proteins. Escherichia coli, Enterobacter, Serratia, Citrobacter, 
and Proteus organisms are peritrichous (i.e., they have flagella that grow from many 
places on the cell surface). Klebsiella species are nonmotile and nonflagellated and 
thus have no H antigens.  
 
FIGURE 26-2 Structure and antigenic composition of coliforms and Proteus 
species. 
Some strains of coliform and Proteus species have pili (fimbriae). Pili are associated 
with adhesive properties and, in some cases, are correlated with virulence. Different 
pilial colonization factors generally are detectable as hemagglutinins that can be dis-
tinguished by the type of erythrocyte agglutinated and by the susceptibility of the 
hemagglutination to inhibition by the sugar mannose. Sex pili, which have receptors 
for "male" specific bacterial viruses and are genetically determined by extrachromo-
somal plasmids, are important in coliform ecology and in the epidemiology of dis-
eases produced by coliforms and Proteus species in that sex pili are involved in ge-
netic transfer by conjugation (e.g., chromosome-mediated and plasmid-mediated 
drug resistances or virulence factors).  
 106 
Major Surface Antigens 
K antigens (capsule antigens) are components of the polysaccharide capsules. Cer-
tain K antigens (e.g., K88 and K99 of E coli) are pilus-like proteins. The K antigens 
often block agglutination by specific O antisera. In the past, K antigens routinely 
were differentiated into A, L, and B groups on the basis of differences in their labil-
ity to heat; however, these criteria are subject to difficulties that make the distinction 
tenuous. Some Citrobacter serotypes produce Vi (virulence) antigen, a K antigen al-
so found in Salmonella typhi. Species of Proteus, Enterobacter, and Serratia appar-
ently have no regular K antigens. However, the K antigens are important in the path-
ogenesis of some coliforms. A diffuse slime layer of variable thickness (the M anti-
gen) also may be produced but, unlike the K antigens, it is nonspecific and is sero-
logically cross-reactive among different organisms.  
The outer membrane of the bacterial cell wall of these species contains receptors for 
bacterial viruses and bacteriocins (plasmid-encoded, antibiotic like bactericidal pro-
teins called colicins in E coli that are active against the same or closely related spe-
cies). The outer membrane also contains lipopolysaccharide (LPS), of which the li-
pid A portion is endotoxic and the O (somatic) antigen is serotype specific. The sero-
logic specificity of the O antigens is based on differences in sugar components, their 
linkages, and the presence or absence of substituted acetyl groups. Loss of the O an-
tigen by mutation results in a smooth-to-rough transformation, which often involves 
changes in colony type and saline agglutination, as well as loss of virulence . Certain 
strains of P vulgaris (OX-19, OX-2, and OX-K) produce O antigens that are shared 
by some rickettsiae. These Proteus strains are used in an agglutination test (the Weil-
Felix test) for serum antibodies produced against rickettsiae of the typhus and spot-
ted fever groups (see Ch. 38).  
Toxins 
Enterotoxigenic strains of Klebsiella, Enterobacter, Serratia,Citrobacter, and Proteus 
also have been isolated from infants and children with acute gastroenteritis. The en-
terotoxins of at least some of these organisms are of the heat-labile and heat-stable 
types and have other properties in common with the E coli toxins (see Ch. 25). How-
ever, the importance of the coliforms and Proteus, other than E coli, in enteric infec-
tions is questionable 
Pathogenesis 
The process of disease production by coliforms is, in many cases, poorly understood. 
Production of disease by coliforms or Proteus species in extraintestinal sites often 
involves specific serotypes of the organisms and special virulence factors. For exam-
ple, respiratory tract infections by K pneumoniae predominantly involve capsular 
types 1 and 2, whereas urinary tract infections often involve types 8, 9, 10, and 24. 
Similarly, only a few polysaccharide K antigens (types 1, 2, 3, 5, 12, and 13) of E 
coli are found with high frequency in urinary tract and other extraintestinal infec-
tions. These observations suggest that different serotypes may have specific patho-
genicities. An alternative explanation is that such strains may simply be the most 
prevalent types in the normal gut flora.  
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There is good evidence for specific pathogenicity in E coli strains that cause ex-
traintestinal infections (Table 26-3). Approximately 80 percent of E coli isolates in-
volved in neonatal meningitis carry the K1 antigen, a fact attributable, at least in 
part, to the higher resistance to phagocytosis of K1-positive strains. Certain O anti-
gens (O7 and O18) are found in combination with K1, usually in strains that are iso-
lated from cases of neonatal bacteremia and meningitis and that show increased re-
sistance to the bactericidal effects of serum complement. Interestingly, the E coli K1 
antigen, composed of neuraminic acid, shows immune cross-reactivity with the 
group B meningococcal polysaccharide capsule.  
 
Escherichia coli strains isolated from extraintestinal infections often possess a num-
ber of properties not usually found in random fecal isolates. These include produc-
tion of soluble and cell-bound hemolysins, the colicin V plasmid, production of the 
siderophores aerobactin and enterochelin, and special pilial antigens for adherence to 
target cells. The hemolysin kills host cells and makes iron more available by releas-
ing hemoglobin-bound iron from lysed red cells. To strip iron from the host iron-
binding proteins ( transferrin and lactoferrin), E coli produces siderophores of both 
the hydroxamate (aerobactin) and phenolate (enterochelin) types. Common or type 1 
pili may mediate adherence to bladder cells; P-pili are virulence factors for strains 
causing pyelonephritis; S-pili, which recognize O-linked sialo-oligosaccharides of 
glycophorin A, are associated with meningitis and urinary tract infections. Certain 
afimbrial adhesions and outer membrane proteins also have been associated with 
urinary tract infections.  
The enzyme urease, produced by Proteus, and to a lesser extent by Klebsiella spe-
cies, is thought to play a major role in the production of infection-induced urinary 
stones. Urease hydrolyzes urea to ammonia and carbon dioxide. Alkalinization of the 
urine by ammonia can cause magnesium phosphate and calcium phosphate to be-
come supersaturated and crystallize out of solution to form, respectively, struvite and 
apatite stones. Bacteria within the stones may be refractory to antimicrobial therapy. 
Large stones may interfere with renal function. The ammonia produced by urease ac-
tivity may also damage the pithelium of the urinary tract.  
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Except in cases of bacteremia and other systemic infection, there is little evidence 
that endotoxin plays a role in most coliform and Proteus diseases. Humans with coli-
form bacteremia show many of the typical effects of endotoxin, including fever, de-
pletion of complement, release of inflammatory mediators, lactic acidosis, hypoten-
sion, vital organ hypoperfusion, irreversible shock, and death.  
Host Defenses 
It cannot be overemphasized that coliforms (except for E coli in enteric diseases) and 
Proteus species are unlikely to cause disease unless the local or generalized host de-
fenses fail in some way. The normal gastrointestinal flora, which includes E coli and, 
frequently, other coliforms and Proteus species in small numbers, is important in 
preventing disease through bacterial competition. Prolonged antibiotic therapy com-
promises this defense mechanism by reducing susceptible components of the normal 
flora, permitting nosocomial coliform strains or other bacteria to colonize or over-
grow. 
The organisms may breach anatomic barriers through third-degree burns, ulcers as-
sociated with solid tumors of the skin and mucous membranes, intravenous catheters, 
and surgical or instrumental procedures on the biliary, gastrointestinal, and genitou-
rinary tracts. The lungs may be violated by instrumentation, as in tracheal intubation, 
or even by aerosols from contaminated nebulizers or humidifiers, which carry organ-
isms to the terminal alveoli.  
Corticosteroid administration, radiotherapy, and the increased steroid levels associat-
ed with pregnancy tend to decrease host control over infections (e.g., by depressing 
the immune response). Cytotoxic drugs also are immunosuppressive. Cancer-or 
drug-induced neutropenia is an important predisposing factor in bacteremia. Devital-
ized tissue or foreign bodies may be a source of organisms and may also shelter the 
organisms from phagocytes and antimicrobial factors.  
The interaction of multiple predisposing factors often determines the clinical course 
and outcome of coliform or Proteus infection. For example, the mortality of bacte-
remia increases progressively when the underlying disease (e.g., cancer or diabetes) 
is rated as nonfatal, ultimately fatal (death within 5 years), or rapidly fatal (death 
within 1 year). Similarly, coliform and Proteus infections commonly are more severe 
in the very old and very young.  
Epidemiology 
The epidemiology of coliform and Proteus infections is complex and involves multi-
ple reservoirs and modes of transmission. Klebsiella, Enterobacter, Serratia, 
Citrobacter, and Proteus species live in water, soil, and occasionally food and, in 
many cases, form part of the intestinal flora of humans and animals. Escherichia coli 
is believed not to be free living, and its presence in environmental samples is taken 
as indicating recent fecal contamination. In fact, water quality is determined by the 
presence of the rapid lactose fermenting E coli, Klebsiella, and Enterobacter (coli-
form counts) and E coli (fecal coliform counts) using special selective media. 
Coliform and Proteus organisms causing infection may be exogenous or endogenous. 
While most nosocomial infections appear to arise from endogenous flora, studies of 
hospitalized adults and infants have shown that the intestinal tract is progressively 
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colonized by nosocomial coliforms with increasing length of hospitalization. Patients 
being treated with antibiotics, severely ill patients, and (probably) infants are more 
likely to be colonized, and other sites of colonization such as the nose and throat may 
be important in such patients. Colonized patients have a higher risk of nosocomial 
infection than patients who are not colonized.  
The bacteria may be acquired indirectly via various vehicles or by direct contact . A 
variety of vehicles have been implicated in the spread of nosocomial pathogens. For 
example, Klebsiella, Enterobacter, and Serratia species have all been recovered in 
large numbers from hospital food, particularly salads, with the hospital kitchen being 
a primary source . An outbreak of urinary tract infections due to multiply drug-
resistant S marcescens was associated with contaminated urine- measuring contain-
ers and urinometers. Serious outbreaks or individual cases of bacteremia due to coli-
forms have been associated with extrinsic contamination of intravenous fluids or 
caps during manufacture and with extrinsic contamination of intravenous fluids and 
administration sets in the hospital environment. Other medical devices and medica-
tions have served as vehicles for the spread of nosocomial pathogens. Occasionally, 
transmission may be via members of the hospital staff who are colonized with noso-
comial pathogens in the rectum or vagina or on the hands; however, passive carriage 
on the hands of medical personnel constitutes the major mode of transmission.  
Certain properties of the coliforms may be important in the epidemiology of hospi-
tal-acquired infections. Coliform bacteria other than E coli frequently are found in 
tap water or even distilled or deionized water. They may persist or actively multiply 
in water associated with respiratory therapy or hemodialysis equipment. Klebsiella, 
Enterobacter, and Serratia species, like Pseudomonas species, may exhibit increased 
resistance to antiseptics and disinfectants. The same group of coliforms has a selec-
tive ability over other common nosocomial pathogens (including E coli, Proteus spe-
cies, Pseudomonas aeruginosa, and staphylococci) to proliferate rapidly at room 
temperature in commercial parenteral fluids containing glucose.  
Diagnosis 
Because the coliforms and Proteus can cause many types of infection, the clinical 
symptoms rarely permit a diagnosis. Culturing and laboratory identification are usu-
ally required. Selected characteristics that are useful in the differentiation of coliform 
bacilla and Proteus species found in human clinical specimens are shown in Table 
26-4. The organisms have simple nutritional requirements and grow well on mildly 
selective media commonly used for members of the Enterobacteriaceae, but not on 
some moderately and highly selective enteric plating media (Salmonella-Shigella, 
bismuth sulfite, and brilliant green agar). Extraintestinal specimens such as urine, pu-
rulent material from wounds or abscesses, sputum, and sediment from cerebrospinal 
fluid should be plated for isolation on blood agar and a differential medium such as 
MacConkey or eosin-methylene blue agar. The finding of more than 105 organ-
isms/ml in clean voided midstream urine is often taken as "significant bacteriuria." 
However, in acutely symptomatic females and with other types of specimens (i.e., 
those obtained by catheterization or suprapubic aspiration) from either sex, a more 
appropriate threshold, particularly in the presence of pus cells and the absence of epi-
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thelial cells, might be more than 102 colonies of a known uropathogen/ml. Because 
urine is a good growth medium for many microbes, specimens should be refrigerated 
(4oC) if transport to the laboratory is delayed longer than 30 minutes, unless a urine 
transport container with preservative is used.  
Isolation of certain coliforms or Proteus species from fecal specimens may be facili-
tated by adding a moderately selective medium such as xylose-lysine-desoxycholate 
(XLD) or Hektoen enteric agar. Use of tetrathionate or selenite broth for enrichment 
of enterotoxigenic strains from feces is not recommended because both media inhibit 
various genera of coliforms. The strong (E coli, K pneumoniae, Enterobacter aero-
genes) and occasionally the slow or weak (Serratia, Citrobacter) lactose-fermenting 
coliforms produce characteristic pigmented colonies on the enteric plating media. A 
striking characteristic of Proteus species is their propensity to swarm over the surface 
of most plating media, making the isolation of other organisms in mixed cultures dif-
ficult. The swarming growth appears as a rapidly spreading thin film, sometimes 
with changing patterns of whirls and bands. Sorbitol MacConkey agar is useful for 
screening EHEC (commonly E. coli O157:H7) on which sorbitol-negative colonies 
are nonpigmented and considered suspicious for the organism. Unless the physician 
specifically requests that the laboratory look for the possibility of E coli as an en-
teropathogen, tests for pathogenic strains, including toxin assays, serotyping, and 
serogrouping, will not be done.  
In cases of suspected bacteremia, replicate bottles (one cultured aerobically, the other 
anaerobically) containing 25 to 100 ml of appropriate medium with anticoagulant 
(e.g., sodium polyanetholesulfonate) are inoculated with 10-ml portions of blood. It 
is usually necessary to take multiple specimens, both before and after antibiotic ther-
apy is started. It is important to take specimens after antibiotic treatment is started so 
that therapeutic failure can be recognized while the bacteremia may still be amenda-
ble to more aggressive medical or surgical treatment.  
All of the coliforms and Proteus species are Gram negative, facultative anaerobic, 
non-spore- forming rods that are typically motile, except for Klebsiella, which is 
nonmotile. The oxidase test is negative, and nitrates are reduced to nitrites. Proteus 
species and all coliforms ferment glucose, but fermentation of other carbohydrates 
varies. Lactose usually is fermented rapidly by Escherichia, Klebsiella and some En-
terobacter species and more slowly by Citrobacter and some Serratia species. Pro-
teus, unlike the coliforms, deaminates phenylalanine to phenylpyruvic acid, and it 
does not ferment lactose. Typically, Proteus is rapidly urease positive. Some species 
of Klebsiella, Enterobacter, and Serratia produces a positive urease reaction, but they 
do so more slowly. A battery of tests for biochemical properties is required to identi-
fy the coliforms and Proteus to the species level. Commercial identification systems 
are now widely used by most US clinical laboratories and consist of "kits" or minia-
turized biochemical tests which are read manually (e.g., API-20E and BBL Crystal) 
or automatically (e.g., Vitek or MicroSCAN).  
The coliforms are characterized by great antigenic diversity caused by various com-
binations of specific H, K, and O antigens. For example, approximately 50 H, 90 K, 
and 160 O antigens have been identified among various strains of E coli. In contrast, 
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Klebsiella, with no H antigens, has 10 O antigens and approximately 80 K antigens. 
Serologic identification of the coliforms and Proteus species, commonly by reference 
laboratories, is an extremely important epidemiologic tool. Similarly, other phenoty-
ing methods including biotyping (biochemical profiles), antibiograms (patterns of 
resistance to antimicrobal agents), and bacteriocin and phage typing have been wide-
ly used in epidemiologic studies, particularly of multiresistant isolates of coliforms 
and Proteus. Recently, genotyping methods such as plasmid profiles (determined by 
agarose gel electrophoresis), RFLP (restriction fragment link polymorphism) of total 
DNA, pulsed-field gel electrophoresis, targeted analysis of DNA polymorphism, ri-
botype, and arbitrarily primed PCR (polymerase chain reaction) have been used in 
epidemiological studies. In hospital-acquired infections, for example, the same or a 
small number of serologic or plasmid types suggests  
single sources of infection. The finding of multiple serotypes or plasmid profiles 
suggests multiple sources of infection or endogenous infections.  
Control 
Prevention of coliform and Proteus infections, particularly those that are hospital ac-
quired, is difficult and perhaps impossible. Sewage treatment, water purification, 
proper hygiene, and other control methods for enteric pathogens will reduce the inci-
dence of E coli enteropathogens. However, these control measures are rarely availa-
ble in less developed regions of the world. Breast-feeding is an effective means of 
limiting outbreaks of enteropahogens in infants. Aggressive infection control com-
mittees in hospitals can do much to reduce nosocomial infections through identifica-
tion and control of predisposing factors, education and training of hospital personnel, 
and limited microbial surveillance. Except for investigations of potential outbreaks, 
routine culturing of personnel, patients, and the environment is not warranted. Selec-
tive decontamination of the digestive tract with a suitable nonabsorbable antimicro-
bial regimen may be useful during outbreaks caused by nosocomial coliforms and 
Proteus. Meticulous hand washing after each patient contact a highly effective means 
of reducing the transmission of nosocomial pathogens (Fig. 26-3)is infrequently or 
poorly performed by some hospital personnel. In a study conducted in an intensive 
care unit following an educational campaign on the importance of hand washing, the 
compliance was 17 percent for physicians, 100 percent for nurses, 82 percent for res-
piratory technicians, and 88 percent for diagnostic services personnel. 
Active or passive immunization against coliforms and Proteus species is not prac-
ticed. However, vaccines or hyperimmune sera for the six common Gram negative 
pathogens (E coli, Klebsiella, Enterobacter, Serratia, Pseudomonas aeruginosa, and 
Proteus) probably would have a major impact on morbidity and mortality from noso-
comial infections. In a trial, the mortality was reduced markedly in a group of pa-
tients with Gram-negative bacteremia who had been given antiserum against a mu-
tant E coli with an exposed lipopolysaccharide core.  
Ampicillin, sulfonamides, cephalosporins, tetracycline, trimethoprim-
sulfamethoxazole, nalidixic acid, ciprotloxacin, and nitrofurantoin have been useful 
in treating urinary tract infections by coliforms and Proteus species.  
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FIGURE 26-3 Major routes of transmission and prevention of spread of noso-
comial pathogens. 
Gentamicin, amikacin, tobramycin, ticarcillin/clavulate, imipenem, aztreonam, and a 
variety of third-generation cephalosporins may be effective for systemic infections; 
however, laboratory tests for drug susceptibility are essential. For example, resist-
ence of E coli to ampicillin, and first generation cephalosporins is increasing rapidly 
to the extent that they can no longer be considered primary drugs of choice in empir-
ical treatment of urinary tract infections. Likewise, emergence of coliforms with 
chromosomal or plasmid-encoded extended spectrum B-lactamase activity is causing 
global problems with resistance to third generation cephalosporins. Some coliforms 
have multiple resistance due to the presence of R plasmids transmissible by conjuga-
tion. Conjugative resistance plasmids allow the transfer of resistance genes among 
species and genera that normally do not exchange chromosomal DNA (Ch. 5). In 
some cases, resolution of the infection may require drainage of abscesses or other 
surgical intervention.  
Measures commonly used to control epidemics of antibiotic resistant Gram-negative 
bacilli have included: (1) closing the unit to new admissions until control of the out-
break is underway; (2) reinforcing hand-washing practices; (3) gown and glove iso-
lation, often combined with isolation of patients in separate quarters; and (4) restrict-
ing the use of the antibiotic to which the offending clone is resistant.  
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